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Abstract  
There is an urgent need for the development of leukaemia-targeted 
immunotherapeutic approaches. Wilms’ tumour antigen (WT1), M-phase 
phosphoprotein 11 (MPP11) and proteinase-3 (PR-3) proteins are overexpressed in 
leukemic cells and represent attractive immunotherapeutic candidates. The first part 
of this study explored the feasibility of using an approach to develop a novel 
leukaemia vaccine by modifying the sequence of low avidity HLA-A*0201-
restricted peptide epitopes derived from WT1 protein (WT1-126126-134 and WT1-
187187-195).  The modified WT1-Db126 showed enhanced binding ability to the 
HLA-A*0201 molecule, increased the frequency of IFN-γ producing cytotoxic T 
lymphocyte (CTL), and boosted the lytic activity of the generated CTL against 
HLA-matched leukaemia cells. Interestingly, the CTL line generated with the 
modified epitope was able to recognize the wild-type peptide presented by target 
cells. The second part of this study identified a novel epitope derived from WT1 
antigen (WT1-60237-251). This epitope was recognized by a CD4+ T cells in an 
HLA-DRB1*04-restricted manner and secreted Th2 cytokines (IL-5 and IL-4). The 
third part of the study aimed to identify potential CD8+ CTL epitopes in the 
sequence of MPP11 and PR-3 that may bind to HLA-A*0201 molecule and provoke 
specific CTL responses.  A potential HLA-A*0201 binding epitope named MPP-437-
45 derived from the MPP11 protein was identified which was used to generate a CTL 
line. This CTL line specifically recognized peptide-loaded target cells in both 
ELISPOT and cytotoxic assays. Importantly, this CTL line exerted a cytotoxic effect 
towards the CML leukemic cell line K562-A2.1. The study also demonstrated that 
PR-3-derived peptides PR-129129-137 and PR-99-17 were not immunogenic since they 
were incapable of inducing specific CD8+ T cell responses. 
 
In conclusion, modification of the WT1-Db126 epitope resulted in enhancement of 
its immunogenicity without altering its antigenic specificity. The WT1-60 and MPP-
4 peptides have been identified as novel CD4 and CD8 T-cell epitopes, respectively. 
 3 
Table of Contents 
Title Page…………………………………………………………………… 1 
Abstract ……………………………………………………………………..                                                                                                                   2 
Table of Contents …………………………………………………………...                                                                             3 
List of Figures ………………………………………………………………                                                                                                        7 
List of Tables …………………………………………………………......... 13 
List of Abbreviations ………………………………………………….........                                                                                              14
Acknowledgements……………………………………………………......... 17 
 
 
1. INTRODUCTION………………………………………………………..18 
1.1. Leukaemia ............................................................................................. 19 
1.1.1. General characteristics and classification ............................................... 19 
1.1.2. Incidence and mortality.......................................................................... 25 
1.1.3. Prognosis ............................................................................................... 25 
1.1.3.1. Acute myelogenous leukaemia............................................................... 25 
1.1.3.2. Chronic myelogenous leukaemia............................................................ 27 
1.1.3.3. Acute lymphoblastic leukaemia ............................................................. 27 
1.1.3.4. Chronic lymphoblastic leukaemia .......................................................... 28 
1.1.4. Treatment .............................................................................................. 28 
1.2. Tumour Immunology............................................................................. 29 
1.2.1. Tumour immune surveillance theory...................................................... 29 
1.2.2. Cancer immunoediting theory ................................................................ 33 
1.2.3. Immune recognition of tumour cells....................................................... 34 
1.2.3.1. Natural killer cells.................................................................................. 35 
1.2.3.2. T lymphocytes or T cells........................................................................ 36 
1.2.4. Mechanisms of tumour escape ............................................................... 39 
1.3. Immunotherapy for Leukaemia .............................................................. 40 
1.3.1. Allogeneic hematopoietic stem cell transplantation ................................ 40 
1.3.2. Potential target antigens of the GvL effect ............................................. 41 
1.4. Candidate antigens for leukaemia immunotherapy ................................. 45 
1.4.1. Wilms’ tumor 1 (WT1) .......................................................................... 45 
1.4.2. M-Phase Phosphoprotein 11 (MPP11).................................................... 45 
1.4.3. Proteinase-3 (PR-3)................................................................................ 46 
 4 
1.4.4. Approaches for the identification of tumour antigens ............................. 48 
1.4.5. Modalities of T-cell-mediated immunotherapy....................................... 52 
1.4.5.1. Peptide-based vaccines .......................................................................... 52 
1.4.5.2. Full-length tumour antigen vaccines....................................................... 53 
1.4.5.3. Whole-tumour cell vaccines................................................................... 53 
1.4.5.4. Dendritic cell-based vaccines................................................................. 54 
1.5. Aims of this Study ................................................................................. 55 
2. MATERIALS AND METHODS………………………………………...57 
2.1. Patients and Donors ............................................................................... 58 
2.2. Preparation of Peripheral Blood Mononuclear Cells............................... 58 
2.3. T lymphocyte Epitope Prediction and Peptide Synthesis ........................ 58 
2.3.1. WT1-pepmix ......................................................................................... 58 
2.3.2. WT1 peptides ........................................................................................ 59 
2.3.3. MPP11 and PR-3 peptides ..................................................................... 59 
2.4. T2 Binding Assay .................................................................................. 60 
2.5. Culture and Generation of Target Antigen Presenting Cells (APCs) ....... 63 
2.5.1. Cell lines................................................................................................ 63 
2.5.2. Generation of B-lymphoblastoid cell lines ............................................. 63 
2.5.3. Generation of PHA blast ........................................................................ 63 
2.5.4. Generation of mature dendritic cells from autologous monocytes........... 64 
2.5.4.1. Isolation of monocytes for subsequent dendritic cell generation ............. 64 
2.5.4.2. Generation of mature conventional dendritic cells.................................. 65 
2.5.4.3. Generation of mature fast dendritic cells ................................................ 65 
2.6. Generation of T lymphocyte lines .......................................................... 65 
2.6.1. Isolation of CD8+ T lymphocytes ........................................................... 65 
2.6.2. Generation of anti-peptide specific CD8+ T lymphocytes ....................... 66 
2.6.3. Generation of anti-peptide specific CD4+ T lymphocytes ....................... 67 
2.7. Generation of T Lymphocyte Clones...................................................... 67 
2.7.1. Cloning of WT1 T cell line .................................................................... 67 
2.7.1.1. T cell cloning by limiting dilution assay................................................. 67 
2.7.1.2. T cell cloning using dynabeads .............................................................. 68 
2.7.2. Cloning of MPP11 T cell line................................................................. 68 
2.8. Flow Cytometry Analysis ...................................................................... 69 
2.9. Cytotoxicity Assay (Chromium Release Assay) ..................................... 69 
 5 
2.10. T  Cell Proliferation Assay..................................................................... 70 
2.11. Enzyme-Linked Immunospot Assay (ELISPOT).................................... 70 
2.12. Enzyme-Linked Immunosorbent Assay (ELISA) ................................... 71 
2.13. RNA Preparation ................................................................................... 71 
2.14. Reverse Transcription (RT).................................................................... 72 
2.15. Conventional Reverse Transcription- Polymerase Chain Reaction (RT-
PCR)……………………………………………………………………..................72 
2.16. Quantitative Real Time RT-PCR for WT1 Expression in Patients’ 
Leukemic Cells .................................................................................................... 74 
2.17. Statistical Analysis................................................................................. 74 
3. WT1 PEPTIDE ANALOGOUE WT1-126Y ENHANCES LEUKEMIA 
LYSIS………………………………………………………………………………75 
3.1. Introduction ........................................................................................... 76 
3.2. Aim ....................................................................................................... 76 
3.3. Results ................................................................................................... 77 
3.3.1. WT1 antigen screening in leukaemia patients and normal donors........... 77 
3.3.2. Identification of peptides predicted to highly bind to the HLA-A0201 
molecule……………………………………………………………………………81 
3.3.3. Generation of WT1 peptide-specific cytotoxic T cell lines ..................... 93 
3.3.4. Enhanced cytotoxicity of CTL generated against WT1-126Y................. 98 
3.3.5. WT1-126Y peptide increased the frequency of IFN-γ producing T cells104 
3.3.6. Evaluation of WT1 expression and lytic activity of anti-WT1 T cell lines 
against HLA-A0201-matched leukemic cells...................................................... 107 
3.4. Discussion ........................................................................................... 110 
4. IDENTIFICATION OF A NOVEL WT1-DERIVED EPITOPE 
RECOGNIZED BY HUMAN CD4+ T CELLS………………………………......114 
4.1. Introduction ......................................................................................... 115 
4.2. Aim ..................................................................................................... 116 
4.3. Results ................................................................................................. 116 
4.3.1. Generation of T-cell lines against the WT1-Pepmix and analysis of their 
HLA restriction .................................................................................................. 116 
4.3.2. Generation of specific responses against WT1-Pepmix using dynabeads125 
4.3.3. Identification of a novel WT1-60 peptide recognized by TCL-57 T 
cells………………………………………………………………………………..127 
 6 
4.3.4. Generation of TCL-57 derived T cell clones using the WT1-60 peptide and 
analysis of their HLA-restriction ........................................................................ 131 
4.3.5. Evaluation of the cytokine profile of the TCL-57 T cell line and its 
derivative clones ................................................................................................ 134 
4.3.6. Proliferative activity of TCC-15 clone against HLA-DR-matched leukemic 
cells……………………………………………………………………………….134 
4.4. Discussion ........................................................................................... 140 
5. IMMUNOGENICITY OF M-PHASE PHOSPHOPROTEIN 11 AND 
PROTEINASE-3 IN LEUKAEMIAS…………………………………………….143 
5.1. Introduction ......................................................................................... 144 
5.2. Aim ..................................................................................................... 144 
5.3. Results ................................................................................................. 145 
5.3.1. MPP11 antigen screening in leukaemia patients and normal donors ..... 145 
5.3.2. Selection of potential CTL epitopes derived from MPP11 and PR3 
proteins…………………………………………………………………………....149 
5.3.3. Generation of MPP11 specific T lymphocyte lines by T2 cells............. 157 
5.3.4. Generation of MPP11 specific T lymphocyte lines by DC2d................ 168 
5.3.5. CD8+ T cell responses to MPP11- derived peptides.............................. 168 
5.3.5.1. MPP-4 CTL s produced specific IFN-γ ................................................ 168 
5.3.5.2. MPP-4 CTLs specifically lysed MPP-4-pulsed target cells................... 178 
5.3.5.3. Cloning of MPP-4 CTLs ...................................................................... 179 
5.3.6. Generation of PR3 specific T lymphocyte lines.................................... 188 
5.3.7. CD8+ T cell responses to PR3-derived peptides.................................... 188 
5.3.7.1. IFN-γ and granzyme B production by PR3 T cell lines......................... 188 
5.3.7.2. Cytotoxic activity of anti-PR3 CTLs .................................................... 198 
5.4. Discussion ........................................................................................... 204 
6. GENERAL DISCUSSION……………………………………………...209 
7. REFERENCES………………………………………………………….216 
8. APPENDIX……………………………………………………………...277 
 7 
List of Figures 
Figure  1.1. The process of hematopoiesis………………………………………… 21 
Figure  1.2. Development of leukaemia from HSCs………………………………. 22 
Figure  1.3. Major histocompatibility complex class I presentation pathway………38 
Figure  1.4.The basic steps of reverse immunology approach for the identification of 
immunogenic epitopes……………………………………………………………...50 
Figure  2.1. Principles of T2 binding assay…………………………………………62 
Figure  3.1.RT-PCR analysis of WT1 gene expression in PBMCs from AML, ALL 
patients and normal donors…………………………………………………………79 
Figure  3.2. Wild-type (WT1-126N, WT1-187N) and the modified (WT1-126Y, 
WT1-187Y) peptides binding affinities to HLA-A*0201 molecule as predicted by 
the computer-based epitope prediction program BIMAS…………………………..83 
Figure  3.3. Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells 
cultured overnight in the absence or in the presence of 50, 30, 15, 7 and 1µM of the 
WT1-126N peptide…………………………………………………………………84 
Figure  3.4. Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells 
cultured overnight in the absence or in the presence of 50, 30, 15, 7 and 1µM of the 
WT1-126Y peptide…………………………………………………………………85 
Figure  3.5. Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells 
cultured overnight in the absence or in the presence of 50, 30, 15, 7 and 1µM of the 
WT1-187N peptide…………………………………………………………………86 
Figure  3.6. Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells 
cultured overnight in the absence or in the presence of 50, 30, 15, 7 and 1µM of the 
WT1-187Y peptide…………………………………………………………………87 
Figure  3.7. Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells 
cultured overnight in the absence or in the presence of 70, 7 and 0.7µM of the WT1-
126N peptide……………………………………………………………………..... 88 
Figure  3.8. Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells 
cultured overnight in the absence or in the presence of 70, 7 and 0.7µM of the WT1-
126Y peptide………………………………………………………………………. 89 
Figure  3.9. Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells 
cultured overnight in the absence or in the presence of 70, 7 and 0.7µM of the WT1-
187N peptide………………………………………………………………………. 90 
 8 
Figure  3.10.Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells 
cultured overnight in the absence or in the presence of 70, 7 and 0.7µM of the WT1-
187Y peptide………………………………………………………………………. 91 
Figure  3.11.The binding ability of WT1-derived peptides to HLA-A*0201 molecule 
as measured by a standard T2 stabilization assay…………………………………. 92 
Figure 3.12. Method used to generate CTLs specific for 126N and its analogue 
(126Y) peptides……………………………………………………………………. 95 
Figure  3.13. Efficiency of magnetic bead cell separation…………………………. 96 
Figure  3.14.Flow cytometry analysis of CD1a and CD83 expression in the mature-
monocytes derived DC-32………………………………………………………... 97 
Figure 3.15. Cytotoxicity assay with T cells generated against WT1-126N and WT1-
126Y peptides from a healthy HLA-A*0201 donor………………………………100 
Figure  3.16. Inhibition of lytic activity of BC-32 T cell lines generated against WT1-
126N and WT1-126Y peptides after blocking with an anti-ABC antibody showing 
the restriction response to the HLA-A*0201 molecule…………………………...101 
Figure  3.17. Non-specific lysis by BC-21 T cell lines generated against WT1-126N 
and WT1-126Y peptides as tested using a standard chromium release assay…….102 
Figure  3.18. Non-specific lysis by BC-37 T cell lines generated against WT1-126N 
and WT1-126Y peptides as tested using a standard chromium release assay…….103 
Figure 3.19.Specific production of IFN- by the two T cell lines generated against 
the wild type 126N and its analogue 126Y peptides as measured by an ELISPOT 
assay……………………………………………………………………………… 105 
Figure  3.20. Non-specific IFN- release by BC-21 CTLs generated against the WT1-
126N and WT1-126Y peptides using an IFN-γ- ELISPOT assay………………...106 
Figure  3.21. Non-specific IFN- release by BC-37 CTLs generated against the WT1-
126N and WT1-126Y peptides using an IFN-γ- ELISPOT assay………………...106 
Figure 3.22.Cytotoxicity assay showing the lytic activity of the 126N and 126Y T 
cell lines against HLA-A*0201-matched (AML-28) and non-matched AML-27 
cells………………………………………………………………………………..109 
Figure  4.1. Flow cytometry analysis of CD1a and CD83 expression in the mature-
monocytes derived DCs…………………………………………………………...119 
Figure  4.2. Sequence list of the 110 single WT1-derived micro-scale peptides…..120 
 9 
Figure  4.3. Proliferative activity of T-cell lines generated against the WT1-
Pepmix…………………………………………………………………………….121 
Figure  4.4. Proliferative activity of the T-cell line 57 generated against the WT1-
Pepmix…………………………………………………………………………….122 
Figure  4.5. Effect of blocking antibodies on the proliferative responses of TCL-
57…………………………………………………………………………………..123 
Figure  4.6. Flow cytometry analysis of CD8, CD4, CD25 and FOXP3 expression in 
the TCL-57………………………………………………………………………...124 
Figure  4.7. The efficiency of the dynabead T cell expander in activating exhausted T 
cells………………………………………………………………………………..126 
Figure  4.8. Screening of TCL-57 specificity using a microscale WT1 peptide set.129 
Figure 4.9. Proliferative activity of TCL-57 against the peptides WT1-60, WT1-61, 
WT1-79, WT1-80 and WT1-96 only……………………………………………...130 
Figure  4.10. Proliferative activity of T cell clones generated from TCL-57……...132 
Figure  4.11. Proliferative activity of TCC-15 and TCC-19 T cell clones………...133 
Figure  4.12. Cytokine productions by the TCL-57 T-cell line……………………136 
Figure  4.13. Cytokine production by the T cell clones TCC-15 and TCC-19…….137 
Figure 4.14. Evaluation of proliferation of TCC-15 against different HLA-matched 
leukemias………………………………………………………………………….139 
Figure 5.1.RT-PCR analysis of MPP11 gene expression in PBMCs from AML, ALL 
patients and normal donors……………………………………………………….. 147 
Figure  5.2. MPP11 Protein sequence…………………………………………….. 151 
Figure  5.3. PR-3 protein sequence……………………………………………….. 151 
Figure  5.4. Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells 
cultured overnight in the absence or in the presence of 30 µM of WT1-187N or each 
MPP11-derived peptide…………………………………………………………...153 
Figure 5.5.Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells 
cultured overnight in the absence or in the presence of 30 µM of each PR-3-derived 
peptide……………………………………………………………………………..154 
Figure  5.6.The binding ability of MPP11-derived peptides to the HLA-A*0201 
molecule as measured by the T2 peptide-binding assay…………………………..155 
Figure  5.7.The binding ability of PR-3 derived peptides to the HLA-A*0201 
molecules as measured by the T2 binding assay………………………………….156 
 10 
Figure  5.8.Non-specific IFN- release of BC-21 CTLs generated by T2 cells against 
the MPP-3, MPP-4 and WT1-126N peptides using an IFN-γ- ELISPOT assay….159 
Figure 5.9.Non-specific IFN- release of BC-32 CTLs generated by T2 cells  against 
the MPP-3, MPP-4 and WT1-126N peptides using an IFN-γ- ELISPOT assay….161 
Figure  5.10.Non-specific lysis by BC-21 CTLs generated by T2 cells against MPP-3 
peptide as tested using a standard chromium release assay……………………….162 
Figure  5.11.Non-specific lysis by BC-21 CTLs generated by T2 cells against MPP-4 
peptide as tested using a standard chromium release assay……………………….163 
Figure 5.12.Non-specific lysis by BC-21 CTLs generated by T2 cells against WT1-
126N peptide as tested using a standard chromium release assay………………...164 
Figure  5.13.Non-specific lysis by BC-32 CTLs generated by T2 cells against MPP-3 
peptide as tested using a standard chromium release assay……………………….165 
Figure  5.14.Non-specific lysis by BC-32 CTLs generated by T2 cells against MPP-4 
peptide as tested using a standard chromium release assay……………………….166 
Figure 5.15.Non-specific lysis by BC-32 CTLs generated by T2 cells against WT1-
126N peptide as tested using a standard chromium release assay………………...167 
Figure  5.16.Specificity of BC-21 CTLs generated by DC2d against the MPP-3 and 
MPP-4 peptides using an IFN-γ- ELISPOT assay………………………………...170 
Figure  5.17. Non-specific IFN- release of BC-32 CTLs generated by DC2d cells 
against the MPP-4 and the MPP-3 peptides using an IFN-γ- ELISPOT assay……171 
Figure  5.18.Non-specific IFN- release of BC-37 CTLs generated by DC2d cells 
against the MPP-4 and the MPP-3 peptides using an IFN-γ- ELISPOT assay……172 
Figure  5.19.Non-specific IFN- release of BC-41 CTLs generated by DC2d cells 
against the MPP-4 and the MPP-3 peptides using an IFN-γ- ELISPOT assay……173 
Figure  5.20.Specificity of BC-21 CTLs generated by DC2d against the MPP-4 
peptides using granzyme B and perforin ELISPOT assay………………………...174 
Figure  5.21.Non-specific granzyme B and perforin release by BC-32 CTLs 
generated by DC2d cells against the MPP-4 peptides using an ELISPOT assay…175 
Figure  5.22.Non-specific granzyme B and perforin release of BC-37 CTLs generated 
by DC2d cells against the MPP-4 peptides using an ELISPOT assay…………….176 
Figure  5.23.Non-specific granzyme B and perforin release of BC-41 CTLs generated 
by DC2d cells against the MPP-4 peptides using an ELISPOT assay…………….177 
 11 
Figure  5.24. Recognition of HLA-A0201+ target cells by BC-21 T cell line generated 
by DC2d against MPP-4 peptide as tested using a standard chromium release 
assay……………………………………………………………………………… 180 
Figure  5.25.Non-specific lysis by BC-32 T cell line generated by DC2d against 
MPP-4 peptide as tested using a standard chromium release assay……………….181 
Figure  5.26.Non-specific lysis by BC-37 T cell line generated by DC2d against 
MPP-4 peptide as tested using a standard chromium release assay……………….182 
Figure  5.27.Non-specific lysis by BC-41 T cell line generated by DC2d against 
MPP-4 peptide as tested using a standard chromium release assay……………….183 
Figure  5.28.Non-specific lysis by BC-21 T cell line generated by DC2d against 
MPP-3 peptide as tested using a standard chromium release assay……………….184 
Figure  5.29. Non-specific lysis by BC-32 T cell line generated by DC2d against 
MPP-3 peptide as tested using a standard chromium release assay……………….185 
Figure  5.30. Non-specific lysis by BC-37 T cell line generated by DC2d against 
MPP-3 peptide as tested using a standard chromium release assay……………….186 
Figure  5.31. Non-specific lysis by BC-41 T cell line generated by DC2d against 
MPP-3 peptide as tested using a standard chromium release assay……………….187 
Figure  5.32.ELISPOT assay for IFN- production by BC-32 T cell lines generated 
by DC2d cells against peptides derived from the PR-3 antigen…………………..190 
Figure  5.33. ELISPOT assay for IFN- production by BC-37 T cell lines generated 
by DC2d cells against peptides derived from the PR-3 antigen…………………..192 
Figure  5.34. ELISPOT assay for IFN- production by BC-41 T cell lines generated 
by DC2d cells against peptides derived from the PR-3 antigen…………………..193 
Figure  5.35. ELISPOT assay for granzyme B production by BC-37 T cell lines 
generated by DC2d cells against the peptides derived from PR-3 antigen………..194 
Figure  5.36. ELISPOT assay for granzyme B production by BC-32 T cell lines 
generated by DC2d cells against the peptides derived from PR-3 antigen………..195 
Figure  5.37. ELISPOT assay for granzyme B production by BC-41 T cell lines 
generated by DC2d cells against the peptides derived from PR-3 
antigen……………………………………………………………………………..196 
Figure  5.38. Non-specific lysis by BC-32 T cell line generated by DC2d against PR-
129 peptide as tested using a standard chromium release 
assay……………………………………………………………………………….199 
 12 
Figure  5.39.Non-specific lysis by BC-32 T cell line generated by DC2d against PR-9 
peptide as tested using a standard chromium release assay……………………….200 
Figure 5.40. Recognition of peptide pulse target cells by BC-32 T cell line generated 
by DC2d against PR-169 peptide as tested using a standard chromium release 
assay……………………………………………………………………………….201 
Figure 5.41.Non-specific lysis by BC-37 T cell lines generated by DC2d against the 
PR-3 peptides as tested using a standard chromium release assay………………..202 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
List of Tables 
Table  1.1.  The French-American-British (FAB) classification of acute leukaemia.23 
Table  1.2.  World health organization (WHO) classification of acute leukaemia….24 
Table 1.3. Tumour antigens expressed in leukaemias …………………………......44 
Table  1.4.  Internet-based prediction algorithms…………………………………...51 
Table  2.1.  Primer sequences……………………………………………………….73 
Table   2.2.  PCR conditions………………………………………………………...73 
Table  3.1.  Clinical features of leukaemia patients with WT1 gene expression……80 
Table  3.2.  Clinical characteristics of patients and donors used in the study……..108 
Table  4.1.  HLA typing of normal donors used to generate anti-WT1 T cell lines.118 
Table  4.2.  Results of the attempts to clone the TCL-57………………………….132 
Table  4.3.  Patients information…………………………………………………...138 
Table  5.1.  Clinical features of leukaemia patients with MPP11 gene expression..148 
Table  5.2.  Peptide Sequences derived from MPP11 and their binding prediction to 
HLA- A*0201 molecule…………………………………………………………..152 
Table  5.3.  Peptide Sequences derived from PR3 and their binding prediction to 
HLA- A*0201   molecule…………………………………………………………152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
List of Abbreviations  
ABL Abelson 
ALL acute lymphocytic leukaemia  
ALP alkaline phosphatase  
AML acute myelogenous  leukaemia 
APC antigen presenting cell 
APL acute promyelocytic leukaemia 
ATCC American Type Culture Collection 
ATRA all-trans retinoic acid  
BCG bacillus Calmette-Guérin  
BCL2 B-cell CLL/lymphoma 2  
BCR breakpoint cluster region 
BIMAS bioinformatics and molecular analysis section  
BSA bovine serum albumin 
CD cluster of differentiation 
CLL chronic lymphocytic leukaemia  
CM complete medium  
CML  chronic myelogenous  leukaemia 
CR complete remission 
CTLA-4 cytotoxic T-lymphocyte antigen 4  
CTLs cytotoxic T Lymphocytes 
DC dendritic cells  
DLI donor lymphocyte infusions  
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNTP deoxyribonucleoside triphosphate 
DTT dithiothreitol  
E.coli Escherichia coli 
E:T ratio effector:target ratio 
EBV Epstine barr virus  
EDTA ethylenediaminetetra-acetic acid 
ELISPOT enzyme-linked immunospot assay 
FAB French-American-British  
FACS fluorescence- activated cell sorter 
FCS fetal calf serum 
FI fluorescence index  
FITC fluorescein isothiocyanate 
FLT3 fms-like tyrosine kinase 3 
FOXP3 forkhead box protein  P3 
GM-CSF granulocyte-macrophage colony stimulating factor 
GvHD graft-versus-host disease 
GvL graft-versus-leukaemia  
HLA human leukocyte antigen 
 15 
HPLC high performance liquid chromatography 
HRP horseradish peroxidase  
HSCs hematopoietic stem cells 
HSCT hematopoietic stem cell transplantation  
IFN-γ interferon-gamma 
IFN-α  interferon-alpha 
IgG immunoglobulin G 
IgVH immunoglobulin heavy chain  
IL-10 interleukein-10  
IL-12 interleukein-12  
IL-2 interleukein-2  
IL-4 interleukein-4  
IL-6 interleukein-6  
Il-7 interleukein-7  
KIR killer cell immunoglobulin-like receptors  
LAAs leukaemia-associated antigens  
LCL lymphoblastoid cell lines  
LPS lipopolysaccaride 
mAbs monoclonal antibodies  
MCA methylchlanthrene 
MDS myelodysplastic syndrome 
mHAs minor histocompatibilty antigens 
MHC major histocompatibility complex 
MICA MHC-class I-related chain A 
MICB MHC-class I-related chain B 
MPN myeloproliferative neoplasm 
MPP11 M-Phase Phosphoprotein 11  
mRNA messenger RNA 
NE neutrophil elastase 
NK natural killer  
NKT natural killer T  
NPM1 nucleophosmin  
N-terminus amino-terminal 
PBMCs peripheral blood mononuclear cells 
PBS  phosphate buffered saline  
pfp pore-forming protein  
Ph Philadelphia  
PHA phytohaemagglutinin 
PML-RARα promyelocytic leukemia-retinoic acid receptor α  
PR-3 Proteinase-3 
PRAME preferentially expressed antigen of melanoma  
RAG recombination-activating gene 
RHAMM receptor for hyaluronic-acid-mediated motility  
RT-PCR reverse transcriptase-polymerase chain reaction 
 16 
SCID severe-combined immunodeficiency  
SEREX serological analysis of recombinant cDNA expression 
libraries  
STAT1 signal transducer and activator of transcription 1 
TAP transporter associated with associated with antigen 
processing 
TCL T cell line 
TCR T-cell receptor 
TGF-β1 transforming growth factor-beta 1  
Th T helper 
TILs tumour-infiltrating lymphocytes 
TMB tetramethylbenzidine 
TNF-α tumour necrosis factor-alpha  
Tregs regulatory T cells 
ULBPs unique long16-binding proteins 
VEGF vascular endothelial growth factor 
WBC white blood cells  
WHO World Health Organization 
WT1 Wilms’ tumour 1 
Y tyrosine  
ZAP-70 zeta-associated protein of 70 kD  
γδ T cells gamma delta T cells 
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1.1.  Leukaemia 
1.1.1. General characteristics and classification 
Leukaemia is a term which refers to several types of cancers that affect the blood-
forming cells in the bone marrow. Formation of blood cells takes place within the 
bone marrow in a process called hematopoiesis where hematopoietic stem cells 
(HSCs) give rise to all mature blood cell types (Figure  1.1.)  In leukaemia, abnormal 
cells grow and multiply without control and hence accumulate in the bone marrow 
and peripheral blood leading to a decrease in normal blood cell production. These 
leukaemia cells are generally white blood cells (WBC) that are unable to carry out 
the functions of the normal cells. Current evidence indicates that HSCs are the target 
for the genetic and epigenetic events that lead to the emergence of leukemic clone 
(Figure 1.2; reviewed in Passegue et al., 2003). On the other hand, studies performed 
on mouse models of certain types of human leukemias showed that restricted 
progenitors or even differentiated cells may also become malignantly transformed 
(reviewed in Passegue et al., 2003) .   
 
Patients with leukaemia share similar symptoms such as fatigue, shortness of breath, 
headaches, swollen spleen, ecchymoses, epistaxis and increased risk of infections 
(Resto, Caballero et al. 2000; Bozzone 2009). These symptoms are due to anaemia, 
neutropenia and thrombocytopenia or from infiltration of malignant cells into tissues 
(Devine and Larson, 1994). The exact cause of leukaemia is not known but it 
commonly arises as result of chromosomal rearrangements. These rearrangements 
consist of translocations, inversions, or deletions in genes that regulate blood cell 
development or homeostasis (Mitelman, 2000). However, several risk factors have 
been identified. These include smoking (Kane et al., 1999), exposure to ionizing 
radiation or to certain chemicals such as benzene (Travis et al., 1994), radiation 
therapy and some types of chemotherapy used to treat other cancers (Smith et al., 
2003). The blood disorder myelodysplastic syndrome and myeloproliferative 
disorder as well as some genetic diseases such as Down's syndrome are also linked 
to an increased risk of leukaemia. Additionally, infection with some viruses such as 
human thymus derived T-cell leukaemia virus (HTLV-1) and Epstein-Barr virus 
(EBV) causes some forms of leukaemia (Mahieux and Gessain, 2003, Lombardi et 
al., 1987).   
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Leukaemia is classified into four major categories depending on the particular cell 
type affected (myeloid or lymphoid) as well as the rate of cell growth (acute or 
chronic). The four major types are: acute lymphoblastic leukaemia (ALL), chronic 
lymphoblastic leukaemia (CLL), acute myelogenous leukaemia (AML) and chronic 
myelogenous leukaemia (CML). Acute leukaemias are characterized by abnormal 
proliferation and expansion of malignantly transformed hematopoietic stem cells 
that accumulate in the marrow and blood and may spread to other organs of the body 
such as lymph nodes, spleen, liver and central nervous system (Devine and Larson, 
1994). Chronic leukaemias, on the other hand, develop more slowly and involve 
more mature white blood cells. 
 
Acute leukaemias are further classified into distinct subtypes using different 
classification schemes. The most frequently used are the French-American-British 
(FAB) classification and the newer World Health Organization (WHO) 
classification. The FAB system classified acute leukaemias according to the 
morphology of the predominant leukemic cell type along with some cytochemical 
findings (Bennett et al., 1985, Bennett et al., 1976). This system has categorized 
ALL into three subtypes (L1-L3) and AML into eight subtypes (M0-M7; Table  1.1). 
The WHO classification scheme contains more prognostic information as it 
integrates not only morphological but also immunological, cytogenetic, molecular 
genetic and clinical features in constructing its classification system (Vardiman et 
al., 2009). Entities of acute leukaemias recognized by WHO classification are shown 
in Table  1.2. 
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Figure  1.1.  The process of hematopoiesis.  
Hematopoietic stem cells (HSCs) can be divided into long-term hematopoietic stem cells (LT-HSCs) 
and short-term hematopoietic stem cells (ST-HSCs). The LT-HSCs are highly self-renewing cells that 
reconstitute the host for its entire life span whereas the ST-HSCs reconstitute the host for a limited 
period. The ST-HSCs give rise to two multipotent progenitors: common myeloid progenitors (CMPs) 
and common lymphoid progenitors (CLPs). The CMPs give rise to granulocyte/macrophage 
progenitors (GMP), which then differentiate into monocytes/macrophages and granulocytes, and to 
megakaryocyte/erythroid progenitors (MEP), which produce megakaryocytes/platelets and 
erythrocytes. The CLPs give rise to T lymphocytes, B lymphocytes and natural killer cells. Both 
CMPs and CLPs give rise to dendritic cells. Figure adapted with modification from (Passegue et al., 
2003). 
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Figure  1.2.  Development of leukaemia from HSCs. 
 Accumulation of the genetic and epigenetic events in HSC compartment eventually lead to the 
emergence of leukemic clone due to impaired differentiation, increased cell survival, increased 
proliferation capacity, increased self renewal and genomic instability. Figure adapted with 
modifications from (Rossi et al., 2008, Passegue et al., 2003).  
 23 
Table  1.1.  The French-American-British (FAB) classification of acute leukaemia, 
 adapted with modification from (Devine and Larson, 1994). 
 Morphologic Features Frequency 
ALL Subtypes 
   
L1 small homogenous cells 
70% in children 
30% in adults 
 
L2 large heterogeneous cells  
27% in children 
65% in adults 
 
L3 large homogenous cells 
3-5% in both 
children and 
adults 
 
AML Subtypes 
   
M0 large granular myeloblasts 2-3%  
M1 large poorly differentiated myeloblasts 20%  
M2 myeloblasts with maturation 25-30%  
M3 hypergranular promyelocytes 8-15%  
M4 myelomonoblasts 20-25%  
M4Eo myelomonoblasts with abnormal eosinophils 5%  
M5 monoblasts, promonocytes or moncytes 10%  
M6 erythroblasts 5%  
M7 large and small megakaryoblasts 1-2%  
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Table  1.2.  World health organization (WHO) classification of acute leukaemia,  
adapted with modification from (Vardiman et al., 2009). 
Acute Myeloid Leukaemia  
 
 acute myeloid leukaemia with recurrent genetic abnormalities such as AML with 
t(8;21), AML with inv(16) or t(16;16),  AML with t(9;11), AML with t(6;9), and acute 
promyelocytic leukaemia (APL) with t(15;17). 
 
 acute myeloid leukaemia with multilineage dysplasia: AML developed following 
myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm 
(MDS/MPN).   
 
 therapy-related AML: AML developed as a complication after cytotoxic and/or 
radiation therapy. 
 
 acute myeloid leukaemia not otherwise specified: AML subtypes that do not fall into 
one of the above groups. 
 
 myeloid leukaemia associated with  Down's syndrome  
 
Acute leukaemias of ambiguous lineage 
 
 acute undifferentiated leukaemia  
 
mixed phenotype acute leukaemia with t(9;22),  or with t(v;11q23)  
 
mixed phenotype acute leukaemia, B/myeloid  
 
mixed phenotype acute leukaemia, T/myeloid  
 
provisional entity natural killer (NK) cell lymphoblastic leukaemia/lymphoma 
 
B lymphoblastic leukaemia/lymphoma 
 
 B lymphoblastic leukaemia/lymphoma, NOS 
 
 B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities such as 
t(9;22), t(v;11q23) and t(12;21). 
 
T lymphoblastic leukemia/lymphoma 
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1.1.2. Incidence and mortality 
Leukaemia is among the ten most commonly occurring cancers in the whole world 
(Ferlay et al., 2010). In Saudi Arabia, around 5.8% of all cancer cases analyzed 
during the year 2005 were leukemias, making it the fifth most common cancer in 
this country (Al-Eid and Arteh, 2009). The overall incidence of leukaemia 
worldwide in year 2008 was 5.1 cases per 100.000 population and the mortality rate 
was 3.6 cases per 100.000 population (Ferlay et al., 2010). Furthermore, it is the 
most frequent type of cancer found in children accounting for more than 30% of all 
childhood cancers (Al-Eid and Arteh, 2009, Bozzone, 2009). The survival rate for 
children with leukaemia is greater than 80%, whereas only 30-40% of adult 
leukaemia patients survive the disease for five years after diagnosis (Faderl et al., 
2003, Jabbour et al., 2005). 
 
The incidence rate of leukaemia varies with race, age, and gender. Caucasians were 
found to have higher incidence rates of leukaemia (12.8 per 100.000) than that found 
in American Indians/Alaskan Natives (7.0 per 100.000) and Asian Americans  (7.3 
per 100.000;Bozzone, 2009). Adult Hispanics had lower incidence rates of 
leukaemia whereas Hispanic children had the greatest incidence when compared to 
other non-Hispanic White and Black individuals (Matasar et al., 2006). The reasons 
for the variation in different populations are not currently understood. Leukaemia 
incidence is higher in males than in females. Approximately 56% of all cases are 
seen in males while females account for only 44% of the cases (Bozzone, 2009).  
Incidence rate by age differs for each type of leukaemia. In general, children up to 
four years old and adults over 70 years have the highest incidence (Faderl et al., 
2003, Hoelzer and Gokbuget, 2000). The most common types of leukaemia found in 
adults are AML and CLL while ALL is the most common form of leukaemia in 
children (Bozzone, 2009, Robak and Wierzbowska, 2009).  
 
1.1.3. Prognosis  
1.1.3.1. Acute myelogenous leukaemia  
Prognostic factors which predict the outcome in AML patients can be divided into 
two categories. The first category contains factors that predict the treatment-related 
death. These factors are related to patient characteristics such as age and general 
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health condition (Dohner et al., 2010). Infants, elderly and patients with hepatic or 
renal dysfunction, and central nervous system involvement have poor outcome 
(Appelbaum et al., 2006, Juliusson et al., 2009, Merck). The other category contains 
factors related to characteristics of the AML clone and predicts resistance to 
treatment (Dohner et al., 2010). The most important factors among this category are 
cytogenetic analysis and molecular genetic findings performed at diagnosis 
(Grimwade, 2001, Grimwade et al., 1998, Byrd et al., 2002). It has been reported 
that 55-78% of adults with AML have cytogenetic abnormalities at diagnosis 
(Marosi et al., 1992, Fischer et al., 1996, Tien et al., 1995, Stasi et al., 1993). Based 
on these cytogenetic findings, AML patients have been categorized into three risk 
groups: favourable, intermediate, or adverse. The prognostic group with favourable 
cytogenetic is defined by the presence of chromosomal translocation between 
chromosome 8 and 21, translocation within chromosome 16 or chromosome 16 
inversion. The intermediate prognostic group includes patients with normal 
karyotypes as well as patients with cytogenetic abnormalities not classified as 
favourable or adverse. Patients with chromosomal abnormalities such as deletion or 
loss of chromosome 5 or 7, chromosome 3 inversion and translocation between 
chromosome 6 and 9 fall into an adverse risk group (Slovak et al., 2000, Byrd et al., 
2002, Grimwade et al., 1998, Dohner et al., 2010). The molecular genetic changes in 
AML blasts that have prognostic significance include mutations in or overexpression 
of specific genes. Mutations in FLT3 gene (Fms-like tyrosine kinase 3), a gene 
encoding for a receptor tyrosine kinase, are one of the most frequent genetic 
alterations occurring in AML. Patients harboring such mutations have a poorer 
outcome (Whitman et al., 2001, Kottaridis et al., 2001). The Wilms’ tumor 1 (WT1) 
is a transcription factor that is overexpressed in most AML patients.  Mutations in 
the gene encoding WT1 represent an adverse prognostic factor (King-Underwood 
and Pritchard-Jones, 1998, Virappane et al., 2008, Renneville et al., 2009). On the 
contrary, some studies have reported a favourable outcome associated with 
mutations in the nucleophosmin gene (NPM1) (Schnittger et al., 2005, Dohner et al., 
2005). Other factors predicting resistance to treatment in AML are the presence of 
transmembrane transporter proteins that actively extrudes certain chemotherapeutic 
compounds from leukemic cells (Musto et al., 1991, Wood et al., 1994),  high WBC 
count at time of diagnosis (Dohner et al., 2010) and having secondary AML 
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(therapy-related AML or AML with a previous history of MDS or MDS/MPN) 
compared with de novo AML (Estey et al., 1997, Estey and Dohner, 2006).  
 
1.1.3.2. Chronic myelogenous leukaemia  
The main prognostic factors for CML patients are the disease phase and presence or 
absence of the Philadelphia (Ph) chromosome. Philadelphia chromosome is a short 
chromosome 22 that results from the reciprocal translocation between chromosome 
9 and 22 and leads to the generation of an abnormally active BCR-ABL1 tyrosine 
kinase (Nowell and Hungerford, 1960, Rowley, 1973). Patients diagnosed in the 
advanced phase and patients who don’t have the Ph chromosome have worse 
outcomes (Hernandez-Boluda and Cervantes, 2009, Ezdinli et al., 1970, 
Theologides, 1972, Gomez et al., 1981). Further prognostic factors that are 
associated with poor prognosis among Ph chromosome-positive patients in the 
chronic phase of the disease include older age, spleen enlargement, very high or 
very low platelet counts, increased blood percentage of blasts and increased number 
of eosinophils  (Jacquillat et al., 1978, Sokal et al., 1984, Tura et al., 1981).  
 
1.1.3.3. Acute lymphoblastic leukaemia  
Acute lymphoblastic leukaemia prognostic factors include age, initial WBC count, 
number of chromosomes and associated structural abnormalities (Mandrell, 2009).  
Survival decreases with increasing age (Chessells et al., 1998). It also decreases with 
high initial WBC count (Hoelzer and Gokbuget, 2000). The cytogenetic-molecular 
abnormalities occur in about 80% of children and 60-70% of adults (Faderl et al., 
1998). In childhood ALL, hyperdiploid karyotype, which refers to leukemic blasts 
with chromosome number ranging from 51-68, is associated with a better clinical 
outcome; whereas having a normal number of chromosomes (diploid) or normal 
chromosome number with abnormal morphology (pseudodiploid) is associated with 
an intermediate outcome. A poor prognosis is associated with hypodiploid ALL 
where chromosomes number is less than 45 (Mandrell, 2009). Adult patients with 
either hyperdiploid (>50, 47-50, with 6q-) or diploid karyotypes have a better 
prognosis (Bloomfield et al., 1989). The translocation t(12;21) is the most frequent 
translocation occurring in childhood ALL cases and it indicates a favourable 
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prognosis (Mandrell, 2009), whereas the t(9;22) translocation is most frequently 
found in adult patients and has been linked with poor prognosis (Faderl et al., 1998).  
 
1.1.3.4. Chronic lymphoblastic leukaemia  
Prognostic factors associated with a shorter survival time in patients with CLL 
include rapid lymphocyte doubling time, expression of B-cell CLL/lymphoma 2 
(BCL2), elevated serum thymidine kinase,  CD38 positivity, absence of mutations in 
genes encoding immunoglobulin heavy chain (IgVH), and expression of the 
intracellular signaling molecule zeta-associated protein of 70 kD (ZAP-70) (Crespo 
et al., 2003, Faderl et al., 2002, Hallek et al., 1999, Hamblin et al., 1999, Jelinek et 
al., 2001, Montserrat et al., 1986). The cytogenetic abnormality associated with 
favourable prognosis is deletion of 13q. An intermediate risk is associated with 11q 
deletions, 12q trisomy and normal karyotypes whereas the worst prognosis is 
associated with 17p deletions (Dohner et al., 2000).  
 
1.1.4. Treatment  
Current treatment modalities for leukaemia include chemotherapy, radiation therapy 
and immunotherapy. The choice of treatment depends on the leukaemia subtype, 
patients’ risk factors, age and general health. Immediate treatment is required in case 
of acute leukemias due to rapid progression of malignant cells which can be fatal 
within weeks or months (Devine and Larson, 1994). Usually treatment of acute 
forms consists of two phases: remission-induction and post-remission therapy. The 
induction therapy is usually a chemotherapy that aims to reduce the number of 
leukemic cells to achieve a complete remission (CR), a condition where patients 
have normal peripheral blood counts and less than 5% of leukemic cells in their 
bone marrow (Devine and Larson, 1994).  The goal of post-remission therapy is to 
prolong the remission period as long as possible by destroying the remaining 
undetectable leukemic cells which could contribute to relapse.  Strategies for post-
induction therapy include treatment with intensive high-dose chemotherapy (termed 
consolidation therapy), or low-dose chemotherapy (termed maintenance therapy) or 
chemoradiotherapy with either allogeneic or autologous stem cell transplantation 
(see section 1.3.1) (Devine and Larson, 1994, Tallman et al., 2005). 
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The outcome of patients with particular leukemic subtypes has been greatly 
improved with the use of specific targeted therapies such as all-trans retinoic acid 
(ATRA), tyrosine kinase inhibitors and monoclonal antibodies. The efficacy of these 
targeted therapies was superior when used in combination with chemotherapy. All-
trans-retinoic acid is used to treat APL patients with the translocation t(15;17) which 
occurs in more than 95% of the APL patients. The t(15;17) translocation results in a 
fusion transcript that gives rise to the promyelocytic leukaemia-retinoic acid 
receptor α (PML-RARα). Treatment with ATRA brings on complete remissions in 
most APL patients by forcing APL-blasts to differentiate into mature granulocytes 
(Huang et al., 1988, Tallman et al., 1997). Selective tyrosine kinase inhibitors that 
block the activity of the deregulated BCR-ABL1 tyrosine kinase are used to treat 
patients with Ph chromosome. Approximately 95% of CML patients and 15-30% of 
adults with ALL have the Ph chromosome (Bernstein, 1988, Faderl et al., 1998). 
Imatinib, the first tyrosine kinase inhibitor used, has become the standard therapy for 
CML patients as it induces high rates of complete responses and improves survival 
(O'Brien et al., 2003, Druker et al., 2001b). Philadelphia-positive ALL patients used 
to have the worst prognosis; however, promising results have been achieved with the 
use of imatinib (de Labarthe et al., 2007, Yanada et al., 2006, Druker et al., 2001a). 
The monoclonal antibodies rituximab (anti-CD20) and alemtuzumab (anti-CD52) 
have been shown to be effective in patients with ALL, B cell-CLL and refractory 
CLL (Byrd et al., 2003, Stilgenbauer and Dohner, 2002, Thomas et al., 2006). A 
number of monoclonal antibodies have been used to treat AML patients. Among 
these, gemtuzumab ozogamicin which consists of an anti-CD33 antibody linked to 
an immunotoxin is being evaluated in randomized trials (Robak and Wierzbowska, 
2009).  Preliminary results indicate that the addition of gemtuzumab ozogamicin to 
standard chemotherapy has improved outcomes in AML patients (Chevallier et al., 
2008).  
 
1.2. Tumour Immunology 
1.2.1. Tumour immune surveillance theory 
The ability of the immune system to survey the body and destroy any transformed 
cells before they appear clinically was first suggested by Paul Ehrlich in the early 
20th century (Ehrlich, 1909). In 1949, Sir Macfarlane Burnet published his theory of 
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acquired immunological tolerance which states that self-reactive lymphocytes are 
deleted in prenatal life during the development of the immune system (Burnet, 
1949). Burnet’s theory was experimentally verified by Medawar and colleagues 
(Billingham et al., 1953) and led to the abandonment of the concept proposed by 
Ehrlich. However, tumour transplantation experiments performed during the 1950s 
in genetically identical mice strongly suggested the existence of antigens associated 
with tumour cells enabling them to be recognized and eliminated by the immune 
system (Baldwin, 1955, Foley, 1953, Prehn and Main, 1957). In these experiments, 
mice could reject transplanted autologous tumour when challenged with a second 
injection of the same tumour cells. Consequently, Burnet and Lewis Thomas 
adopted Ehrlich’s early idea and proposed that major function of the immune system 
is to protect from neoplastic disease (Burnet, 1970, Burnet, 1957, Thomas, 1959). 
The term immunological surveillance was coined by Burnet who assumed that 
lymphocytes play the key role in identifying and eliminating malignant cells 
(Burnet, 1967, Burnet, 1970, Burnet, 1964).  
 
The validity of the theory was tested for the first time when the nude strain of mice 
became available to researchers. These mice lack a functional thymus making them 
severely immunocompromised. According to the immune surveillance theory, 
immunocompromised individuals will be more susceptible to develop tumours than 
those with a competent immune system. Nevertheless, early experiments, carried out 
in 1970s, showed that there was no increase in the incidence of either spontaneously 
arising or chemically induced tumours among the athymic nude mice compared with 
their normal wild-type counterparts (Rygaard and Povlsen, 1974, Stutman, 1974, 
Burstein and Law, 1971). In contrast, several studies confirmed that the immune 
surveillance mechanisms were able to eliminate the growth of tumour cells induced 
by oncogenic viruses in mice (Fefer et al., 1968, Fefer et al., 1967, Klein, 1976). 
These findings suggested that the immune surveillance in mice targeted 
transforming viruses but not tumours themselves. Shortly afterwards, the hypothesis 
was retrieved when it became clear that nude mice were not completely 
immunocompromised, since detectable populations of functional αβ T cells were 
found in this strain of mice (Ikehara et al., 1984, Maleckar and Sherman, 1987). In 
addition to αβ T cells, other components of the immune system, able to develop 
totally outside the thymus, have been discovered and found to be present in large 
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numbers in nude mice such as natural killer (NK) cells and gamma delta (γδ) T cells 
(Hayday, 2000). Repetition of the experiments carried out by Stutman (1974) using 
mice with different genetic backgrounds revealed that athymic nude mice did form 
more tumours than the immunocompetent controls after treatment with different 
doses of the chemical carcinogen, methylcholanthrene (MCA; (Engel et al., 1996). 
Moreover, it has been found that tumour formation induced by MCA was greater in 
immunodeficient severe-combined immunodeficiency (SCID) mice than in their 
normal counterparts (Engel et al., 1997).  
Stronger evidence for the existence of immune surveillance was gathered using 
genetically altered strains of mice and monoclonal antibodies (mAbs) specific for 
various components of the immune system. Interferon-gamma (IFN-γ) is a 
pleiotropic cytokine secreted by activated NK cells and activated thymus-derived 
(T) cells (Boehm et al., 1997). Several studies have shown that this cytokine plays a 
critical role in protecting the host against the growth of transplanted tumours, as well 
as the formation of chemically induced and spontaneously arising tumours (Dighe et 
al., 1994, Kaplan et al., 1998, Shankaran et al., 2001). One of these studies  showed 
that transplanted murine immunogenic fibrosarcoma cell line (Meth A) grew faster 
in mice treated with anti-IFN-γ than their control counterparts (Dighe et al., 1994). 
These tumour cells were made insensitive to IFN-γ by the insertion of a genetically 
engineered truncated IFN-γ receptor -subunit. The insensitive tumour cells 
displayed enhanced tumorgenicity and were resistant to LPS induced tumour 
rejection, as compared with control tumours when transplanted into naïve syngeneic 
hosts (Dighe et al., 1994). Another study showed that IFN-γ-deficient mice 
developed more spontaneous lymphomas and lung tumours compared with 
genetically matched wild type controls (Street et al., 2002). Mice lacking either IFN-
γ receptor  chain or signal transducer and activator of transcription 1 (STAT1), the  
transcription factor necessary for mediating interferon receptor signaling, were 
found to be more susceptible to MCA-induced tumours than their wild-type controls 
(Kaplan et al., 1998). Additionally, IFN-γ-insensitive mice lacking the genes 
encoding for the tumor-suppressor protein p53 developed tumours more rapidly than 
wild-type mice (Kaplan et al., 1998). These mice also developed a wider spectrum 
of tumours compared with mice lacking only p53 (Kaplan et al., 1998).  In vivo 
depletion studies showed that adoptively transferred lymphocytes were not able to 
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induce regression of established tumours in mice depleted of IFN-γ (Barth et al., 
1991, Tuttle et al., 1993).  
 
Perforin is another key component that has been shown to play an important role in 
tumour surveillance. It is a pore-forming protein (pfp) stored in cytoplasmic 
granules of cytotoxic lymphocytes (CD8+ T cells and NK cells). It mediates the 
main effector mechanism used by cytotoxic lymphocytes to induce apoptosis in 
target cells (Russell and Ley, 2002). Compared with perforin-competent controls, 
mice lacking perforin were more susceptible to tumour formation induced by MCA 
(Smyth et al., 2000a, van den Broek et al., 1996, Street et al., 2001). Perforin-
deficient mice also had an increased incidence of spontaneously disseminated 
lymphomas (Smyth et al., 2000b, Street et al., 2002, Street et al., 2004). When 
syngeneic tumour cell lines were injected into perforin-deficient mice and their 
normal counterparts, tumour cells were eliminated 10-100-fold more efficiently by 
perforin-sufficient mice (van den Broek et al., 1996). 
 
A study carried out using mice lacking recombination activating gene 1 and 2 
proteins (RAG1 and RAG2) strongly supported the concept of lymphocytes 
protecting the host against tumour growth (Shankaran et al., 2001). RAG1 and 
RAG2 proteins are responsible for the rearrangement of VDJ DNA segments that 
leads to the formation of antibody molecules as well as T-cell receptors. Mice 
deficient in either of these genes fail to rearrange lymphocyte antigen receptors and 
thus completely lack natural killer T (NKT),  T and B lymphocytes (Shinkai et al., 
1992). Mice lacking the gene RAG-2 had a higher incidence of spontaneous and 
chemically induced tumours than matched wild-type controls. Interestingly, mice 
lacking both RAG2 and STAT1 genes developed spontaneous breast tumours that 
were not observed in wild type or RAG2-deficint mice (Shankaran et al., 2001). The 
role of NK cells in protecting against tumour formation and metastasis was 
highlighted in several studies. These studies showed that NK cell-deficient mice 
have an increased incidence of spontaneous tumours and cancer metastasis (Haliotis 
et al., 1985, Gorelik et al., 1982, Talmadge et al., 1980, Smyth et al., 2000a). In 
addition, mice that were depleted of both NK and NKT cells by the anti-NK1.1 
monoclonal antibody were two to three times more susceptible to MCA-induced 
tumour formation than control mice (Smyth et al., 2001).  
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In humans, the concept of tumour immune surveillance has gained more supporting 
evidence through several clinical observations. One of the observations was the 
increased risk of developing malignancies in immunosuppressed transplant 
recipients. Some follow-up studies of these patients have shown a higher incidence 
of virally induced tumours compared with the normal population whereas the 
incidence of non-virally induced tumours was not increased (Penn, 1988, Sheil et al., 
1997). Nevertheless, other studies have also shown that the incidence of developing 
a variety of non-virally induced cancers is higher in immunosuppressed patients than 
in the general population (Birkeland et al., 1995, Pham et al., 1995, Sheil, 1986, 
Penn, 1996, Vajdic et al., 2006). Another observation was the existence of a 
significant relationship between the presence, location, and activation state of 
lymphocytes in a tumour (tumour-infiltrating lymphocytes; TILs) and improved 
prognosis. Such a relationship was first observed in melanoma patients in whom the 
presence of TILs in the vertical growth phase of primary cutaneous melanomas was 
correlated with survival (Clemente et al., 1996, Clark et al., 1989, Mihm et al., 
1996). The presence TILs was also correlated with improved outcome in patients 
with broad range of cancers including ovarian, breast, colorectal, gastric, 
oesophageal and squamous cell lung carcinoma (Naito et al., 1998, Schumacher et 
al., 2001, Yoshimoto et al., 1993, Zhang et al., 2003, Ishigami et al., 2000, Villegas 
et al., 2002). Finally, spontaneous regression of cancers has been occasionally seen 
in patients with melanoma, neuroblastoma and renal cancer indicating that the 
immune system may develop efficient anti-tumour immune responses (Bodurtha et 
al., 1976, Menzies and McCarthy, 1997, Everson and Cole, 1966).  
 
1.2.2. Cancer immunoediting theory 
Despite the evidence in support of immunosurveillance, cancers continue to occur in 
immunocompetent hosts, which suggests failure of the immune system to prevent 
tumour growth and metastasis even in immunocompetent environments (Dunn et al., 
2002). As a result, an updated immunosurveillance hypothesis called cancer 
immunoediting has been proposed by Schreiber and his colleagues (Dunn et al., 
2002). This hypothesis proposes that the immune system not only controls the 
growth of tumour cells but also indirectly shapes the neoplastic disease. According 
to the hypothesis, the process of immunoediting consists of three stages: elimination, 
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equilibrium and escape. The first stage represents the original concept of the 
immunosurveillance theory. It starts when tissues surrounding the growing 
transformed cells induce inflammatory signals that lead to recruitment of innate 
immune cells including NKT, NK, γδ T cells, macrophages and dendritic cells 
(DCs). The infiltrating lymphocytes (NKT, NK and γδ T cells) recognize the 
transformed cells and release IFN-γ which induces tumour cell death. Chemokines, 
released from tumour cells themselves as well as from surrounding tissues, also 
promote death of the tumour cell by preventing angiogenesis. Immature DCs ingest 
tumour cell debris and home to draining lymph nodes where they activate tumour-
specific naïve T cells. The activated tumour-specific T cells migrate to the tumor site 
and destroy antigen-bearing tumour cells.  In the equilibrium stage, lymphocytes and 
IFN-γ exert a selective pressure on tumour cell variants that have survived the 
elimination process leading to selection of tumour cells with reduced 
immunogenicity. This process is perhaps the longest of the three stages and may 
occur over a period of many years in humans. Tumour cell variants that have 
acquired insensitivity to immunological detection enter the escape phase, where they 
expand in an uncontrolled manner resulting in clinically detectable malignant 
disease (Dunn et al., 2002).  
 
1.2.3. Immune recognition of tumour cells  
The immune system is a network of organs and tissues as well as humoral factors 
that work together to eradicate any invading pathogens and malignant cells. It has 
the ability to discriminate between self and non-self. It is composed of two main 
arms, innate and adaptive arms. Innate immunity is the first line of defence, whereas 
adaptive immunity is involved in the late phase of host defence.  Innate immunity 
includes physical barriers such as skin, soluble factors such as complement and 
cellular components. The cellular components of innate immunity are neutrophils, 
monocytes, macrophages, NK, NKT, and γδ T cells. Receptors for these cells are 
fixed in the genome, requiring no rearrangements and recognize conserved 
molecular patterns that are specific to pathogens. Adaptive immunity mediates 
highly specific immune responses and displays immunologic memory, therefore 
subsequent exposure to the same antigen leads to faster and more vigorous 
responses. It includes B and T lymphocytes. These cells have receptors with great 
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variation, able to recognize an unlimited number of highly specific pathogens 
through rearrangements of receptor gene segments (Melief, 1992).  Both arms of the 
immune system play an essential role in the elimination of cancer cells. The major 
effector cells of innate immunity are NK cells and of adaptive immunity are T cells 
(Caligiuri et al., 2004).  
 
1.2.3.1. Natural killer cells  
Natural killer cells are characterized by their potent cytolytic activity against tumor 
and virally infected cells. Unlike T lymphocytes, NK cells do not possess clonally 
distributed antigen receptors. However, they share certain functions with T cells 
such as cytolytic effector mechanisms and cytokine production. In this, NK cells use 
perforin and granzymes to achieve the cytolytic activity against target cells and 
secrete cytokines such as IFN-γ, tumour necrosis factor–alpha (TNF-α) and 
granulocyte macrophage-colony stimulating factor (GM-CSF) that mediate 
inflammatory responses (Biron et al., 1999, Moretta, 2005).  
 
NK cells recognize their targets through an array of surface receptors that have 
either inhibitory or activating function (Moretta et al., 1996, Long and Wagtmann, 
1997, Lanier, 1998, Moretta et al., 2000). The engagement of NK inhibitory 
receptors to their ligands on target cells generates a signal that inhibits NK cell lysis-
a mechanism known as missing self recognition, whereas engagement of activating 
NK receptors to their ligands delivers a signal that lead to target lysis-a mechanism 
known as induced self recognition. The ligands for the inhibitory receptors are major 
histocompatibilty complex (MHC) class I molecules and these are of two main 
types; the killer cell immunoglobulin-like receptors (KIR) which specifically 
recognize human leukocyte antigen (HLA)-A, -B, and –C alleles, and 
CD94/NKG2A which identifies the polymorphic HLA-E molecules (Braud et al., 
1998, Moretta et al., 1996, Vilches and Parham, 2002). Loss or down regulation of 
MHC class I molecules is frequently seen in tumours (Marincola et al., 2000). 
Ligands that have been identified to be recognized by activating receptors are stress-
inducible molecules such as MHC-class I-related chain A/B (MICA/B), and the 
unique long 16-binding proteins (ULBPs). These molecules are highly expressed by 
cells suffering from stress resulting from either viral infections or neoplastic 
transformation and are recognized by the activating receptor, NKG2D (Bauer et al., 
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1999, Cosman et al., 2001).  Therefore, tumour cells that have lost or express low 
levels of class I MHC molecules and tumour cells that have up regulated ligands for 
activating receptors, even in the presence of normal levels of MHC class I 
molecules, will be targeted by NK cells. Besides their potent anti-tumour cytolytic 
activity, activated NK cells facilitate adaptive anti-tumour immune responses by 
stimulating the maturation of DCs (Degli-Esposti and Smyth, 2005). 
 
1.2.3.2. T lymphocytes or T cells 
T lymphocytes are considered to be the most efficient cells in mediating anti-tumour 
immune responses. They are characterized by the presence of a unique receptor on 
their cell surface called T-cell receptor (TCR) which is a heterodimer consisting of 
either αβ or γδ chains. The majority of T cells express αβ TCR chains and either 
CD4 or CD8 molecules.  CD4+ T lymphocytes generally function as cytokine-
secreting T helper cells (Th), while CD8+ T lymphocytes generally function as 
cytotoxic T cells (CTLs) (Delves and Roitt, 2000). Besides helper T cells, there are 
also CD4+ regulatory T cells (Tregs) which are able to control effector responses 
(Thornton and Shevach, 1998, Takahashi et al., 1998).  
 
Unlike B cells which recognize free antigens, the TCR recognizes peptide antigens 
that are displayed on the cell surface in combination with MHC molecules. MHC 
molecules are highly polymorphic cell surface glycoproteins encoded by genes 
within the major histocompatibility complex. Class I molecules are made up of a 
heavy α chain and a non-covalently associated light chain, β2-microglobulin. Class 
II molecules are made up of α and β chains. The presentation of protein antigens to 
T cells in the context of MHC molecules involves two distinct intracellular 
processing pathways. The endogenous pathway generally presents peptides derived 
from cytoplasmic proteins in the context of class I MHC molecules to CD8+ T cells, 
whereas the exogenous pathway mainly presents peptides derived from processing 
of engulfed extracellular proteins in the context of class II MHC molecules to CD4+ 
T cells (Doyle and Strominger, 1987, Norment et al., 1988). Antigen processing and 
presentation by the MHC class I pathway involves three major steps: processing of 
endogenous proteins by the proteasome, transporting the generated peptides by 
transporter associated with antigen processing (TAP) and peptide binding to nascent 
MHC molecules (Figure  1.3). All nucleated cells express MHC class I molecules on 
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their surfaces. Therefore, malignantly transformed cells presenting epitopes derived 
from tumour antigens could be recognized and eliminated by effector CD8+ T cells. 
In contrast class II molecules are only expressed by professional antigen presenting 
cells i.e. DCs, B cells and macrophages. For optimal activation of CD8+ T cells, the 
signal generated by the interaction between the peptide-MHC complex and the T-
cell receptor is not sufficient. A second signal designated as co-stimulation is 
required. It is provided by the interaction between CD28 on the T cell surface and 
members of the B7 family (CD80/B7-1, CD86/B7-2) located on the surface of 
antigen presenting cells (Lenschow et al., 1996). If a naïve T cell - i.e., a cell that 
has not yet encountered a specific antigen - recognizes an antigen in the presence of 
adequate costimulatory signals, cells will be primed and activated. Activated T cells 
proliferate by clonal expansion and differentiate into both effector and memory cells 
(van Stipdonk et al., 2001). On the other hand, if T cell stimulation occurs in the 
absence of appropriate costimulatory signals, this will lead to T cell 
unresponsiveness (anergy) or apoptosis and death -a mechanism which gives rise to 
the induction of peripheral T cell tolerance (Lenschow et al., 1996). Additionally, T 
cells express inhibitory receptors, such as cytotoxic T lymphocyte-4 (CTLA-
4/CD152) and programmed death-1 (PD-1) that negatively regulate T cell function 
(Walunas et al., 1994, Carreno and Collins, 2002).  
 
CD8+ T cells induce cytolysis of their target cells through at least two different 
mechanisms:  the granule exocytosis pathway which is mediated by perforin and 
granzymes or Fas-mediated pathway by upregulation of membrane-bound Fas 
ligand (FasL/CD95L) which interacts with the Fas receptor (CD95) on target cells. 
CD8+ T cells also produce a number of cytokines including TNF-α and IFN-γ 
(Delves and Roitt, 2000). 
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Figure  1.3.  Major histocompatibility complex class I presentation pathway.  
Three major steps contribute to this pathway.  The first step is the degradation of endogenous proteins 
into smaller fragments by the proteasome which is a large multienzyme complex in the cytosol. The 
resulting peptides are translocated into the lumen of endoplasmic reticulum by TAP where they bind 
to nascent MHC class I molecules and transported through Golgi apparatus to the cell surface. Figure 
adapted with modifications from (Heath et al., 2004) 
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1.2.4. Mechanisms of tumour escape 
Surviving tumours developed different mechanisms to escape recognition by the 
host immune system. Some of these mechanisms involve alterations in the 
expression of effector molecules crucial for T cell recognition. These mechanisms 
include: alterations in the expression of HLA class I and class II molecules, 
mutations of β2-microglobulin, downregulation of TAP, loss of tumour antigens, 
decreasing the expression of the co-stimulatory molecules such as B7 molecules, 
and enhancing the expression of co-inhibitory molecules such as B7-H1 molecule 
(Dorfman et al., 1997, Marsman et al., 2005, Jager et al., 2001, Marincola et al., 
2000, Dong et al., 2002, Dermime et al., 1997, Bicknell et al., 1996, Vitale et al., 
1998, Ghebeh et al., 2008). Impaired binding of perforin to the tumour cell 
membrane is a mechanism used by tumour cells to resist killing by cytolytic cells 
(Lehmann et al., 2000).  Down regulation of Fas and mutations in Fas as well as in 
TNF-related apoptosis-inducing ligand receptors have also been reported in some 
tumours (Real et al., 2001, Shin et al., 2001). Tumours can kill infiltrating immune 
cells by expressing FasL without damaging themselves (Whiteside, 2002). In 
addition, tumors and a subset of DCs constitutively express the enzyme indoleamine 
2,3-dioxygenase which induces tryptophan deficiency in the tumour 
microenvironment and sensitizes activated T cells to apoptosis (Uyttenhove et al., 
2003, Munn et al., 2004). 
    
Tumours can also evade immune recognition by secreting a number of 
immunosuppressive mediators such as IL-6, IL-10, macrophage-colony stimulating 
factor (M-CSF) vascular endothelial growth factor (VEGF), transforming growth 
factor beta (TGF-β), soluble FasL and soluble MICA. These suppressive mediators 
promote tumour growth by inhibiting anti-tumour immune responses and/or 
recruiting immune cells with regulatory functions favourable for the tumour. IL-10, 
TGF-β and VEGF suppress DCs differentiation and maturation (Gabrilovich et al., 
1998, Kim et al., 2006). Immature DCs in turn induce either T-cell unresponsiveness 
or Tregs, a suppressor subset of CD4+ T cells that have been shown to inhibit anti-
tumour specific T cells (Almand et al., 2001, Jonuleit et al., 2000, Dhodapkar et al., 
2001, Hawiger et al., 2001, Zou, 2005, Lehe et al., 2008). IL-6 and M-CSF secreted 
by tumour cells and tumour environmental macrophages switch DC differentiation 
towards macrophage differentiation (Menetrier-Caux et al., 1998). Soluble FasL and 
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soluble MICA inhibit anti-tumour activity of both cytotoxic T cells and NK cells 
(Doubrovina et al., 2003, Webb et al., 2002). Besides the induction of immature 
DCs and Tregs, tumour mediators promote the recruitment  of myeloid suppressor 
cells which inhibit priming of naïve T cells (Bronte et al., 2001).   
 
1.3.  Immunotherapy for Leukaemia 
1.3.1. Allogeneic hematopoietic stem cell transplantation 
Allogeneic hematopoietic stem cells transplantation (HSCT) is an efficient therapy 
for a variety of haematological malignancies, including leukemias. It was developed 
with the aim of restoring the hematopoietic stem cell compartment in patients 
following a myeloablative conditioning regimen i.e. high dose chemotherapy and/or 
total body irradiation. It is now known that donor immune cells transplanted with the 
stem cell allograft, or arising from it, recognize and eliminate residual leukaemia 
cells in the recipient - an immunological effect known as graft-versus-leukaemia 
(GvL). The donor immune cells may also attack normal host tissues such as skin, 
gastrointestinal tract and liver giving rise to a graft-versus-host disease (GvHD) 
complication. Another possible consequence of the HSCT is graft rejection, 
occurring when recipient immune cells attack and destroy the transplanted graft, 
leading to a host-versus-graft (HvG) reaction (Appelbaum, 2001).  
 
The existence of a GvL effect has been supported by studies showing that relapse 
rates following allogeneic transplantation were lower in patients who developed 
GvHD compared with those who did not (Weiden et al., 1979, Weiden et al., 1981). 
The relapse rates were also lower in patients who received allogeneic transplants 
compared with those who received syngeneic transplants i.e. from their identical 
twin (Gale et al., 1994, Fefer et al., 1987). However, the most important evidence 
for the existence of the GvL effect came form the astonishing success of donor 
lymphocyte infusions (DLI). In DLI, patients relapsing following allogeneic HSCT 
are treated with infusions of lymphocytes obtained from the peripheral blood of the 
original stem cell donor. Using this immunotherapeutic approach, complete 
remissions could be re-induced in most relapsed CML and some AML patients 
(Kolb et al., 1995, Kolb et al., 1990). The reactions occurring during the GvL effect 
are mainly mediated by donor CD4+ and CD8+ T lymphocytes. Evidence for this 
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came from increased relapsed rates in patients who received T cell-depleted grafts in 
an attempt to prevent GvHD activity (Apperley et al., 1986, Hale et al., 1988). 
Besides T cells, NK cells have also been shown to contribute to the GvL response in 
cases of mismatched hematopoietic transplants (Ruggeri et al., 2002, Giebel et al., 
2003). The GvL effect could be separated form GvHD in some patients because 
relapsed rates were reduced in a subset of patients who received allogeneic HSCT 
but did not develop GvHD and remissions could be achieved after DLI without 
developing GvHD (Giralt and Kolb, 1996, Kolb and Holler, 1997, Horowitz et al., 
1990, Collins et al., 1997). These findings led to efforts to develop T-cell based 
therapy for leukaemia patients that aim to augment the GvL effect without causing 
GvHD.  
 
1.3.2. Potential target antigens of the GvL effect   
Targets recognized by alloreactive donor T cells during a GvL response include 
antigenic peptides that are either derived from polymorphic minor histocompatibility 
antigens (mHAgs) or derived from antigens that are associated with the malignant 
phenotype, known as leukaemia antigens (Appelbaum, 2001). The mHAgs are 
immunogenic peptides derived from intracellular proteins that differ between the 
donor and the recipient as a result of genomic polymorphisms. These antigens have 
been shown to be targets of alloreactive T cells in both GvL and GvHD reactions 
(Warren et al., 1998, Goulmy et al., 1983, Goulmy et al., 1996). Some of the 
identified mHAgs, including HA-1 and HA-2, are derived from proteins expressed 
only in hematopoietic cells, whereas other mHAgs are broadly expressed in all or 
most tissues (den Haan et al., 1998, den Haan et al., 1995, de Bueger et al., 1992). 
Several studies have demonstrated that T cells specific for the hematopoietic 
restricted mHAgs, but not the broadly expressed antigens represent ideal 
immunotherapeutic targets that would enhance the GvL activity with minimal 
GvHD (Akatsuka et al., 2003, Mutis et al., 1999a, Bonnet et al., 1999, Mutis et al., 
1999b, Dickinson et al., 2002, Stumpf et al., 2009, Ofran et al., 2010).  
 
Leukaemia antigens fall into two major categories: leukaemia-specific antigens and 
leukaemia-associated antigens (LAAs). Examples for each category are presented in 
Table 1.3 (Borrello and Sotomayor, 2002). The specific antigens are those resulting 
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from mutations or chromosomal translocations as well as antigens that are derived 
from viral proteins. Examples of this group include BCR-ABL found in CML and 
PML-RARα found in APL patients. The BCR-ABL is a chimeric protein that results 
from a t(9;22) translocation found in 95% of CML patients. Chromosomal 
translocation is a common finding in leukaemia that results in the generation of 
fusion genes coding for chimeric proteins. The joining region of the chimeric 
proteins generates unique epitopes that are tumour specific and therefore represent 
attractive targets for immunotherapy. Several CTL epitopes derived from the joining 
region of the BCR-ABL have been identified. These epitopes were found to bind to 
several HLA alleles, including HLA-A2, -A3, A11 and -B8 molecules and to elicit 
specific CTL responses in vitro (Yotnda et al., 1998, Clark et al., 2001, Bocchia et 
al., 1996, Osman et al., 1999a). The associated antigens are normal proteins that are 
aberrantly expressed or over-expressed in leukemic cells compared with normal 
cells.  This category can be subdivided into two groups according to their expression 
patterns in normal and malignant tissues. These groups are overexpressed antigens 
and cancer-germ line antigens. Overexpressed antigens are normal proteins that are 
expressed in normal tissues at low levels and expressed constitutively in tumour 
cells. Since these proteins are self normal proteins, immunological tolerance may 
exist and prevent their recognition by T cells. However, the overexpression of these 
normal proteins can break the immunological tolerance towards these antigens 
(Dermime et al., 2002). The WT1 and proteinase-3 (PR-3) are examples of 
overexpressed leukaemia antigens that have been shown to be recognized by 
autologous CTLs. M-Phase Phosphoprotein 11 (MPP11) and the receptor for 
hyaluronic-acid-mediated motility (RHAMM/CD168) are overexpressed antigens 
that were identified as potential LAAs by serological screening of myeloid 
leukaemia patients (Greiner et al., 2003, Greiner et al., 2002). In addition, an HLA-
A0201-restricted CTL epitope derived from RHAMM has been also identified 
(Greiner et al., 2005). Cancer-germ line antigens result from reactivation of genes 
which are normally silent in normal cells and become activated in different tumours. 
Their expression in normal tissues is restricted to placental trophoblasts and 
testicular germ cells. They represent attractive targets for specific immunotherapy 
since germ line cells lack MHC class I and class II molecules, epitopes of these 
antigens will not be expressed by these tissues (Borrello and Sotomayor, 2002). 
Preferentially expressed antigen of melanoma (PRAME) is a cancer-testis antigen 
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that has been shown to elicit humoral immune response in 47% of AML patients 
(Greiner et al., 2000). 
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Table  1.3.  Tumour antigens expressed in leukaemias, adapted with modification 
from (Borrello and Sotomayor, 2002). 
Category of Antigen Leukaemia type  
 
Specific-leukaemia antigens  
 
 
 Fusion gene products 
 
 
  -BCR-ABL Chronic myelogenous leukaemia 
 
  -DEK-CAN Acute myelogenous leukaemia 
 
  -AML/ETO Acute myelogenous leukaemia 
 
  -PML-RARα Acute Promyelocytic leukaemia  
 
 Viral-Associated Antigens  
 
  - HTLV-1 Adult T-cell leukaemia 
 
Associated-leukaemia antigens  
 
 
 Cancer-germ line antigens 
 
 
  -PRAME Acute myelogenous leukaemia 
 
 Overexpressed Antigens 
 
 
  - Proteinase-3  Acute myelogenous leukaemia 
and  
Chronic myelogenous leukaemia  
 
  - WT-1 Acute myelogenous leukaemia, 
Chronic myelogenous leukaemia 
and Acute lymphoblastic 
leukaemia 
 
  -MPP11 Acute myelogenous leukaemia 
and  
Chronic myelogenous leukaemia 
 
  -RHAMM Acute myelogenous leukaemia 
and  
Chronic myelogenous leukaemia 
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1.4. Candidate antigens for leukaemia immunotherapy  
1.4.1. Wilms’ tumor 1 (WT1) 
The WT1 gene encodes a zinc finger transcription factor that is normally expressed 
in tissues of mesodermal origin during embryogensis, including the kidney, gonads, 
heart, mesothelium and spleen. It has been shown to be responsible for childhood 
renal cancer (Call et al., 1990). It is overexpressed in acute myelogenous and 
lymphoblastic leukaemia, chronic myelogenous leukaemia and also in various types 
of solid tumours including lung and breast cancer (Oji et al., 1999, Bergmann et al., 
1997, Menssen et al., 1995, Loeb et al., 2001, Oji et al., 2002). The higher 
expression levels of WT1 in leukaemia patients have been found to be associated 
with poor prognosis (Bergmann et al., 1997, Inoue et al., 1997, Boublikova et al., 
2006). Therefore, WT1 is important as a prognostic marker as well as in the 
detection and monitoring of minimal residual disease in leukaemia and 
myelodysplastic syndrome (Inoue et al., 1994). WT1-derived HLA class I peptide 
epitopes with various HLA restrictions including HLA-A201, -A24, -A206 and -
A01 have been identified (Azuma et al., 2002, Bellantuono et al., 2002, Oka et al., 
2000, Li et al., 2008, Asemissen et al., 2006). Class II epitopes derived from WT1 
have also been identified (Kobayashi et al., 2006, Fujiki et al., 2007, Knights et al., 
2002, May et al., 2007). Furthermore, natural specific humoral immune responses to 
the WT1 antigen have been reported in patients with haematological malignancies 
(Elisseeva et al., 2002, Wu et al., 2005). For these reasons, WT1 has been 
considered as an attractive target for cancer immunotherapy.  
 
1.4.2. M-Phase Phosphoprotein 11 (MPP11)  
MPP11 was discovered by Matsumoto-Taniura et al (1996) using MPM2 
monoclonal antibody, which recognizes several important mitosis phosphoproteins 
found to be present during mitosis (Davis et al., 1983). Recently, it has been 
reported that MPP11 function as a ribosome-associated molecular chaperon 
(Hundley et al., 2005, Otto et al., 2005). MPP11 maps to the critical region of 
chromosome 7q22-31.1, which is a critical common position in human cancer 
(Resto et al., 2000, Zenklusen and Conti, 1996). MPP11 has been detected by 
serological analysis of cDNA expression libraries (SEREX) in solid tumours and 
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haematological malignancies including melanoma, breast, renal cell carcinoma, 
small cell lung cancer and leukaemia (Gure et al., 2000, Greiner et al., 2003). The 
humoral immune responses to MPP11 have been detected in patients with AML and 
CML, but not in healthy donors or patient with autoimmune diseases (Greiner et al., 
2003). Moreover, this protein has been found to be expressed extensively in AML, 
and CML patients as compared to normal controls (Schmitt et al., 2006, Greiner et 
al., 2003, Greiner et al., 2004).  Immuno-histochemical staining of primary tumour 
sections and Western blot analysis of head and neck squamus cell cancer (HNSC 
cell lines revealed tumour-specific overexpression of MPP11 protein (Resto et al., 
2000). Additionally, fluorescence in situ hybridization analysis carried out on 
HNSCC cell lines showed an increase in  the copy number of MPP11 along with 
chromosome 7 suggesting an oncogenic role for MPP11 (Resto et al., 2000). The 
specific overexpression of MPP11 by tumour tissues (with the exception of very low 
expression in testis, kidney, and lung) makes it an attractive target for cancer 
immunotherapy (Greiner et al., 2004).  
    
1.4.3. Proteinase-3 (PR-3) 
PR-3 is a serine protease enzyme that is induced at the promylocytic stage of 
differentiation and stored in azurophilic granules of promyelocytes (van der Woude 
et al., 1985). PR-3 is known to be a target of anti-neutrophil cytoplasmic antibody 
(Hernandez-Caballero et al.) in patients who have the autoimmune disease 
Wegener's granulomatosis (Williams et al., 1994). Furthermore, proliferative T cell 
responses against purified PR-3 protein has been documented in these patients 
(Ballieux et al., 1995). PR-3 belongs to the group of primary granule proteins, which 
are aberrantly expressed in myeloid leukaemias. It is highly overexpressed by cells 
from CML patients and differentially expressed by some AML cells (Muller-Berat 
et al., 1994, Yong et al., 2008). Importantly, it may be involved in the process of 
leukemogenesis because antisense oligodeoxynucleotides against PR-3 were able to 
inhibit cell proliferation and induce differentiation in an HL-60 promyelocytic 
leukaemia cell line (Bories et al., 1989). Therefore, PR-3 is of great interest as a 
source of leukaemia antigens for immunotherapy (Barrett and Rezvani, 2006, 
Fujiwara et al., 2005). 
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An antigenic HLA-A*0201-restricted epitope, named PR1 (VLQELNVTV), derived 
from the PR-3 antigen has been identified (Molldrem et al., 1996) and is being used 
in clinical trials for leukaemia patients (Heslop et al., 2003, Clinical Trials.gov, 
2006, Clinical Trials.gov, 2009, Qazilbash et al., 2004). This epitope was identified 
by Molldrem et al. (1996) who used BIMAS algorithm software program to identify 
PR-3-derived peptides with high binding affinities to the most frequent HLA-A 
allele, HLA-A*0201. The predicted peptides were used to elicit peptide-specific 
CTLs in vitro from healthy HLA-A*0201 donor lymphocytes which  specifically 
lysed  HLA-A*0201 positive myeloid leukemias overexpressing proteinase-3 
(Molldrem et al., 1996). In a subsequent study, Molldrem and his colleagues showed 
that the same CTLs were able to inhibit the colony formation in vitro by leukemic 
but not normal CD34+ cells (Molldrem et al., 1997). Furthermore, both cell lysis and 
inhibition of progenitor formation correlated with the amount of intra-cytoplasmic 
PR-3 expression by the leukaemia target cells (Molldrem et al., 1996, Molldrem et 
al., 1997). The PR-1 T cell epitope was then thoroughly investigated.  Only T cells 
with high avidity exerted an anti-leukemic effect following isolation of high and low 
avidity anti-PR-1 T cells from normal individuals (Molldrem et al., 2003). In 
accordance with previous results that showed the presence of PR-1-specific T cells 
in healthy individuals at low frequencies (Molldrem et al., 1999), Molldrem et al. 
reported high frequencies of cytotoxic T cells specific to the PR-1 epitope in CML 
patients responding to interferon-α {} and also in a group of patients responding to 
allogeneic bone marrow transplantation (BMT) treatment. This suggests that the PR-
1-specific CTLs expand in responding patients and contribute to remission 
(Molldrem et al., 2000). The existence of natural immune response to PR1 that can 
be amplified in the presence of leukemic cells was demonstrated by the Barrett 
group {Rezvani, 2003 #119} who found that PR-1-specific memory T-cell 
frequencies of around 1/100 000 exist in healthy donors, while blood taken from 
patients in remission showed one and two log increases over the normal baseline. 
PR-1 peptide sequence is also expressed by neutrophil elastase (NE) which is 
another granular serine protease found to be highly expressed in CML progenitors 
(Fujiwara et al., 2004, Yong et al., 2008). Interestingly, it has been reported that a 
high expression levels of both PR-3 and NE in CD34+ progenitors were associated 
with  longer survival in patients with CML suggesting T-cell mediated responses 
against these overexpressed antigens (Yong et al., 2007, Yong et al., 2006). 
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1.4.4. Approaches for the identification of tumour antigens 
Different approaches have been used to identify tumour antigens that induce 
immune responses in humans. The first approach used is based on the identification 
of targets that were recognized by patients' tumour-specific CTLs clones. To identify 
such antigens, genomic DNA libraries or cDNA libraries prepared from tumour cells 
were transfected into cells expressing the appropriate MHC molecule. The tumour-
specific T cells were then tested for their ability to recognize the antigen by 
releasing cytokines or lysing specific target cells (van der Bruggen et al., 1991, 
Kawakami et al., 1994). The majority of genes encoding tumour antigens in solid 
malignancies have been identified using this approach (Wang and Rosenberg, 1996).  
 
Another approach based on a biochemical purification method is also used. This 
method involves acid-elution of peptides from MHC molecules purified from 
tumour cells and separation of the eluted peptides by high performance liquid 
chromatography. Peptide fractions are then loaded onto MHC-matched APCs to test 
their ability to elicit T-cell responses. The reactive peptides are further analyzed 
using tandem mass spectrometry which allows the isolation and sequencing of 
individual peptides. Once the amino acid sequence is identified, database searches 
can be used to determine the source of the antigen (Hunt et al., 1992, Cox et al., 
1994, Skipper et al., 1999, van Bergen et al., 2007, den Haan et al., 1995).  
 
SEREX (serological analysis of recombinant cDNA expression libraries) as well as 
proteomics are used for identification of tumour antigens based on detection of 
proteins that elicit spontaneous humoral immune responses in cancer patients. In the 
SEREX method, a cDNA library is constructed from a fresh tumour specimen, 
packaged into a lambda-phage vector and expressed in Escherichia coli (E.coli). The 
recombinant proteins are transferred onto nitrocellulose membranes and screened for 
recognition by high-titer IgG antibodies present in the patient’s serum (Sahin et al., 
1995, Chen et al., 1997). Some T cell defined antigens could be also detected using 
SEREX analysis, indicating that this approach is useful in identifying tumour 
antigens that are recognized by antibodies (Sahin et al., 1995). More importantly, at 
least two of the newly SEREX-identified antigens were subsequently shown to elicit 
specific T-cell responses (Chen et al., 1997, Greiner et al., 2005). The other method, 
proteomics, analyzes cellular extracts as well as serum proteins from normal and 
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cancer patients to compare and identify differentially expressed tumour antigens. It 
uses two-dimensional western blotting experiments to separate proteins followed by 
incubation with sera from cancer patients. Mass spectrometry and database search 
are then used to identify reactive target proteins (Le Naour, 2007, Chen et al., 2002, 
Cui et al., 2005).    
 
Analyzing gene expression profiles in cancer cells and comparing them with those in 
normal counterparts is used to identify any abnormal genes (mutated or virally-
derived) or normal but overexpressed genes that are aberrantly expressed in tumour 
cells.  The techniques used to analyze the expression of genes include gene 
microarrays, serial analysis of gene expression (SAGE) and cDNA subtraction 
(Velculescu et al., 1995, Wang et al., 2000).  
 
Candidate tumour antigens that have been identified by approaches such as SEREX 
or gene expression analyses can be searched for their epitopes using computer based 
prediction algorithms available on the worldwide web. This approach is known as 
reverse immunology or epitope deduction. It has been used to identify CTL epitopes 
not only from tumour antigens but also from viral antigens, microbial antigens and 
autoantigens (Satoh et al., 2005, Capo et al., 2005, Hassainya et al., 2005).  It is 
based on the identification of peptides that are predicted to bind to a given MHC 
class I allele. Subsequently the immunogenicity of the identified peptides is studied 
by challenging CD8+ T cells with APCs-loaded peptides. The basic steps of this 
method are shown in Figure  1.4. Nowadays other steps involved in the antigen 
processing and presentation by MHC class I pathway i.e. proteasome processing and 
TAP translocation, can be also predicted. Table  1.4 list algorithms that have been 
established for prediction of either one step of the presentation pathway or a 
combination of these steps. Among these the bioinformatics and molecular analysis 
section (BIMAS) and the SYFPEITHI database are the most commonly used 
algorithms (Kessler and Melief, 2007).  
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Candidate antigen
MHC binding prediction
(using algorithms such as BIMAS and 
SYFPEITHI)
Candidate peptides
Testing MHC binding experimentally
(T2 binding assay)
Generation of anti-peptide specific 
CTLs
Testing CTLs specificity 
(cytotoxic assay, cytokine analysis,
tetramer analysis)
In vitro analysis in HLA-transgenic
mice
Phase I clinical trial
 
 
Figure  1.4. The basic steps of reverse immunology approach for the identification of 
immunogenic epitopes.  
A candidate antigen is selected and screened for peptides that bind well to a particular class I allele 
using computer programs. The predicted peptide sequences are synthesized and their binding 
affinities are measured using assays such as the T2 binding assay (see Materials and Methods, section 
2.4). Peptides with high binding affinities are pulsed onto APCs and peptide-specific CTLs are 
generated in vitro. The generated CTLs are tested for their specificity and subsequently for their 
recognition of tumour cells expressing the antigen of interest. The next step is to test the 
immunogenicity of the epitope in HLA-transgenic mice. If the epitope gives positive results, 
candidate antigens can be classified as tumour antigen and tested in clinical phase I trials. Figure 
adapted with modifications from (Schultze and Vonderheide, 2001). 
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Table  1.4.  Internet-based prediction algorithms, adapted with modification from 
(Kessler and Melief, 2007). 
 
Program 
Prediction of   
URL 
 MHC  
class I 
Proteasome 
cleavage 
TAP   
 
BIMAS 
 
+ 
   
http://bimas.dcrt.nih.gov/molbio/hla_bind 
HLA-A2 (no name) +   http://zlab.bu.edu/SMM/ 
IEDB (HLA class 1) +   http://tools.immuneepitope.org/analyze/ht
ml/ 
MAPPP (combined)  +  http://www.mpiib-
berlin.mpg.de/MAPPP/expertquery.html 
MAPPP (Fragpredict)  +  http://www.mpiib-
berlin.mpg.de/MAPPP/cleavage.html 
MHC II (no name) +   http://bioinfo.weizmann.ac.il/mhc2motifs/ 
MHC-BPS +   http://bidd.cz3.nus.edu.sg/mhc/ 
MHCPred   + http://www.jenner.ac.uk/MHCPred 
Multipred +   http://research.i2r.a-star.edu.sg/multipred/ 
NetChop  +  http://www.cbs.dtu.dk/services/NetChop 
NetMHC +   http://www.cbs.dtu.dk/services/NetMHC 
nHLAPred  +   http://www.imtech.res.in/raghava/propred1
/index.html 
PAProC  +  http://paproc.de 
Pcleavage  +  http://www.imtech.res.in/raghava/pcleavag
e/ 
PREDEP +   http://margalit.huji.ac.il/ 
PREDTAP   + http://antigen.i2r.a-star.edu.sg/predTAP/ 
ProPred-I + +  http://www.imtech.res.in/raghava/propred1
/index.html 
RANKPEP + +  http://bio.dfci.harvard.edu/Tools/rankpep.h
tml 
SVMHC +   http://www-bs.informatik.uni-
tuebingen.de/SVMHC/ 
SVRMHC +   http://svrmhc.umn.edu/SVRMHCdb/ 
SYFPEITHI +   http://www.syfpeithi.de 
TAPPred   + http://imtech.res.in/raghava/tappred/ 
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1.4.5. Modalities of T-cell-mediated immunotherapy   
The identification of several leukaemia antigens that can be specifically recognized 
by antigen-specific T cells, has led to the development of immunotherapeutic 
regimens using T cells. There are two types of T-cell-mediated immunotherapy: the 
passive adoptive T-cell transfer and active immunostimulatory vaccination (Kessler 
and Melief, 2007).  The widely used form of adoptive transfer of T cells is the 
infusion of unmanipulated donor lymphocytes to treat leukemic patients who have 
relapsed after allogeneic HSCT. This therapy is curative in a significant percentage 
of patients (Kolb et al., 1995). The other form of adoptive therapy utilizes the 
identification and expansion of autologous or allogeneic antigen-specific cells that 
specifically target leukemic cells, followed by administration to cancer patients 
(Rosenberg et al., 2008). T cells specific for leukaemia antigens can be isolated from 
the leukaemia patient or can be generated in vitro using leukaemia antigen-loaded 
APCs (Amrolia et al., 2003).  Another method is the transfer of a TCR gene specific 
for leukaemia antigen, such as WT1 via lymphocyte transfection (Stauss et al., 
2008). Active vaccination based on the use of either defined or undefined tumour 
antigens, include the following strategies: 
 
1.4.5.1. Peptide-based vaccines  
Peptide-based vaccines deliver a peptide or multiple synthetic peptides of tumour 
antigens that can be recognized by the patient immune system in an MHC-restricted 
manner. Several phase I and II clinical vaccine trials that investigate the clinical 
significance of MHC class I-restricted peptides derived from BCR-ABL, WT1, PR-3 
as well as RHAMM have been performed in leukaemia patients and have showed 
some encouraging results (Cathcart et al., 2004, Qazilbash et al., 2004, Oka et al., 
2004, Mailander et al., 2004, Schmitt et al., 2008, Pinilla-Ibarz et al., 2000). A 
number of strategies have been established to improve this type of vaccination. 
These strategies include injection of a peptide vaccine together with an adjuvant 
such as montanide or peptide loaded onto DCs (Osman et al., 1999b, Qazilbash et 
al., 2004, Pinilla-Ibarz et al., 2000). It is well known that a CD4+ T-helper response 
is required for robust and persistent CD8+ T-cell responses (Janssen et al., 2003, 
Kumaraguru et al., 2004). Therefore, a tumour-specific Th1 epitope can be 
incorporated along with the CTL epitope to enhance the CTL-mediated tumour 
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destruction (Smits et al., 2009). Another strategy known as epitope enhancement has 
also been used. Epitope enhancement strategies rely on the use of heteroclitic 
(modified) peptides. These peptides are synthetic variants of the natural peptide 
sequence with the same HLA-binding specificity and avidity, but with enhanced 
affinity to class I MHC molecules or to TCR (Smits et al., 2009). This strategy has 
been used to enhance the immunogenicity of peptides derived from leukaemia 
antigens such as BCR-ABL, CD33 and WT1 as well as peptides derived from 
melanoma associated antigens such as MART-1/Melan-A and gp100 (Tsuboi et al., 
2002, Pinilla-Ibarz et al., 2005, Valmori et al., 1998, Parkhurst et al., 1996, Bae et 
al., 2004a).   
 
1.4.5.2. Full-length tumour antigen vaccines 
Recombinant viral vectors or naked DNA plasmids that encode defined full-length 
tumour antigens are used to deliver full-length tumour antigen vaccines (Kessler and 
Melief, 2007). Viral vectors have the ability to initiate immune responses with 
inflammatory reactions occurring as a result of the viral infection. According to the 
danger theory (Matzinger, 1994), viral infection should attract professional APCs 
necessary for antigen presentation (Dermime et al., 2002). In a mouse model, 
vaccination with adenovirus encoding the WT1 antigen was shown to elicit potent 
anti-WT1 responses, protect mice from leukemic cell challenge and retarded tumour 
growth (Osada et al., 2009). A DNA-based vaccine targeting the leukaemia antigen 
PML-RARα in a mouse model induced protective immune responses against 
leukaemia progression when combined with the conventional ATRA therapy (Padua 
et al., 2003).  
 
1.4.5.3. Whole-tumour cell vaccines 
Whole-tumour cell vaccines are among the earliest forms of cellular therapy that has 
been used to vaccinate cancer patients. It usually consisted of autologous irradiated 
tumour cells or tumour-derived lysates. In order to induce the required immune 
response in tumour-bearing patients, tumour-cell vaccines were mixed with bacterial 
adjuvants such as Bacillus Calmette-Guerin (BCG) or cytokines such as IL-2 and 
GM-CSF (Powles et al., 1975, Powles et al., 1977, Zhang et al., 2005). Nowadays, 
tumour cells can be genetically modified to express high levels of co-stimulatory 
molecules, such as CD80 and /or cytokines, such as IL-2 and GM-CSF (Chan et al., 
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2005, Stripecke et al., 2000).  When using this kind of vaccination, all antigens that 
could serve as targets for the immune system will be included in the vaccine without 
the need for their prior identification. However, the main limitation for this approach 
is the need for a personalized vaccine. This problem has been solved by the use of 
allogeneic tumour-cell vaccination in which cell lines derived from the tumour type 
which is the therapeutic target can be established in vitro, genetically modified, and 
used as a single reagent (Dermime et al., 2002).   
 
1.4.5.4. Dendritic cell-based vaccines  
Dendritic cells represent the most powerful APCs capable of priming effective T cell 
responses (Banchereau and Steinman, 1998). Immature DCs constitutively express 
high levels of MHC molecules, costimulatory and adhesion molecules and possess 
an extraordinary capacity to capture and process antigens. Upon maturation, DCs are 
able to stimulate CD4+ T cells via HLA class II and CD8+ T cells via interaction of 
HLA class I-a process known as cross-priming. DCs also stimulate NK cells and B 
cells (Banchereau and Palucka, 2005). Besides these properties, the possibility to 
generate large numbers of functional human DCs ex vivo has opened the way to use 
these cells in vaccination trials. Two general strategies have been used to obtain 
human DCs for vaccine therapy:  immature DC precursors can be purified from 
peripheral blood or DCs can be derived in vitro from peripheral blood CD14+ 
monocytes or CD34+ hematopoietic stem cells using GM-CSF and IL-4 (Borrello 
and Sotomayor, 2002). Different approaches for the development of DC-based 
vaccines have been used in leukaemia patients and many of which were effective in 
inducing anti-leukaemia immune responses. DCs were loaded with peptides derived 
from the leukaemia antigens PML-RARα, or transfected with mRNA encoding WT1 
antigen (Osman et al., 1999b, Smits et al., 2009). DCs were also loaded with 
undefined leukaemia antigens derived from apoptotic or necrotic leukaemia cells, 
leukaemia cell lysates or acid eluted peptides (Delluc et al., 2007, Weigel et al., 
2006, Jarnjak-Jankovic et al., 2005, Lee et al., 2004, Spisek et al., 2002). Leukaemia 
cells induced to express DCs properties by differentiation, fusion or genetic transfer 
have been also used (Klammer et al., 2005, Roddie et al., 2000, Roddie et al., 2006). 
Importantly, these leukemic cells maintain expression of leukemic antigens but also 
have some immuno-stimulatory features of DCs.  
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1.5. Aims of this Study 
In order to improve the T-cell-based immunotherapeutic approaches for leukaemia 
patients, this study aimed to enhance the immunogenicity of previously identified 
epitopes derived from WT1 antigen as well as to identify novel potential epitopes 
derived from other leukaemia-associated antigens such as MPP11 and PR-3.  
 
The Db126126-134 (126N=RMFPNAPYL) and WH187187-195 (187N=SLGEQQYSV) 
are HLA-A*0201-resticted epitopes derived from the WT1 antigen. These epitopes 
have been shown to elicit specific CTL responses. The aim of the first part of the 
study was to improve the immunogenicity of these epitopes using an epitope 
enhancement approach consisting of replacing the first amino acid of the epitope 
sequence with a tyrosine. The modified peptides may then display stronger binding 
affinities to the HLA-A*0201 molecule and enable a more efficient trigger of 
peptide-specific CTLs, recognizing the naturally occurring epitope. The CTL lines 
will be generated by in vitro stimulation of CD8+ T cells, purified from normal 
human HLA-A*0201donor, using autologous-mature DCs loaded with the WT1-
derived peptides. The immunogenicity of the CTLs generated against each analogue 
peptide will be compared with that of the native sequence using cytotoxicity and 
ELISPOT assays against WT1-loaded autologous LCLs and T2 cells and HLA-
matched leukaemia cells. Importantly, the CTLs specific for the analogue peptides 
will be tested for their ability to recognize the native sequences.  
 
Our group has successfully generated Treg clones specific for a peptide derived 
from WT1 antigen, WT1-84-333-347 (RYFKLSHLQMHSRKH), in an HLA-DR04 
restricted manner and showed the existence of this population in leukaemia patients. 
The aim of the second part of the study was to investigate whether Tregs specific for 
WT1-84 peptide could also be generated from other HLA-DR04-matched donors. 
The T cell lines will be generated by in vitro stimulation of PBMCs obtained from 
three normal HLA-DR04+ donors using autologous-mature DCs loaded with the 
WT1-Pepmix. The proliferative activity of the generated T cell lines will be tested 
for their ability to recognize WT1-84 peptide using proliferation assay against WT1-
Pepmix/ WT1-84 peptide loaded autologous APCs. 
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The third part of the study aimed to identify novel CD8+ CTL epitopes in the gene 
sequence of MPP11 and PR-3 which may bind to the HLA-A*0201 molecule and 
provoke specific CTL responses. Identification of such novel CTL epitopes derived 
from these leukaemia-associated antigens is a crucial step for the development of 
leukaemia-specific therapies. These epitopes will be used as targets for the 
generation of antigen specific T-cells which subsequently could be utilized in 
adoptive therapy or the development of vaccines efficient in eradicating minimal 
residual leukemic cells in leukaemia patients expressing elevated levels of MPP11 
and/or PR3. The identification of the novel CTL epitopes will be carried out by 
screening the amino acid sequence of MPP11 and PR-3 antigens for potential HLA-
A*0201 binding peptides using epitope prediction programs. CTL lines will be 
generated against candidate peptides by in vitro stimulations of CD8+ T cells, 
purified from normal human HLA-A*0201donors, using APCs-loaded peptides. The 
generated CTL lines will be tested for the ability to generate anti-peptide specific 
responses using cytotoxicity and ELISPOT assays against peptide-loaded target cells 
and HLA-matched leukaemia cells. 
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2.  MATERIALS AND METHODS 
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2.1. Patients and Donors 
All samples were obtained with informed consent at King Faisal Specialist Hospital 
and Research Centre (KFSH&RC), Saudi Arabia. Blood samples were obtained 
from patients with AML and ALL patients. Information such as the percentage of 
the blast cells in the patients’ blood samples as well as the patients’ status were 
obtained from the clinic. Leukocyte-rich Buffy coats not older than eight hours were 
obtained from healthy volunteers from the Blood Bank.  
2.2. Preparation of Peripheral Blood Mononuclear Cells   
Peripheral blood mononuclear cells (PBMCs from leukaemia patients and healthy 
donors were isolated from heparinized blood by density gradient centrifugation over 
Ficoll–Paque PLUS (Amersham Biosciences) according to the manufacturers’ 
instructions. Briefly, blood samples were diluted with 2-4 volumes of phosphate-
buffered saline containing 0.5% fetal calf serum (PBS/FCS).Each sample was then 
carefully layered over a Ficoll-Paque Plus layer in sterile centrifuge tubes. The 
samples were centrifuged at 2000 rpm. The interface cells (PBMCS i.e. lymphocytes 
and monocytes) were aspirated and placed in a sterile centrifuge tube and washed in 
cold PBS/FCS.  The cells were further washed twice and cryopreserved by 
resuspending in 90% FCS + 10% DMSO, and aliquoted into freezing containers 
(Nalgene cryogenic vials) for 2h at –80˚C and then in liquid nitrogen at -192°C until 
further processing. The HLA typing of these samples was carried out at the routine 
Immunopathology Laboratory.  
 
2.3. T lymphocyte Epitope Prediction and Peptide Synthesis 
2.3.1. WT1-pepmix 
A pool of 110 peptides spanning the entire length of the WT1 protein designated as 
WT1-Pepmix and a micro-scale WT1 peptide set containing each peptide in a single 
well were obtained from JPT Peptide Technologies (Jerini AG, GmbH) with a purity 
of more than 70% by HPLC. The peptides were 15 amino acids long with an overlap 
of 11 amino acids. 
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2.3.2. WT1 peptides 
A tyrosine (amino acid substitution in the sequence of the following 9-mer WT1 
peptide) was carried out at the N-terminus in: Peptide Db126 for arginine (wild type 
126N126-134 = RMFPNAPYL, analogue 126Y = YMFPNAPYL), and in peptide 
WH187187-195 for Serine (wild type 187N = SLGEQQYSV, analogue 187Y = 
YLGEQQYSV). We compared the predictive binding ability of the wild-type (126N 
and 187N peptides with their corresponding analogues (126Y and 187Y) to the 
HLA-A*0201 molecule using a computer-based epitope prediction program, 
BIMAS. The score predicted by BIMAS algorithm is based on the calculation of the 
theoretical half-time of the peptide dissociation to HLA class I molecules (Parker et 
al., 1994).  
 
Individual 15-mer WT1 peptides used were WT1-60 237-251 
(TMNQMNLGATLKGVA), WT1-61241-255 (MNLGATLKGVAAGSS), WT1-79313-
327 (SASETSEKRPFMCAY), WT1-80317-331 (TSEKRPFMCAYPGCN), WT1-84333-
347 (RYFKLSHLQMHSRKH), and WT1-96381-395 (KPFQCKTCQRKFSRS). In 
addition to peptides derived from the WT1 sequence, hTert672-686 
(RPGLLGASVLGLDDI) HLA-DR*07–restricted peptide derived from the human 
telomerase reverse transcriptase (hTRT) (Schroers et al., 2002), was obtained and 
used as a positive control. 
 
2.3.3. MPP11 and PR-3 peptides 
MPP11 peptide sequences predicted to bind to HLA-A*0201 molecule were 
obtained using the SYFPEITHI prediction program. For PR-3, peptide sequences 
predicted to bind to HLA- A*0201 molecule were obtained using three computer-
based epitope prediction programs (BIMAS, SYFPEITHI and RANKPEP).The 
SYFPEITHI prediction algorithm is a database comprising more than 4500 peptide 
sequences known to bind class I and class II MHC molecules.  The scoring system 
of the SYFPEITHI program is based on the presence of certain amino acids in 
certain positions along the MHC-binding groove (Rammensee et al., 1999). 
RANKPEP server prediction is based on the similarity of an entered protein 
sequence to a set of peptides known to bind to a given MHC molecule. The degree 
of similarity is scored using a Position Specific Scoring Matrixes (PSSM) derived 
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from the aligned peptides that are known to bind to a particular MHC molecule 
(Reche et al., 2002).  
 
The amino acid sequences of MPP11 and PR-3 were entered into the specified 
programs and candidate epitopes were selected based on their predicted ability to 
bind to the HLA- A*0201 molecule. Four 9-mer peptides derived from MPP11 and 
two 9-mer peptides derived from PR-3 were selected as potential epitopes for the 
generation of CTL responses. The four MPP11-derived peptides were: MPP-1N421-
429 (QLLIKAVNL), MPP-2419-427 (DLQLLIKAV), MPP-313-21 (AIMLLLPSA) and 
MPP-437-45 (STLCQVEPV). The PR-3-derived peptides were: PR-129129-137 
(NLSASVATV) and PR-99-17 (ALASVLLAL). In addition to the predicted peptides, 
we modified the sequence of the first predicted peptide derived from MPP11 by 
introducing a Y at its N-terminus (wild type MPP-1N= QLLIKAVNL, analog MPP-
1Y= YMFPNAPYL). Furthermore, PR-169169-177 (VLQELNVTV), a previously 
described HLA-A*0201 epitope derived from PR-3 antigen, was used as a positive 
control (Molldrem et al., 1996). The amino acid sequences of the nonameric 
peptides with a purity of 90% were synthesized and purified by Alta Bioscience 
(Birmingham University, UK).    
 
2.4. T2 Binding Assay  
Peptide binding capacity to the HLA-A*0201 molecule was measured using the 
TAP-deficient, HLA-A*0201-positive cells as described previously (Molldrem et 
al., 1996). T2 cells are a hybrid human cell line produced by fusion of a B 
lymphoblast line 174 with a T lymphoblast line CEM. The cell line has a 
homozygous deletion of the MHC class II region on chromosome 6 including the 
known transporter proteins for antigenic peptide TAP1 and TAP2 genes and 
proteasome genes. They contain the gene HLA-A*0201, but express very low levels 
of cell-surface HLA-A*0201 and are unable to present endogenous antigens 
(Zweerink et al., 1993). Stable HLA-A*0201 expression in T2 cells is observed only 
when peptides that are capable of binding to and stabilizing the cell surface 
expression of the HLA-A*0201 molecule are added exogenously. The principle of 
the assay is as illustrated in Figure  2.1. Briefly, T2 cells were washed three times, 
suspended at 106 cells/mL and incubated for 18 hours in serum-free medium 
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containing different concentrations of peptides and 1 g/mL 2-microglobulin 
(Sigma). Cells were then washed twice with cold FACS buffer (PBS containing 2% 
FCS). Purified rabbit IgG (Sigma) was added to the cell suspension and incubated 
for 15 minutes on ice in order to block the FC receptors. FITC-conjugated mouse 
anti-HLA-A2 antibody (clone: BB7.2; AbD Serotec) was added to the cell 
suspension (1μg/106 cells) and incubated for 30 minutes at 4°C in the dark. The cells 
were washed twice with cold FACS buffer and fixed with PBS/4% 
paraformaldehyde. The level of HLA-A2 expression was analyzed using 
fluorescence-activated cell sorter (FACS) Scan (Becton & Dickinson, 
Immunocytometry Systems, CA, USA). HLA-A2 expression was quantified as 
fluorescence index (FI) according to the following formula: fluorescence index = 
(median fluorescence intensity with peptide - median fluorescence intensity without 
peptide)/ median fluorescence intensity without peptide. All T2 binding assays were 
carried out in duplicate.  
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Figure  2.1.  Principles of T2 binding assay.  
T2 cells are incapable of presenting endogenously synthesized antigens due to a deletion in genes that 
encode the transporter associated with antigen processing (TAP1 and TAP2). Therefore, the HLA-A2 
molecules expressed by these cells are unstable and disassociate in the absence of peptides.  The 
stability of HLA-A2 molecules at the cell surfaces can be achieved by adding exogenous peptides 
with high affinity for HLA-A2. The amount of stable HLA-A2 can be followed using an anti-HLA-
A2 monoclonal antibody and quantified by flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide/MHC Class I complex 
+ HLA-A*0201 Peptide 
MHC Class I molecule 
T2 T2 
 63 
2.5. Culture and Generation of Target Antigen Presenting Cells (APCs) 
2.5.1. Cell lines 
The mutant TAP-deficient cell line T2 (ATCC number CRL-1992) and the HLA-
class I and II negative human CML cell line K-562 (ATCC number CCL-243) were 
purchased from American Type Culture Collection (ATCC, Manassas, VA, USA).  
K-562 cells transfected with HLA-A*0201 gene were kindly provided by Dr. 
Wolfgang Herr (University of Mainz, Germany). The T2 and K562 cells were 
maintained in complete medium (CM) consisting of RPMI 1640 medium (Sigma, 
MO, USA) supplemented with 10% Fetal Calf Serum (FCS) (Cambrex Bio Science, 
MD, USA), 2 mM L-glutamine, 100 IU/ml penicillin and 100 mg/mL streptomycin 
(Sigma).   K562/A*0201 were cultured in CM containing 0.5 mg/mL geneticin 
(G418, Sigma).   
 
2.5.2. Generation of B-lymphoblastoid cell lines 
B-lymphoblastoid cell lines (LCLs) were established from normal donors by 
transformation of B cells using Epstein-Barr virus (EBV) according to a standard 
technique (Neitzel, 1986). The EBV virus stock was produced by the B95.8 cell line 
and was kindly provided by the Derartment of Genetics (Research Centre, 
KFSH&RC). Briefly, PBMCs (107 cells) were incubated with the virus (500 µL) for 
an hour at 37ºC. Then cells were cultured in CM containing 1µg/mL PHA (PHA-P, 
Sigma) and 0.1 ug/mL cyclosporin A and  maintained by twice-weekly refreshing of 
CM. Established LCLs were used after 3-4 weeks of culture. 
 
2.5.3. Generation of PHA blast 
PHA blasts were prepared as described previously (Atanackovic et al., 2003). 
PBMCs were seeded onto 24-well plates (BD Biosciences, USA) at a density of 1-2 
x 106 cells /well into a 24-well culture plate in T cell culture medium. The T cell 
culture medium consisted of X-vivo 15 medium (BioWhittaker, MD), supplemented 
with 10% heat-inactivated human AB serum (Sigma). A concentration of 10 μg/mL 
phytohemagglutinin (PHA) was added to the culture on day 0. Half of the medium 
was replaced with a complete medium containing 20 IU/mL recombinant human 
interleukin-2 (rhIL-2; eBioscience) and 40 ng/mL rhIL-7 on day 3, and this step was 
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subsequently repeated every 3 days. The activated T cell-APCs (T-APCs) were 
checked for class II, CD80, and CD86 expression and then used as target cells 
around day 20 of the culture. 
 
2.5.4. Generation of mature dendritic cells from autologous monocytes 
2.5.4.1. Isolation of monocytes for subsequent dendritic cell generation 
Monocytes (CD14+ cells) were isolated from PBMCs of healthy HLA-A*0201 
positive donors either by negative selection using a MACS human Monocyte 
Isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) or by plastic 
adherence. Monocyte magnetic isolation was done according to the manufacturer’s 
instructions. Briefly, 107 PBMCS were suspended in 30 µL of ice-cold MACS 
buffer (PBS supplemented with 0.5% bovine serum albumin (BSA) and 2 mM 
EDTA) and 10 µL of FcR blocking reagent (human Ig). Non-CD14+ T cells were 
indirectly magnetically labelled by incubating the cells with 10 µL of biotin- 
conjugated antibodies cocktail against CD3, CD7, CD16, CD19, CD56, CD123, and 
Glycophorin A. After 10 minutes of incubation at 4–8°C, 20 µL of anti-biotin micro 
beads (clone:  Bio3-18E7.2; mouse IgG1) and buffer were added. Following an 
additional 15 minutes of incubation at the same temperature as above, cells were 
washed and resuspended in 500 µL of buffer. The MS column (Miltenyi Biotec) 
were prepared by placing it in the magnetic field of a MACS separator and rinsing 
with 500 µL of MACS buffer. The cell suspension was applied onto columns and 
allowed to pass through and effluent was collected (unlabeled cells), representing 
the enriched monocyte fraction.  
 
For monocyte isolation by plastic adherence, PBMCs were cultured at 5 x 106 
cells/mL/well of a 6-well plate (Sigma) in X-vivo 15 medium supplemented with 2 
mM L-glutamine (DC-medium), and allowed to adhere in a 5% CO2 incubator at 
37°C for 90-minutes. Non-adherent cells and media were removed and fresh DC-
medium was added to the cells. After a second incubation period, non-adherent cells 
and media were removed and the adherent cells were washed carefully with pre-
warmed medium. The isolated monocytes were resuspended in fresh DC-medium. 
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2.5.4.2. Generation of mature conventional dendritic cells  
The isolated monocytes were cultured in six-well plates in DC-medium in the 
presence of 50 ng/mL rhIL-4 and 100 ng/mL recombinant human granulocyte 
macrophage colony-stimulating factor (rhGM-CSF; R&D Systems, MN). Immature 
dendritic cells (DC) were stimulated into maturity by adding 20 ng/mL recombinant 
human tumour necrosis factor- α (rhTNF-α; R&D Systems), 10 ng/mL rhIL-1β 
(eBioscience, CA) and 25 mg/mL polyinosinic acid:poly-CMP (Poly I:C; Sigma) on 
day 6 and mature dendritic cells (DCs) were harvested on day 7. 
 
2.5.4.3. Generation of mature fast dendritic cells  
Fast dendritic cells (DC2d) were generated according to previously published 
protocols (Dauer et al., 2003, Ho et al., 2006) with minor modifications. Briefly, 
DC-medium supplemented with 100 ng/mL rhGM-CSF and 50 ng/mL rhIL-4 was 
added to monocytes cultured in 6-well plates. Maturation cytokines, 10 ng/mL 
rhTNF, 10 ng/mL rhIL-1, 10 ng/mL rhIL-6 (R&D Systems) and 1 M PGE2 
(Sigma), were added to the cultures on the next day. Cultures were incubated for an 
additional day before mature DC2d were harvested. 
 
2.6.  Generation of T lymphocyte lines  
Different approaches have been used to generate CD8+ T lymphocyte lines. These 
approaches include the use of mature conventional DCs or mature fast DCs to prime 
naïve CD8+ T cells. Two rounds of T cell-stimulation were sufficient to prime the T 
cells. Following priming, DCs or monocytes were used to expand the generated T 
cell lines. Another approach employed the use of T2 cells to prime and to expand 
naïve CD8+ T cells. A single approach was used to generate CD4+ T lymphocyte 
lines. In this approach, mature conventional DCs were used to prime naïve CD4+ T 
cells and monocytes or T-APCS were used to expand the generated T cell lines. 
 
2.6.1. Isolation of CD8+ T lymphocytes 
CD8+ T lymphocytes were negatively separated from PBMCS obtained from healthy 
HLA-A0201 positive donors using MACS CD8+ T Cell Isolation Kit II (Miltenyi 
Biotec). Following the manufacturer’s protocols, 107 PBMCS were suspended in 40 
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µL of ice-cold MACS buffer. Non-CD8+ T lymphocytes were indirectly 
magnetically labelled by incubating the cells with 10 µL of a cocktail of biotin-
conjugated antibodies against CD4, CD14, CD16 CD19, CD36, CD56, CD123, TCR 
γ/δ and Glycophorin A. After 10 minutes of incubation at 4–8°C, 20 µL of anti-
biotin microbeads (clone:  Bio3-18E7.2; mouse IgG1) and buffer were added. After 
an additional 15 minutes of incubation at the same temperature, cells were washed, 
resuspended in 500 µL of buffer, and applied to the prepared MS columns (Miltenyi 
Biotec). The effluent (unlabeled cells) was collected, representing the enriched 
CD8+ T cell fraction.  
 
2.6.2. Generation of anti-peptide specific CD8+ T lymphocytes 
Some of the CD8+ T cell lines were generated using protocol adapted from previous 
studies (Molldrem et al., 1996, Houbiers et al., 1993). Briefly, T2 cells were washed 
three times in serum-free medium and incubated with each peptide at concentrations 
of 50 μM/mL and 1 μg/mL β2-microglobulin at 37 C, 5% CO2 for 2 hours. The 
peptide-pulsed T2 cells were then irradiated with 7500 rad, washed once and added 
to freshly purified CD8+ in T lymphocyte culture medium (X-vivo 15 medium 
supplemented with 2 mM L-glutamine and 10% human serum) at a T lymphocyte: 
T2 ratio of 5:1.  After 7-10 days of T cell stimulation, the second stimulation was 
performed and on the following day, 20 IU/mL of rhIL-2 was added. The cultured T 
lymphocytes were maintained by restimulations with peptide-pulsed T2 cells. After 
the third in vitro stimulation, peptide-stimulated cells were tested for their 
cytotoxicity using chromium release assays. DC-loaded peptides were used to in 
vitro prime some of the purified CD8+ T lymphocytes. Briefly, the mature DCs 
growing in DC medium were harvested, washed once with the same medium and  
incubated with the peptides at concentration of 50 μM/mL and 5 μg/mL β2-
microglobulin for 2 hours at 37 C, 5% CO2. The peptide loaded DCs were then X 
irradiated (2500 rads), washed once and added to the CD8+ T lymphocytes at 20:1 to 
5:1 T lymphocytes: DCs ratio. rhIL-7 (20 ng/mL) and rhIL-12 (100 pg/mL) were 
added to each culture. The cells were incubated in 2 mL T cell culture medium in 
24-well plates. After 7-10 days, T lymphocyte were harvested, washed and re-
stimulated with peptide loaded DC2d as previously described and rhIL-2 (20 
IU/mL) was added the following day. The cultured T lymphocytes were maintained 
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by re-stimulation with autologous peptide-loaded antigen presenting cells (DCs or 
freshly prepared adherent monocytes) and fed with rhIL-2 the next day. T 
lymphocyte lines against the different peptides were generated. Responder T 
lymphocytes were tested for their specificity and cytotoxic activity using Enzyme-
Linked Immunospot Assay (ELISPOT) Assay and Chromium Release Assay against 
different targets. 
 
2.6.3. Generation of anti-peptide specific CD4+ T lymphocytes 
Irradiated DCs (2500 rads) were pulsed with 10 μg/mL WT1-Pepmix in DC medium 
and incubated for 4 h at 37C, 5% CO2. DCs were co cultured with autologous 
PBMCs at a 10:1 T-cell to DC ratio. T cell culture medium containing 10 ng/mL 
rhIL-7, and 20 pg/mL rhIL-12 (R&D Systems) was used. After 7-10 days of co-
culture, a similar second stimulation was performed and 260 IU/mL rhIL-2 was 
added 2 days after re-stimulation. T cells were re-stimulated with autologous 
peptide-loaded cells (freshly prepared adherent monocytes or T-APC) and 260 
IU/mL rhIL-2 was added 2 days after each re-stimulation.  
 
After several rounds of antigen-specific re-stimulation, dynabeads CD3/CD28 T cell 
expander (Invitrogen Dynal, USA) was used to activate T cells according to the 
manufacturers’ protocol.  The beads are superparamagnetic polystyrene beads 
coated with monoclonal antibodies against the CD3 and CD28 cell surface 
molecules of T cells. For T cell stimulation, 1 bead/5-10 T cells was added to T cells 
cultured in T cell culture medium containing 260 IU/mL rhIL-2. Cells were 
expanded for up to 2 weeks before antigen-specific re-stimulation was repeated.  
 
2.7.  Generation of T Lymphocyte Clones  
2.7.1. Cloning of WT1 T cell line 
2.7.1.1. T cell cloning by limiting dilution assay 
WT1-TCL57 was cloned using a limiting dilution method as mentioned above 
except that HLA-matched allogeneic LCLs were used to stimulate the T cell line. 
The T cells were seeded at 1, 2 and 5 cells/well/200 μL in T cell culture medium in 
96-well U-bottomed plates. Allogeneic PBMCs were irradiated with 2500 rad and 
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used as a feeder layer (25 x 103 cells/well). LCLs were incubated separately in X-
Vivo 15 with 50 μM/mL of WT1-peptides for 2 hr at 37C. LCLs were then 
irradiated with 7500 rad, washed once and used for T cell stimulation (50 x 103 
cells/well) in the presence of 130 IU/mL of rhIL-2.   
 
2.7.1.2. T cell cloning using dynabeads 
The T cells were seeded at 5 cells/well/200 μL T cell culture medium containing 
dynabeads CD3/CD28 T cell expander (1 bead/5-10 T cells) and rhIL-2 (130 
IU/mL) in 96-well V-bottomed plates. The cultures were fed with fresh medium 
containing rhIL-2 (130 IU/mL) every 3-4 days and kept for 2-4 weeks. Growing 
clones were transferred to 96-U-bottomed plates and re-stimulated with irradiated 
peptide-pulsed T-APC. Clones were tested for their specificity against target APC-
pulsed with or without WT1-peptides (WT1-60, WT1-61, and WT1-80) using the 
proliferation assay.  
 
2.7.2. Cloning of MPP11 T cell line 
T lymphocytes lines were cloned by limiting dilution as described before (Dermime 
et al., 1996, Ho et al., 2006) with minor modifications. T lymphocytes were seeded 
at 1, 2 and 5 cells/well/200 μL T cell culture medium in 96-well U-bottomed plates. 
Allogeneic PBMCs were X-irradiated (2500 rads) and used as a feeder layer (25 x 
103 cells/well). T2 cells were incubated separately in X-Vivo 15 (5 X 106 cells/mL) 
with 5 μg/mL β2-microglobulin and 50 μM/mL of MPP-4 peptide for 2 hours at 
37C. T2 cells were then irradiated (7500 rads), washed once and used for T cell 
stimulation (50 x 103 cells/well) in the presence of 130 IU/mL of rhIL-2. 5ng/mL 
rhIL15 (R&D Systems) and 30ng/mL OKT3 were also added to the wells. The 
plates were incubated for 2-4 weeks. Cultures were re-fed with fresh medium 
containing rhIL-2 (130 IU/mL) every 3-4 days. Wells with positive signs of growth 
were selected for expansion. Growing clones were transferred to 96-well flat-
bottomed plates, and each clone was stimulated with irradiated peptide- pulsed T2 
cells. The activation cycle was repeated after 7-10 days of culture at lymphocyte: T2 
ratios of 20:1 to 5:1. Clones were screened for their lytic activity against T2-pulsed 
with or without peptide using a Chromium Release Assay.  
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2.8. Flow Cytometry Analysis  
Cells were collected into FACS tubes (Falcon) and washed with cold FACS buffer. 
Purified rabbit IgG (Sigma) was added to the cell suspension and incubated for 15 
minutes on ice in order to block the FC receptors. Fluorochrome-conjugated mouse 
anti-human antibody was added to the cell suspension (1 μg/106 cells), with a 
control sample labelled with isotype-matched monoclonal antibody. The cells were 
incubated on ice for 30-60 minutes in the dark, washed twice with cold FACS 
buffer, fixed with 300 μl of PBS/4% paraformaldehyde and analyzed using FACS 
Scan.  The following antibodies were purchased from AbD Serotec, NC, anti-CD14-
FITC (clone: TuK4). Antibodies purchased from Dakocytomation, CA, were anti-
CD8-FITC (clone: DK25), anti-CD3-APC (clone: UCHT1) and anti-CD4-FITC 
(clone: MT310). Anti-CD1a-FITC (clone: HI149) and anti-CD83-PE (clone: 
HB15e) were obtained from BD Biosciences, USA. In addition, Tregs were 
phenotyped using a kit obtained from eBioscience and used according to the 
manufacturer’s instructions. Briefly, the T cells were stained with a cocktail of anti-
CD4-FITC and anti-CD25-PE, fixed, permeabilized using the Foxp3 staining buffers 
and subsequently stained with anti-Foxp3-APC. Analyses were performed using 
FACS Scan (Becton & Dickinson, Immunocytometry Systems, CA, USA). 
 
2.9. Cytotoxicity Assay (Chromium Release Assay) 
Cytotoxicity assays were performed 5 days after the in vitro stimulation.  Target 
cells were removed from culture, washed in RPMI1640 serum-free medium, re-
suspended in a minimal volume (± 50 μL) of RPMI1640 and incubated with Cr51 
(100 μCi) per target for 90 minutes. Target cells labeled with peptide were 
concurrently incubated with the appropriate peptide at 50 μM/mL. The cells were 
then washed and placed in 96 V bottomed wells at 103 cells/100 μL/well. The 
effector T lymphocytes were washed, and added in triplicate at varying quantities to 
the target cells, to give varying effector to target (E:T) ratios in a final volume of 
200 μL/well. The plates were spun for 5 minutes (300g) and incubated for 4 hours at 
37 ˚C and 5% CO2 before 100 μL supernatants were removed and transferred to 
1450 Microbeta Plus Wallac plates (Wallac, Turku, Finland). 150 μL scintillation 
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fluid, Optiphase HiSafe 2 (Wallac), was added to each well and the plates were heat-
sealed using a Microsealer system (Wallac).  
Chromium release was assessed by a liquid scintillation counter (Wallac). Target 
cells were also incubated with 0.2% Tween 20 or medium alone to assess the 
maximum and minimum (spontaneous) release of the chromium respectively. 
Spontaneous release was maintained and never exceeded 20% of the maximum 
release. The percentage of specific lysis was calculated as: % Specific lysis = 
(experimental release - spontaneous release)/(maximal release - spontaneous release) 
x100. In some of the experiments, 10 µg/mL anti-class I ABC blocking antibody 
(clone: W6/32, AbD Serotec) was added to target cells before T lymphocytes 
addition. 
 
2.10. T  Cell Proliferation Assay 
T-cell proliferation was assessed by tritiated thymidine ([3H]-thymidine) 
incorporation. T cells were seeded in duplicate or triplicate wells of a 96-well U-
bottomed plate.  T cells were cultured with different stimulators at T cells: APCs 
ratio of 1:2 in a final volume of 200 μl of T cell culture medium for 3 d. 
[3H]thymidine (1 µCi per well; Amersham) was added 18 hours before harvest and  
cells were subsequently harvested onto glass fiber filters (Wallac); [3H]thymidine 
incorporation was measured using a 1450 Micro Beta PLUS liquid scintillation 
counter (Wallac). In some of the experiments, 60 µg/mL of the following purified 
and azide-free blocking antibodies were used: anti–HLA-DR (clone: G46-6, BD 
Biosciences), anti–HLA-DP, and anti–HLA-DQ (clones: 1a3 and B7/21 
respectively, Leinco Technologies). The anti-ABC antibody (AbD Serotec) was 
used at 10 µg/mL and mouse isotypes were used as controls.  
 
2.11. Enzyme-Linked Immunospot Assay (ELISPOT) 
ELISPOT assay was performed using IFN-γ, granzyme B and perforin kits 
(Mabtech, Mariemont, OH) according to the manufacturer’s protocol. 5x103 to 
5x104 T lymphocytes/well and 2 x104 to 105 cells/well of different stimulators were 
seeded in Multiscreen 96-well plates (Millipore, MA) pre-coated overnight (4˚C) 
with catching-antibody. The plates were then blocked with T lymphocyte culture 
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medium. After 40 hours incubation (37˚C, 5% CO2), cells were removed and after 
washing, biotinylated monoclonal antibodies specific for IFN-γ, granzyme B, and 
perforin were added and incubated for 3 hours at room temperature (RT). After 
washing, Streptavidin-alkaline phosphatase (ALP) or Streptavidin-horseradish 
peroxidase (HRP) was added to each well and incubated at RT for 2 hours. After 
washing, the appropriate substrate (BCIP/NBT in the case of ALP and AEC in the 
case of HRP) was added to each well and incubated at RT until colour developed 
according to the manufacturer’s instructions. Spots were counted using an 
automated ELISPOT reader (AID, Strasberg, Germany). Antigen-specific T cell 
frequencies were considered to be significantly higher if they were at least two-fold 
higher than in the control wells. 
 
2.12. Enzyme-Linked Immunosorbent Assay (ELISA) 
Supernatants from 48-h T cell cultures were harvested and stored in aliquots at -
80˚C until used. ELISA for human IFN-γ, IL-4, IL-5, IL-10, GM-CSF ELISA kits 
(Mabtech) and transforming growth factor (TGF)-β1 matched antibody pairs (R&D 
Systems) was performed according to the manufacturer’s instructions. Briefly, Nunc 
Maxisorp 96-well plates (eBioscience) were coated with the appropriate capture 
antibodies overnight. To start the assay, plates were washed and blocked with 
blocking buffers for 1 hr at room temperature. Diluted samples and standards were 
added and incubated for 2 hr. The plates were washed, incubated with biotin–
conjugated detection antibodies, washed again and then incubated with Streptavidin-
HRP and washed. Tetramethylbenzidine (TMB) substrate was added for colour 
development.  After suitable time, colour development was stopped by adding 2M 
sulphuric acid.  Optical density was measured in an ELISA reader (Anthosn Lucy 3) 
at 450 nm. 
 
2.13. RNA Preparation  
Total RNA was isolated from PBMCSs using Trizol method. According to the 
manufacturer’s instructions, cells were lysed with 1 ml Tri reagent (Sigma). After 
mixing the lysed cells with chloroform, total RNA content was collected, 
precipitated with isopropanol, washed once with 75% ethanol, dissolved in 
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diethylpyrocarbonate (DEPC)-treated water and stored at -80˚C.  The concentration 
and purity of the extracted RNA was determined by measuring the absorbance at 
260 and 280 nm with a spectrophotometer. 
 
2.14. Reverse Transcription (RT) 
RNA from each sample was treated with DNase1 (Invitrogen, CA) and then reverse-
transcribed in a 25-μL reaction volume.  1 μg RNA in DEPC-treated water was 
incubated at 65˚C for 5 minutes and then mixed with Reaction mix.  Reaction mix 
included RT buffer (50 mM Tris-HCl, PH 8.5; 30 mM KCl; 8 mM MgCl2),   1 mM 
dithiothreitol (DTT), 100 M of dNTP mix, 200 ng of Oligo-d(T) primers, 80 U of 
RNAse inhibitor, and 600 U of Moloney murine leukemia virus reverse transcriptase 
(Invitrogen). The reaction mixture was then incubated at 37˚C for 2 h, boiled for 5 
minutes, placed quickly on ice and stored at -80˚C until use. 
 
2.15. Conventional Reverse Transcription- Polymerase Chain Reaction (RT-
PCR) 
The WT1 and MPP11 mRNA expression was quantified in PBMCs obtained from 
normal donors and leukaemia patients using conventional RT-PCR. 0.1 μg mRNA 
equivalent of cDNA was used. Sequences of the WT-1 and MPP11 primers used 
were based on previous studies (Greiner et al., 2003, Greiner et al., 2004). The 
amplification product of the house keeping gene β-actin served as control of cDNA 
quality. β-actin primers were designed using Oligo 6 software. Table  2.1and Table  
 2.2 display the sequences of the primers and PCR conditions, respectively. mRNA 
isolated from the K562 cell line served as a positive control for WT1 and MPP11 
genes. Distilled water served as a negative control. The PCR products were 
electrophoresed on a 1% agarose gel. Expected band size was 1243 bp, 790 bp for 
MPP11 and WT1, respectively. 
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Table  2.1.  Primer sequences  
 
Antigen 
 
Forward primer 
 
Reverse primer 
 
 
Mpp11 
 
5’AAGATCATTATGCAGTTCTTGGAC 3’ 
 
5’CCAATAACATCTTTGGCAGTTCT3’ 
 
WT1 5’ATGAGGATCCCATGGGCCAGC 3’ 5’CCTGGGACACTGAACGGTCCCCGA3’ 
 
β-actin 5’CCCAGCACAATGAAGATCAAGATCAT 3’ 5’ATCTGCTGGAAGGTGGACAGCGA 3’ 
 
 
Table   2.2.  PCR conditions 
 
Antigen 
 
Denaturation 
 
Annealing 
 
Elongation 
 
Cycles 
 
MgCl2 
 
 
MPP11 
 
94˚C  (1 min) 
 
60˚C (1min) 
 
72 ˚C (1 min) 
 
28 
 
1.5mM 
 
WT1 94˚C  (1 min) 64˚C (1 min) 72 ˚C (1 min) 30 1.5mM 
 
β-actin 94˚C  (1 min) 60˚C (1 min) 72 ˚C (1 min) 28 1.5mM 
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2.16. Quantitative Real Time RT-PCR for WT1 Expression in Patients’ 
Leukemic Cells 
The WT1 mRNA expression was quantified using Light Cycler FastStart DNA 
master SYBR Green 1kit (Roche, Mannheim, Germany) in a Light Cycler (Roche). 
PBGD was used as house-keeping gene. 2 μL cDNA from the K562 cells was used 
to generate standard curves (Greiner et al., 2004) in 5-log steps for WT1 and PBGD.  
Amplification was conducted in a total volume of 20 μL for 40 cycles/10 sec at 
95˚C, 4 sec/64˚C and 35 sec/72˚C. Samples were run in triplicates and their relative 
expression was determined by normalizing the expression of each target to PBGD 
and then comparing this to the normalized expression in a reference sample (K562) 
to calculate a fold change-value. Primers were designed using Oligo 6 software. The 
WT1 forward primer: TTCATCAAACAGGAGCCGAGC and reverse primer: 
GGTGCGAGGGCGTGTGA were used. The PBGD forward primer: 
CATGTCTGGTAACGGCAATG and reverse primer: 
TCTTCTCCAGGGCATGTTCAA were used. All primers were obtained from 
Aragene Laboratory (KFSH&RC).  
 
2.17. Statistical Analysis 
The statistical methods used were the mean, the median, the standard deviation and 
the Student t test.   The mean is the average of a set of data. The standard deviation 
is used to measure the spread or dispersion of data around the mean. The mean and 
the standard deviation were calculated using Excel. The median is defined as the 
numeric value separating the higher half of a sample, a population, or a probability 
distribution, from the lower half. It was calculated using CellQuest software. The 
Student t test was used for comparative analysis as it is the most commonly used 
method to evaluate the differences in means between two groups. A P value less 
than or equal to 0.05 was deemed to be significant in all experiments.  
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3.  WT1 PEPTIDE ANALOGOUE WT1-126Y 
ENHANCES LEUKEMIA LYSIS 
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3.1.  Introduction 
The Wilms tumour antigen 1 (WT1) has been shown to be expressed at low levels in 
some normal cells such as CD34+ stem cells (Ellisen et al., 2001, Menssen et al., 
1997, Inoue et al., 1997). Therefore, many of the potential CTL epitopes against this 
antigen may be absent or suboptimal. This is mainly due to clonal deletion of high-
avidity CTLs during maturation of the immune system (Wood et al., 1987). To this 
end, different groups introduced modifications in the sequence of the anchor 
positions of these ‘sub-optimal’ peptides to improve their binding to HLA class I 
molecules and to increase their immunogenicity (Parkhurst et al., 1996, Chen et al., 
2000, Valmori et al., 1998, Bakker et al., 1997). Besides modification of anchor 
positions, substitution of amino acid residues pointing to the T cell receptor has been 
shown to enhance epitope immunogenicity (Hoffmann et al., 2002, Tangri et al., 
2001, Zaremba et al., 1997). It has been shown that modified peptides used to 
immunized transgenic mice were able to induce potent peptide-specific CTLs that 
induced tumour regression (Dyall et al., 1998, El-Shami et al., 2000, Mullins et al., 
2001, Overwijk et al., 2003). Some of these modified peptides have been effectively 
used to vaccinate cancer patients (Rosenberg et al., 1998), to improve the detection 
of anti-tumour immunity (Chen et al., 2000), or to reverse the unresponsiveness of T 
lymphocytes to wild-type tumour antigens (Hoffmann et al., 2002). Indeed, it has 
been reported that vaccination of cancer patients with WT1-modified peptides 
induced WT1-specific CTLs and resulted in tumour regression (Oka et al., 2004). 
 
3.2. Aim 
The aim of the study was to explore the feasibility of using an approach that 
enhances the immunogenicity of low-avidity restricted peptides without altering 
their antigenic specificity (Tourdot et al., 2000). This approach consists of replacing 
the first amino acid of the epitope by a tyrosine (P1Y). The advantage of this 
strategy is that the P1Y variants are able to efficiently trigger in vivo wild-type 
peptide-specific CTLs which also recognized the naturally occurring epitope 
(Tourdot et al., 2000).  
 
Given that WT1 specific CTLs isolated from leukaemia patients exert a low-avidity 
response (Rezvani et al., 2003, Scheibenbogen et al., 2002), experiments were 
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carried out where a Y amino acid substitution in the sequence of the Db126 and 
WH187 WT1-derived peptides was introduced with the aim of improving their 
binding affinities to MHC I and enhancing the immunogenicity of the peptides. Two 
peptides were selected as they have been reported to be presented by the most 
common Caucasians HLA allele (HLA-A*0201 present in approximately 50% of the 
population) and exert specific lysis against WT1-expressing leukaemia cells (Oka et 
al., 2000). In order to identify leukaemia AML and ALL samples which were 
positive for WT1 for subsequent use in cytotoxicity assays, forty samples were 
analysed for WT-1 expression 
 
3.3. Results  
3.3.1. WT1 antigen screening in leukaemia patients and normal donors 
The mRNA expression pattern of the WT1 antigen was evaluated in PBMCs of 
AML (n=20), ALL (n=20) and in PBMCs of healthy volunteers (n=28) using 
conventional RT-PCR. This screening was performed for two purposes. The first 
purpose was to compare the WT1 gene expression level in acute leukaemia patients 
and in normal donors. The second purpose was to be able to select the HLA-
A*0201+ leukaemia donors expressing the WT1 gene to be used (if needed) as 
targets for T cells generated against the WT1 peptides.   
 
Total RNA was extracted from the PBMCs of patients and healthy donors and 
reverse transcriptized into cDNA using Moloney murine leukaemia virus. The 
extraction and reverse transcription methods are described in Chapter 2 section 2.13 
and 2.14, respectively. The conventional RT-PCR was performed as described in 
Chapter 2 section 2.15. The amplification product of the house keeping gene β-actin 
served as control of cDNA quality. RNA isolated from K562 cell line, which 
expresses WT1, served as a positive control.  Distilled water served as a negative 
control. The expression of the WT1 gene was classified into one of the following 
categories: - , no detectable mRNA expression; +, low expression; ++, moderate 
expression; +++, high expression. The intensity of the positive bands determined the 
level of antigen expression. 
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The results show that 16/20 (80%) of AML patients and 9/20 (45%) of ALL patients 
express the WT1 gene. In total, WT1 expression was detected in 25/40 (62.5%) of 
acute leukaemia patients. However, WT1 expression was not detected in any of the 
27 normal donors tested. Results are shown in Figure  3.1 and Table  3.1. As shown 
in Table  3.1, there was no clear relation between WT1 expression levels and the 
blast number (the percentage of blasts varies between 1% and 99%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 
 
16/20 (80%) AML patients express the  WT1 gene  
 
 
      WT1 
 
 
-actin 
 
 
9/20 (45%) ALL patients express the  WT1 gene  
 
 
      WT1  
 
-actin  
 
           Normal donors 
 
 
      WT1  
 
-actin 
 
Figure  3.1. RT-PCR analysis of WT1 gene expression in PBMCs from AML, ALL patients 
and normal donors.  
80% of AML patients and 45% of ALL patients expressed the WT1 antigen, whereas none of the 
normal donors expressed the WT1 antigen.  
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Table  3.1.  Clinical features of leukaemia patients with WT1 gene expression. 
 
Patients # 
 
 
Subtypes 
 
 
Status 
 
 
% Blast 
 
 
WT1 expression 
 
 
M0 
 
AML 3 
 
New 
 
84 
 
++ 
M1 AML 1 New 61 + 
M2 AML 5 New   1 - 
 AML 7 New 61 + 
 AML 8 New  20 +++ 
 AML 19 New 23 + 
 AML 29 Rel  Post chemo 81 - 
M4E0 AML 13 2nd Rel post allo BMT 10 + 
 AML 36 New 12 ++ 
M4 AML 25 New 52 +++ 
 AML 27 New 81 +++ 
 AML 28 New 61 + 
M5a AML 2 New NR  - 
 AML 12 New  79 - 
M5 AML 11 New 80 ++ 
 AML 16 New 4 ++ 
 AML 24 New 50 +++ 
 AML 31 New 13 ++ 
 AML 34  Rel Post allo BMT 80 +++ 
M6 AML 20 New 65 ++ 
     
Pre T-cell ALL 26 New 99 ++ 
T-cell ALL 1 Rel 6 - 
 ALL 2 Rel  Post-BMT  87 - 
 ALL 3 Rel 87 - 
 ALL 13 New 75 +++ 
 ALL 16 New NR ++ 
 ALL 18 New 94 - 
 ALL 22 New 47 ++ 
 ALL 23 New 84 +++ 
Pre B-cell ALL 4 New 55 + 
 ALL 5 New 56 +++ 
 ALL 20 New 5 + 
 ALL 21 New 83 + 
 ALL 27 New 59 - 
 ALL 28 New 88 - 
 ALL 29 New 2 - 
 ALL 36 Rel on chemo NR - 
B-cell ALL 10 New 59 - 
BP / Biclonal  ALL 7 New 89 - 
ALL 24 NR Rel 61 - 
 
 New, newly diagnosed; Rel, relapsed; - , no detectable mRNA expression; +, low expression; ++, 
moderate  expression; +++, high expression  
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3.3.2. Identification of peptides predicted to highly bind to the HLA-A0201 
molecule 
Two WT1 peptides known to be HLA-A*0201 restricted peptides (Oka et al., 2000), 
were modified by substituting the amino acid at position 1 with tyrosine (Y). The 
binding of the wild-type peptides (126N and 187N) with their corresponding 
analogues (126Y and 187Y) to the HLA-A*0201 molecule was compared using a 
computer-based epitope prediction program 
(http://bimas.dcrt.nih.gov/molbio/hla_bind/). The amino acid sequences of each 
peptide (wild-types and analogues) were entered into the BIMAS program and the 
HLA-A*0201 molecule was selected. After entering the amino acid sequence and 
selecting the MHC type, the predicted binding score for each peptide was obtained. 
The data indicated that this tyrosine modification resulted in a 4.6-fold increase in 
the estimated half-time of disassociation of the modified peptides to HLA-A*0201 
compared with their native counterparts as shown in Figure 3.2 .  
 
The computer-based epitope prediction program has been suggested to have only 
60–80% predictive accuracy (Pinilla-Ibarz et al., 2006). Therefore, the strength of 
the interaction between these peptides and the HLA-A*0201 molecules was directly 
measured using the T2 binding assay. The assay was performed twice; however, 
different concentrations of the WT1-derived peptides were used. T2 cells were 
pulsed with either 50, 30, 15, 7 and 1μM or with 70, 7 and 0.7 μM of each peptide 
overnight at 37˚C in a serum-free medium. Cells were washed, stained with FITC-
conjugated anti-HLA-A2 monoclonal antibody and analyzed by flow cytometry. The 
HLA-A*0201 expression by the T2 cells was quantified as fluorescence index 
according to the following formula: fluorescence index = (median fluorescence 
intensity with peptide - median fluorescence intensity without peptide)/ median 
fluorescence intensity without peptide. Figures 3.3, 3.4, 3.5 and 3.6 show the flow 
cytometric analyses of T2 cells incubated overnight with different concentrations 
(50, 30, 15, 7 and 1μM) of either native or modified 126 and 187 peptides. Figures 
3.7, 3.8, 3.9 and 3.10 show the flow cytometric analyses of T2 cells incubated 
overnight with different concentrations (70, 7 and 0.7μM) of either native or 
modified 126 and 187 peptides. 
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Using different concentrations of the 9-mer peptides, an enhanced binding of the 
126Y analogue peptide was observed compared to the wild-type 126N peptide at all 
doses tested (Figure 3.11A). A concentration of 50 µM of the 126N peptide was 
needed to achieve a 2.5 fluorescence index, while only 15 µM of the 126Y peptide 
was sufficient to reach the 2.5 fluorescence index. However, modification of the 187 
peptide (187Y) did not enhance its binding ability and stabilization of the HLA-
A*0201 molecules (Figure 3.11 B). The same pattern of peptide binding affinity was 
observed when the binding assay was repeated with different peptide concentrations 
(70, 7 and 0.7 μM) (Figure 3.11A and B). 
 
These data show a selective enhancement of peptide binding to HLA-A*0201 after 
modification, and thus demonstrated a good model to test the effect of this process 
on the function of the generated T cells. 
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Figure  3.2.  Wild-type (WT1-126N, WT1-187N) and the modified (WT1-126Y, WT1-187Y) 
peptides binding affinities to HLA-A*0201 molecule as predicted by the computer-based epitope 
prediction program BIMAS.   
Using this program, we have shown that substitution of the tyrosine (Y) at position 1 resulted in 4.6-
fold increase in the estimated half time of disassociation of the modified peptides compared to their 
native counterparts. 
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Figure  3.3.  Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells cultured 
overnight in the absence or in the presence of 50, 30, 15, 7 and 1µM of the WT1-126N peptide.  
Following incubation with different concentrations of the native 126N peptide, the T2 cells were 
stained with HLA-A2 specific monoclonal antibody (BB7.2) and analyzed by flow cytometry. 
*Median fluorescence intensities of T2 cells stained with anti-HLA-A2 antibody.  
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Figure  3.4.  Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells cultured 
overnight in the absence or in the presence of 50, 30, 15, 7 and 1µM of the WT1-126Y peptide. 
Following incubation with different concentrations of the analogue 126Y peptide, the T2 cells were 
stained with HLA-A2 specific monoclonal antibody (BB7.2) and analyzed by flow cytometry. 
*Median fluorescence intensities of T2 cells stained with anti-HLA-A2 antibody. 
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Figure  3.5.  Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells cultured 
overnight in the absence or in the presence of 50, 30, 15, 7 and 1µM of the WT1-187N peptide.  
Following incubation with different concentrations of the analogue 187N peptide, the T2 cells were 
stained with HLA-A2 specific monoclonal antibody (BB7.2) and analyzed by flow cytometry. 
*Median fluorescence intensities of T2 cells stained with anti-HLA-A2 antibody. 
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Figure  3.6.  Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells cultured 
overnight in the absence or in the presence of 50, 30, 15, 7 and 1µM of the WT1-187Y peptide.  
Following incubation with different concentrations of the analogue 187Y peptide, the T2 cells were 
stained with HLA-A2 specific monoclonal antibody (BB7.2) and analyzed by flow cytometry. 
*Median fluorescence intensities of T2 cells stained with anti-HLA-A2 antibody. 
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Figure  3.7.  Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells cultured 
overnight in the absence or in the presence of 70, 7 and 0.7µM of the WT1-126N peptide.  
Following incubation with different concentrations of the native 126N peptide, the T2 cells were 
stained with HLA-A2 specific monoclonal antibody (BB7.2) and analyzed by flow cytometry. 
*Median fluorescence intensities of T2 cells stained with anti-HLA-A2 antibody. 
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Figure  3.8.  Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells cultured 
overnight in the absence or in the presence of 70, 7 and 0.7µM of the WT1-126Y peptide.  
Following incubation with different concentrations of the analogue 126Y peptide, the T2 cells were 
stained with HLA-A2 specific monoclonal antibody (BB7.2) and analyzed by flow cytometry. 
*Median fluorescence intensities of T2 cells stained with anti-HLA-A2 antibody. 
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Figure  3.9.  Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells cultured 
overnight in the absence or in the presence of 70, 7 and 0.7µM of the WT1-187N peptide.  
Following incubation with different concentrations of the native 187N peptide, the T2 cells were 
stained with HLA-A2 specific monoclonal antibody (BB7.2) and analyzed by flow cytometry. 
*Median fluorescence intensities of T2 cells stained with anti-HLA-A2 antibody. 
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Figure  3.10. Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells cultured 
overnight in the absence or in the presence of 70, 7 and 0.7µM of the WT1-187Y peptide.  
Following incubation with different concentrations of the analogue 187Y peptide, the T2 cells were 
stained with HLA-A2 specific monoclonal antibody (BB7.2) and analyzed by flow cytometry. 
*Median fluorescence intensities of T2 cells stained with anti-HLA-A2 antibody. 
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Figure  3.11. The binding ability of WT1-derived peptides to HLA-A*0201 molecule as 
measured by a standard T2 stabilization assay.  
The experiment was performed at either 50, 30, 15, 7 and 1μM or at 70, 7 and 07 μM of each peptide.  
X axis represents different concentrations per well of the peptide tested. Fluorescence index is shown 
on the Y axis.  (A): HLA-A*0201 epitope enhancement of the WT1-126N wild-type peptide by an 
amino acid substitution (Y) at position 1 (126Y) analogue peptide. (B) No enhancement in the case of 
peptide 187Y. 
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3.3.3. Generation of WT1 peptide-specific cytotoxic T cell lines  
The effect of a tyrosine modification of the WT1-126 peptide on its ability to induce 
specific CTL compared with its wild-type peptide, was tested because only the 126Y 
analogue peptide but not the 187Y peptide showed a high binding affinity to the 
HLA-A*0201 molecule compared to their other peptide counterparts. An optimized 
T-cell activation protocol, with CD14+ monocytes-derived DC as antigen presenting 
cells, and purified CD8+ T cells as responders was used in order to generate and 
expand T cell lines specific to the native (126N) and the modified (126Y) peptides. 
The method for the generation of the T cell lines is as illustrated in Figure 3.12. The 
PBMCs were obtained from three normal healthy HLA-A*0201 donors designated 
as BC-21, BC-32 and BC-37, and used as a source of APCs and responder cells. 
Monocytes and CD8+ T cells were isolated from BC-32 by negative selection using 
magnetic beads. Cells were stained with FITC-conjugated anti-CD14 antibody and 
analyzed by flow cytometry in order to determine the degree of purity achieved 
during monocyte separation. Ninety-five percent of the purified cells were CD14+ as 
shown in Figure 3.13A, and were used to generate conventional DCs as described in 
Materials and Methods section 2.5.4.2. For CD8+ T cells, aliquots of cells before and 
after the separation were collected and stained with FITC-conjugated anti-CD8 
antibody. The percentage of CD8+ T cells among PBMC-32 was 22% (Figure 
3.13B) and the purity of the CD8+ T cells fraction was 82% (Figure 3.13C) as 
verified by flow cytometry. DCs were used to prime CD8+ T cells since DCs are the 
most potent stimulators of naïve T lymphocytes. The expression level of CD1a, and 
CD83 on the cell surface of the mature DCs were analysed by flow cytometry. 
Preliminary experiments that used PBMCs obtained from other normal donors were 
carried out to compare the expression levels of the DC-related markers by immature 
as well as mature DCs. These experiments showed that the mature DCs down 
regulated the expression level of CD1a whereas the expression level of the 
activation marker CD83 was up regulated. As shown in Figure 3.14A and B, only 
0.5% of the mature DCs expressed the CD1a marker while 85% of them expressed 
CD83 marker.  
 
To compare the immunogenicity of the native and the modified WT1-126 peptides 
as well as to investigate whether the generated line against the analogue peptide 
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could enhance stronger CTLs response and more importantly whether it cross-
reacted with its naturally occurring counter-part, the CTLs were tested after 3 to 8 
rounds of stimulations against different HLA-A*0201+ targets in the presence or 
absence of autologous peptide using a Chromium Release Assay and an ELISPOT 
assay.  
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Figure  3.12.  Method used to generate CTLs specific for 126N and its analogue (126Y) peptides.  
 Peptide-pulsed autologous DCs were used to prime and re-stimulate CD8+T cells. IL-7 and IL-12 
were added at the initiation of the cultures. IL-2 was added one day after each subsequent stimulation. 
The immunogenicity of the generated CTL lines were tested and compared after 3-8 rounds of 
stimulation. 
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Figure  3.13.  Efficiency of magnetic bead cell separation.  
(A) Flow cytometry analysis of CD14+ cells isolated from PBMC-32 by negative selection (B) Flow 
cytometry analysis of CD8+ in PBMC-32 before separation (C) and after separation. 
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Figure  3.14. Flow cytometry analysis of CD1a and CD83 expression in the mature-monocytes 
derived DC-32.  
(A) Histograms show that 0.5% of DC-32 expresses CD1a marker. (B) Histograms show that 85% of 
DC-32 expresses the activation marker CD83.  
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3.3.4. Enhanced cytotoxicity of CTL generated against WT1-126Y  
We tested the effect of tyrosine modification of the WT-126 peptide on its ability to 
induce specific CTL compared with its wild-type peptide. After three to eight rounds 
of stimulations, the generated T cell lines were tested against the autologous LCLs 
or T2 cells in the presence or absence of autologous peptide using a Chromium 
Release Assay. At the early stages of T cell stimulation, most of the T cells’ 
responses were not specific.  Therefore, the T cell lines were subjected to weekly 
stimulation and the cytotoxic assay was performed five days after each antigen-
specific stimulation.   Cross-reactivity between the two peptides was also tested to 
determine if the analogue peptide 126Y is able to induce an immune response to the 
native peptide (126N). The lytic activity of the T cell lines generated from BC-32 
against 126N and 126Y after four and seven rounds of stimulations are presented in 
Figure 3.15A and B, respectively. Figure 3.15A shows that the CTL raised against 
the native (WT1-126N) and the modified (WT1-126Y) peptides were not able to 
specifically lyse the peptide-loaded LCLs. The assay was done after only four 
rounds of T cell stimulation. Figure 3.15B shows that following the seventh antigen-
specific re-stimulation, specific lysis was recorded against the T2 cells for both BC-
32 T cell lines raised against the 126N peptide and its 126Y analogue, because there 
was no T cell response against the T2 cells in the absence of the peptides. However, 
a significantly (P=0.0006) higher lytic activity was recorded when the T cell line 
raised against the 126Y modified peptide was used (Figure 3.15B). Interestingly, we 
found cross reactivity of each T cell line with the opposite peptide. In this, the T cell 
line generated against the wild-type 126N peptide was able to equally lyse the T2 
cells loaded with the 126N or the 126Y. Similar results were obtained for the T cell 
line generated against the analogue 126N peptide. The generated T cell lines were 
tested against different APCs loaded with the corresponding peptide such as 
autologous LCLs and T2 cells. Usually when the T cells showed a specific killing 
response against one of the peptide-loaded target cells, they will show killing 
responses against other peptide-loaded targets. The 126N and 126Y CTLs failed to 
recognize peptide-loaded LCLs because the test was done after four rounds of T cell 
stimulation. CD8+ T cells needed more rounds of antigen-stimulation before a 
specific response is seen.  
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To confirm that the T cells response generated against both the wild-type 126N and 
the 126Y peptides is restricted to the HLA-A*0201 molecule, an HLA blocking 
assay was performed. Blocking of the HLA-ABC resulted in a strong inhibition of 
the cytotoxic activity of both T cell lines against peptide-loaded T2 cells (Figure 
3.16). However, the isotype control did not inhibit the cytotoxic activity of this T 
cell lines. These data show that the tyrosine modification of the WT1-126 peptide, 
which enhanced their binding to HLA-A*0201, can increase its lytic activity not 
only to the 126Y epitope, but also to the wild-type 126N counterpart.  
 
The lytic activity of the T cell lines generated against the native peptide 126N and its 
analogue 126Y from BC-21 and BC-37 was also tested and compared. However, 
none of these T cell lines elicit any peptide-specific cytotoxic responses. These T 
cell lines were challenged with T2 cells pulsed with no peptide or with each peptide 
at different E:T ratio starting from 100:1.  Figure  3.17A and B shows the failure of 
the 126N and 126Y T cell lines generated from BC-21 to recognize T2 cells loaded 
with either the native or with the analogue peptide.  Similar findings have been 
reported for the T cell lines generated from BC-37. As shown in Figure  3.18A and 
B, BC-37 T cell lines did not exert any specific cytotoxicity towards T2 cells loaded 
with either the native or with the analogue peptide  
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Figure  3.15.  Cytotoxicity assay with T cells generated against WT1-126N and WT1-126Y 
peptides from a healthy HLA-A*0201 donor. 
Cytotoxicity of the T cell line generated against the native 126N peptide is shown with the closed 
symbols. Cytotoxicity of the T cell line generated against the analogue 126Y peptide is shown with 
the opened symbols. (A): Non-specific lysis by CTLs generated against 126N and 126Y peptides 
after the fourth round of in vitro antigen-stimulation. Target cells were autologous LCLs pulsed with 
either no peptide (♦,◊), 126N peptide (■,□) or with 126Y peptide (▲,∆). (B): Specific  lysis by  CTLs 
generated against 126N and 126Y peptides after the seventh round of in vitro antigen-stimulation. 
Target cells were T2 cells pulsed with either no peptide (♦,◊), 126N peptide (■,□) or with 126Y 
peptide (▲,∆). The data are presented as the percentage specific lysis at the indicated E:T ratios. 
Error bars (±SD) represent triplicate wells from one experiment. P value between A and B=0.0006.  
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Figure  3.16.  Inhibition of lytic activity of BC-32 T cell lines generated against WT1-126N and 
WT1-126Y peptides after blocking with an anti-ABC antibody showing the restriction response to the 
HLA-A*0201 molecule.  
The assay was performed after the seventh round of in vitro antigen-stimulation. Ab was added to the 
wells containing T2 cells 20 min before the addition of T cells. The data are presented as the 
percentage specific lysis at E:T ratio of 40:1. Error bars (±SD) represent triplicate wells from one 
experiment. 
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Figure  3.17.  Non-specific lysis by BC-21 T cell lines generated against WT1-126N and WT1-
126Y peptides as tested using a standard chromium release assay.  
The T cell line generated from a normal HLA-A0201+ donor, BC-21, were used as effector cells. 
Target cells were T2 cells pulsed with either no peptide (♦), with 126N peptide (■) or with 126Y 
peptide (▲). (A) Shows the cytotoxicity of the T cell line generated against the native 126N peptide.  
(B) Shows the cytotoxicity of the T cell line generated against the analogue 126Y peptide. The data 
are presented as the percentage specific lysis at the indicated E:T ratios and represents the average of  
two experiments and error bars indicate the SD. 
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Figure  3.18.  Non-specific lysis by BC-37 T cell lines generated against WT1-126N and WT1-
126Y peptides as tested using a standard chromium release assay.  
The T cell line generated from a normal HLA-A0201+ donor, BC-37, were used as effector cells. 
Target cells were T2 cells pulsed with either no peptide (♦), with 126N peptide (■) or with 126Y 
peptide (▲). (A) Shows the cytotoxicity of the T cell line generated against the native 126N peptide.  
(B) Shows the cytotoxicity of the T cell line generated against the analogue 126Y peptide. The data 
are presented as the percentage specific lysis at the indicated E:T ratios and represents the average of 
two experiments and error bars indicate the SD. 
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3.3.5. WT1-126Y peptide increased the frequency of IFN-γ producing T cells 
We have tested the 126N and the 126Y T cell lines for the frequency of IFN-γ 
producing T cells after three rounds of in vitro stimulation using an ELISPOT assay. 
Results obtained from two experiments are shown in Figure  3.19A. Both T cell lines 
generated from BC-32 produced specific IFN-γ in response to stimulation with 
autologous LCL loaded with their corresponding peptide (Figure  3.19A). However, 
the T cell line generated with the analogue 126Y peptide exerted a significantly 
higher number (P=0.0003) of IFN-γ producing T cells compared with that generated 
against the 126N wild-type peptide (Figure  3.19A). The 126N and 126Y T cell lines 
were challenged with the PHA to explore whether the two T cell lines did not differ 
in the proportion of T cells capable of IFN-production. As shown in Figure  3.19B, 
the two lines did not differ in the proportion of T cells capable of IFN- production. 
These data demonstrate that modification of the WT1-126 peptide can increase the 
frequency of IFN-γ producing T cells and thus making them better effector cells. 
 
The 126N and the 126Y T cell lines generated from BC-21 and BC-37 were also 
tested for the frequency of IFN-γ producing T cells. Consistent with the cytotoxic 
findings, these T cell lines did not produce specific IFN- when stimulated with 
autologous LCL loaded with their corresponding peptide (Figure  3.20 and Figure 
 3.21). 
 
 
 
 105 
 B
0
20
40
60
80
100
120
140
126N T cell
line
126Y T cell
line
IF
N
- g 
sp
ot
s/
20
.0
00
 C
D
8+
 T
 
ce
lls
T cells + PHA 
A
0
5
10
15
20
25
30
126N T cell line 126Y T cell lineIF
N
- g
 s
po
ts
/2
0.
00
0 
C
D
8+
 T
 c
el
ls
 
T cells only
T cells + LCL 
T cells + LCL + PEPTIDE 
IF
N
- g 
sp
ot
s/
20
.0
00
 C
D
8+
 T
 
ce
lls
IF
N
- g
 s
po
ts
/2
0.
00
0 
C
D
8+
 T
 c
el
ls
 
 
Figure  3.19. Specific production of IFN- by the two T cell lines generated against the wild type 
126N and its analogue 126Y peptides as measured by an ELISPOT assay.  
The T cell lines were established from BC-32, an HLA-A0201+ donor, and tested following three to 
eight rounds of in vitro T cell stimulations. The background observed when T cells alone were used is 
shown. (A) T cells were stimulated with autologous LCL± peptide for 40 h in anti-IFN- pre-coated 
wells before development of the spots. T cells incubated without stimulators (T cell only) served as a 
baseline. (B) T cells stimulated with PHA did not differ in the proportion of T cells capable of IFN- 
production.   Results are expressed as IFN- γ positive cells per 20.000 CD8+ T cells and are the mean 
of duplicate assays (±SD). 
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Figure  3.20.  Non-specific IFN- release by BC-21 CTLs generated against the WT1-126N and 
WT1-126Y peptides using an IFN-γ- ELISPOT assay. 
The T cell lines were established from BC-21, an HLA-A0201+ donor, and tested following three to 
eight rounds of in vitro T cell stimulations. Targets were autologous LCLs pulsed with either no 
peptide or with peptide. The background observed when T cells alone were used is shown. Results 
are expressed as IFN- γ positive cells per 20.000 CD8+ T cells and are the mean of triplicate assays 
(±SD).  
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Figure  3.21.  Non-specific IFN- release by BC-37 CTLs generated against the WT1-126N and 
WT1-126Y peptides using an IFN-γ- ELISPOT assay. 
The T cell lines were established from BC-37, an HLA-A0201+ donor, and tested following three to 
eight rounds of in vitro T cell stimulations. Targets were autologous LCLs pulsed with either no 
peptide or with peptide. The background observed when T cells alone were used is shown. Results 
are expressed as IFN- γ positive cells per 20.000 CD8+ T cells and are the mean of triplicate assays 
(±SD).  
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3.3.6. Evaluation of WT1 expression and lytic activity of anti-WT1 T cell lines 
against HLA-A0201-matched leukemic cells  
Given the above, the feasibility of using this modification approach of the WT1-126 
peptide to generate CTLs that effectively kill HLA-A*0201-matched leukemic cells 
was tested. The expression of the WT1 mRNA in fresh AML cells (AML-27 and 
AML-28) was examined using Q-RT-PCR. K562 cells, known to express high levels 
of WT1 (Greiner et al., 2004) were used as a positive control. PBMC-32 derived 
from a normal donor was used as a negative control. Higher levels of WT1 
expression were observed in AML samples (Table 3.2). The lytic activity of the two 
T cell lines generated against the 126N and 126Y peptides were then measured 
against PBMCs from HLA-A*0201-matched (AML-28) and non-HLA-A0201 
matched (AML-27) AML patients. Specific lytic activity was recorded for both T 
cell lines against the AML-28 cells expressing the HLA-A*0201 molecule (Figure 
 3.22). However, both T cell lines failed to recognise non-HLA-A*0201 AML-27 
even though they expressed high levels of WT1 (Figure  3.22). Interestingly, the T 
cell line generated with the analogue 126Y peptide exerted a significantly higher 
lytic activity (P=0.0014) compared with that generated against the 126N wild-type 
peptide (Figure  3.22). Altogether, our data indicated that the modified WT1-126Y 
enhanced its binding to HLA-A*0201, increased the frequency of IFN-γ producing 
T cells, and boosted the lytic activity against HLA-matched leukaemia cells. 
Therefore, modification of the WT1-126 peptide provides a potential approach for 
the development of leukaemia vaccine. 
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Table  3.2.  Clinical characteristics of patients and donors used in the study 
Donor/Patient 
Samples 
 
HLA-A 
Type 
 
% Blasts1 
 
QRT-PCR2  
 
RT-PCR3 
 
Status4 
 
FAB-
Type5 
 
PBMC-32 
 
A0201, 29 
 
 
NA 
 
60 
 
- 
 
 
NA 
 
NA 
AML-27 
 
25,29 
 81 7950 +++ 
new 
 M4 
AML-28 A0201, 26 61 1800  + 
new 
 M4 
 
1 % blasts were determined routinely by the hematopathology laboratory 
 
2 Quantitative real-time PCR data for the expression level of WT1 which normalized from K562 
set on 1000 
 
3 Conventional RT-PCR data for the expression of WT1 
 
4 New indicates that samples were taken at first diagnosis 
 
5 French-American-British classification 
 
 NA=not applicable 
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Figure  3.22. Cytotoxicity assay showing the lytic activity of the 126N and 126Y T cell lines 
against HLA-A*0201-matched (AML-28) and non-matched AML-27 cells. 
The T cell lines generated from a normal HLA-A0201+ donor, BC-32, were used as effector cells.  
The T cell lines were tested after eight rounds of in vitro T cell stimulations. The data are presented 
as the percentage specific lysis at E:T ratio of 40:1. Error bars (±SD) represent triplicate wells from 
one experiment. 
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3.4. Discussion 
Majority of tumour-associated antigens, which have been identified so far, are 
derived from self-antigens. Immunological tolerance can prevent the development of 
immune responses against such self-antigens. Therefore, most self/tumour antigens 
used in clinical trials so far showed poor immunogenicity. To circumvent the 
problem of tolerance, Stauss et al. (Bellantuono et al., 2002, Gao et al., 2000) 
developed an allo-restricted CTL against leukaemia. In this approach, T cells from 
HLA-A*0201 donors were stimulated with peptide loaded HLA-A*0201-matched 
APCs. This allowed the generation of high-avidity allo-restricted CTLs against an 
HLAA0201 WT1-derived epitope. Interestingly, the generated CTLs specifically 
lysed WT1 , HLA-A*0201-matched leukaemia cells. More importantly, only the 
high-avidity CTLs were able to eliminate the progenitors of CFU-GM and BFU-GM 
from CD34 CML samples, whereas normal CD34 progenitors/stem cells were 
spared (Bellantuono et al., 2002, Gao et al., 2000). However, as allogeneic APCs 
usually provoke dominant CTL responses against allogeneic epitopes, the isolation 
of HLA-A0201-WT1 peptide-specific allogeneic CTLs was unsuccessful in many 
cases. Another drawback of this strategy is the difficultly in applying such an 
approach in clinical settings. A more promising approach has been recently 
developed by the same group, which rely on introducing the WT1-specific TCR into 
autologous T cells for possible future clinical applications (Xue et al., 2005). 
Because the WT1 is a self-protein expressed at low levels in some normal cells 
(Ellisen et al., 2001, Menssen et al., 1997), many of the potential CTL epitopes from 
this antigen may be absent or ‘sub-optimal’. This is due to clonal deletion of high-
avidity CTLs during maturation of the immune system. Therefore, the induction of 
antitumor immune responses frequently needs to be addressed against those ‘sub-
optimal’ CTL epitopes to enhance their immunogenicity, frequency and hence their 
therapeutic potential. In addition, naturally arising CD25+ CD4+ regulatory T cells 
(Tregs), play an important role in the maintenance of immunologic self-tolerance 
(Sakaguchi et al., 2006). Although this T cell population plays a key role in 
regulating the immune response to self antigen, it has been shown recently that 
Tregs can directly suppress the anti-tumour immune responses in cancer patients 
(Beyer and Schultze, 2006, Clarke et al., 2006, Khazaie and von Boehmer, 2006, 
Orentas et al., 2006). Indeed, another group demonstrated that the depletion of this T 
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cell population resulted in an enhancement of vaccine-mediated anti-tumour 
immunity in cancer patients (Dannull et al., 2005). Furthermore, a recent study 
showed that such response can be largely affected by the presence of CD4 +CD25+ 
Tregs and depletion of this T cell population was necessary for the generation of an 
effective WT1- specific cytotoxic response (Asemissen et al., 2006).  
 
It is known that the immunogenicity of antigenic peptides is dependent on their 
binding affinity to MHC class I molecules; stability of the peptide-MHC complexes; 
and the avidity of the TCR binding to the peptide complex (Yu et al., 2004). It has 
been demonstrated that the poor immunogenicity of some self/tumour antigens is 
due to the instability of the peptide-MHC complex rather than low affinity of T cell 
receptors to peptide-MHC complexes (Yu et al., 2004). Therefore, many studies 
have focused on introduction of a peptide modification to improve the binding of 
self antigenic peptides to their corresponding MHC class I molecules and 
consequently enhance the immunogenicity of these peptides (Bakker et al., 1997, 
Chen et al., 2000, Hoffmann et al., 2002, Parkhurst et al., 1996, Rosenberg et al., 
1998, Tangri et al., 2001, Valmori et al., 1998). In the present study, we have 
applied a previously described  strategy to enhance the immunogenicity of low-
avidity HLA-A0201-restricted peptides without altering their antigenic specificity 
(Tourdot et al., 2000). Briefly, this consists of substituting the first amino acid of the 
epitope with a tyrosine (Y). The importance of this approach is that the resulting 
peptide analogues are able to efficiently trigger in vivo wild-type peptide-specific 
CTLs which also recognised the naturally occurring epitope (Tourdot et al., 2000). 
We have carried out the Y amino acid substitution in the sequence of the two known 
HLA-A*0201- restricted Db126 and WH187 WT1-derived peptides (Oka et al., 
2000). Using a computer-based epitope prediction program, the 126Y and 187Y 
analogue peptides were predicted to bind 4.6-fold more to the HLA-A0201 molecule 
compared to their native 126N and 187N counterparts. However, a significant 
enhancement of the actual binding ability was recorded for the 126Y peptide 
analogue when we used the T2 binding assay. Therefore, we generated CTLs lines 
against the wild-type 126N and its 126Y peptide analogue. Although both peptides 
were able to induce specific cytotoxic immune responses against autologous 
peptide-loaded T2 cells, the CTL line generated with the 126Y peptide showed a 
higher and significant lytic activity compared with the CTL line generated with the 
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126N wild-type peptide. Interestingly, CTL generated against the 126Y analogue 
peptide was able to lyse the T2 target cells when loaded with the wild-type peptide. 
Therefore, modification of the 126 peptide resulted in enhancement of its 
immunogenicity without altering its antigenic specificity. Another important finding 
was the significant high lytic activity observed for the 126Y CTL line against HLA-
A*0201-matched leukemic cells expressing the WT1 antigen. These data imply that 
the generated 126N and 126Y T cell lines were different. In addition, these data 
confirm that T cells generated against the 126Y analogue peptide cross-react also 
with the naturally processed 126N native peptide. These results suggest that 
stimulation with the 126Y peptide analogue induced CTLs with a high TCR avidity. 
Finally, the high lytic activity provoked by the 126Y CTL may also be attributed to 
the significantly high number of anti-126 T cells in this T cell line as demonstrated 
by γ-IFN production. 
 
During the course of this study, Pinilla-Ibarz et al. (Pinilla-Ibarz et al., 2006) 
reported on a similar study based on the same strategy to modify several HLA-
A0201 WT1-derived peptides including the 126N, 187N and their analogues as 
described in the present work. Although, this group did not find any difference in the 
binding affinity between the 2 126N and 126Y peptides, they reported that 
stimulation with the 126Y peptide analogue was able to generate an earlier and 
stronger specific CTL than that generated with the 126N wild-type peptide. 
Consistent with our findings the 126Y CTL line was able to recognise the 126N 
wild-type peptide on the target cells and specifically lyse HLA-A0201-matched 
leukaemia cells expressing the WT1 antigen. Another group has introduced a 
tyrosine modification in position two of a 9-mer WT1-derived peptide which is 
known to bind to the HLA-A*2402 molecule and showed a better binding affinity 
and elicitation of higher lytic activity (Tsuboi et al., 2002). Moreover, the modified 
peptide has been used to vaccinate cancer patients where a clear correlation was 
observed between an increase in the frequencies of WT1-specific CTL after 
vaccination and clinical responses (Oka et al., 2004). 
 
In conclusion, this study is consistent with previously reported findings (Oka et al., 
2004, Pinilla-Ibarz et al., 2006, Tsuboi et al., 2002) and has shed more light on the 
importance of peptide modification as a new approach in elucidating a better 
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immune response, needed to combat cancer. On the basis of these findings, 
leukaemia patients could be clinically tried for vaccination with the current WT1-
126Y peptide analogue or adoptively treated with ex vivo anti-WT1-126Y T cells to 
specifically enhance the graft-versus-leukaemia effect and anti-WT1 CTL 
frequency, which are known to be very low in these patients.  
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4. IDENTIFICATION OF A NOVEL WT1-DERIVED 
EPITOPE RECOGNIZED BY HUMAN CD4+ T 
CELLS 
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4.1. Introduction  
Compelling evidence indicates a key role for regulatory T cells (Tregs) in the host 
response to cancer. In both mice and humans, Treg populations were shown to 
directly suppress anti-tumour immunity and to contribute to tumour growth and 
progression  (Beyer and Schultze, 2006, Ghebeh et al., 2008, Shen et al., 2009, Ke et 
al., 2008, Sakaguchi, 2004, Lizee et al., 2006). Depletion or reduction of this T-cell 
population restored the anti-tumour immunity and resulted in an enhancement of 
vaccine efficacy in cancer patients (Dannull et al., 2005, Ruter et al., 2009, 
Nishikawa et al., 2005, Mahnke et al., 2007). Furthermore, patients with solid 
tumours as well as haematological malignancies have been shown to have increased 
prevalence of Tregs (Sasada et al., 2003, Ichihara et al., 2003, Strauss et al., 2007, 
Miller et al., 2006, Wang et al., 2005b, Beyer et al., 2006) . The presence of 
increased number of Tregs in cancer patients has been shown to be inversely related 
to the outcome of several malignancies (Salama et al., 2009, Heimberger et al., 
2008). Tregs may directly modulate the CD8+ T-cell response or alternatively 
promote tolerization of CD8+ T cells by preventing the licensing of antigen-
presenting cells (APC) by CD4+ T helper cells (Alpan et al., 2004, Bourgeois et al., 
2002). It has became clear that CD8+ T cells generated in the absence of CD4+ T 
cells help may have a normal primary response; however, their cytotoxic memory 
response is severely weakened (Janssen et al., 2003).  
 
In our lab, we generated a T cell line and clones that specifically recognized a WT1-
333-347 (RYFKLSHLQMHSRKH) peptide designated as WT1-84 in an HLA-
DRB1*0402–restricted manner. These T-cell clones produced GM-CSF, IL-4 and 
IL-5 in response to WT1-84 peptide exerting a T helper 2 cytokine profile. 
Importantly, they recognized HLA-DRB1*04 matched fresh leukemic cells 
expressing the WT1 antigen. These clones had a CD4+CD25+Foxp3+GITR+CD127– 
Tregs phenotype and significantly inhibited the proliferative activity of allogeneic T 
cells Importantly, anti–WT1-84 interleukin-5+/granzyme B+/Foxp3+ CD4+ Tregs 
have been detected in five of eight HLA-DR4+ acute myeloid leukaemia patients 
(Lehe et al., 2008).  
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4.2. Aim 
Specific anti-WT1 immune responses have been described in which CD8+ cytotoxic 
T cells have been generated in vitro (Asemissen et al., 2006, Oka et al., 2000, 
Azuma et al., 2002, Bellantuono et al., 2002, Li et al., 2008). However, a recent 
study showed that such response can be largely affected by the presence of 
CD4+CD25+ Tregs in which depletion of this T-cell population was necessary for 
the generation of an effective WT1-specific cytotoxic response (Asemissen et al., 
2006). In our lab, we generated a Treg clones specific for the WT1-84 antigen in an 
HLA-DRB1*0402–restricted manner. We also showed the existence of this T cell 
population in leukaemia patients. The aim of this part of the study was to investigate 
whether this T cell type could also be generated from other HLA-DR04+ donors. In 
this chapter, specific T cell lines and clones were generated against a mixture of 
peptides derived from the WT1 antigen (WT1-Pepmix) and tested for their peptide 
specificity by proliferation assay against different APCs loaded with WT1 peptides 
and also against WT1-expressing leukemic cells.   
 
4.3. Results 
4.3.1. Generation of T-cell lines against the WT1-Pepmix and analysis of their 
HLA restriction   
In order to confirm our previous findings in more HLA-DRB1*04 positive donors, 
T-cell lines from three healthy individuals designated as BC-52, BC-57 and BC-62 
were generated. Two of the donors, BC-52 and BC-62, share the same HLA-DR 
alleles i.e. 0402,1601 and matched with the donor used to generate the WT1-84 
reactive T cell lines in one of the DR alleles i.e., *0402, whereas the BC-57 donor 
has HLA-DR-*0406, 0701 alleles (Table  4.1). PBMCs from the three donors (BC-
52, BC-57 and BC-62) were stimulated for two rounds with autologous-
conventional DCs generated from blood monocytes as described in Materials and 
Methods section 2.5.4.2. The phenotype of the generated DCs from the three donors 
was verified by FACS analysis (Figure  4.1A, B and C). After two rounds of 
stimulation, the cells were re-stimulated with different autologous APCs i.e. 
monocytes and activated T cells (T-APCs). The T-APCs were prepared from a 
single donor (BC-57) as described in Materials and Methods section 2.5.3.  Mature 
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DCs were pulsed with WT1-Pepmix, a mixture of 110 synthetic 15-mer peptides that 
overlaps by 11 amino acids and spans the entire WT1 sequence. Figure  4.2 shows 
the sequence of the 110 peptides of the WT1-Pepmix. Corresponding T-cell lines 
designated TCL-52, TCL-57, and TCL-62 were generated and their proliferative 
activity was assessed in a thymidine uptake [3H]-proliferation assay. All T cell lines 
were tested after the fourth and the fifth round of stimulation and showed specific 
proliferative activity against autologous PBMCs pulsed with WT1-Pepmix (Figure 
4.3 A and B). Both TCL-52 and TCL-62 lines showed high proliferative activity 
against PBMCs pulsed with WT1-84 peptide. Additionally, the HLA restriction of 
the lines was determined in which anti–HLA-DR mAb was found to significantly 
inhibit their proliferation (Figure  4.3A & B). These data indicate that the two cell 
lines (TCL-52 and TCL-62) recognized WT1-84 peptide in an HLA-DR restricted 
manner and thereby confirming the previous findings. The TCL-52 and TCL-62 
were extensively studied by my colleague Cynthia Lehe who published her findings 
in the 2008 August 1 issue of the Cancer Research Journal (Lehe et al., 2008). 
 
The proliferation of TCL-57 against PBMCs and LCLs pulsed with the WT1-84 
peptide was not very strong indicating that the T cells were not recognizing the 
WT1-84 peptide (Figure  4.4). However, the TCL-57 showed strong proliferative 
activity against autologous PBMCs and LCLs pulsed with the WT1-Pepmix as 
shown in Figure  4.4.  The mean proliferation of TCL-57 to the Pepmix was 3.5 and 
1.8 times higher than the proliferation to autologous PBMCs and LCLs pulsed with 
the WT1-84 peptide, respectively (Figure  4.4). To analyze the HLA restriction of the 
TCL-57, an antibody-blocking assay was performed using monoclonal antibodies 
specific to class I and class II molecules. As shown in Figure  4.5, the proliferation of 
TCL-57 was inhibited to some extent by the use of anti-HLA-ABC, anti-HLA-DP 
and anti-HLA-DQ mAb but it was significantly inhibited by using anti-HLA-DR 
mAb. These data indicate that the TCL-57 recognized a peptide within the 110 
WT1-Pepmix peptides in an HLA-DR-restricted manner. The phenotype analysis of 
the generated TCL-57 using the flow cytometry revealed that that 95% of the 
generated T cells were CD4+ T cells (Figure  4.6A). These cells were also analyzed 
for the expression of two important Tregs markers CD25 and Foxp3 in CD4+ T cells. 
As shown in Figure  4.6B, 16.8% of the CD4+ T cells co-express CD25 and Foxp3.  
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Table  4.1.  HLA typing of normal donors used to generate anti-WT1 T cell lines. 
 
Subjects 
 
HLA-A 
 
HLA-B 
 
HLA-DRB1* 
 
HLA-DQ 
 
 
HLA-DP 
 
 
BC-52 
 
ND 
 
ND 
 
0402,1601 
 
0302,0502 
 
 
ND 
 
 
BC-57 
 
 
2,3 
 
5,5 
 
0406,0701 
 
0202,0402 
 
 
0401,0402 
 
BC-62 ND ND 0402,1601 0302,0502 
 
ND 
 
 
ND= not done 
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Figure  4.1.  Flow cytometry analysis of CD1a and CD83 expression in the mature-monocytes 
derived DCs.  
(A) (B) and (C) show the expression level of CD1a marker and the activation marker CD83 in DC-
52, DC-57 and DC-62, respectively.  
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Figure  4.2.  Sequence list of the 110 single WT1-derived micro-scale peptides  
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Figure  4.3.  Proliferative activity of T-cell lines generated against the WT1-Pepmix. 
T cells (25x104 per well) from two T-cell lines (TCL-52 and TCL-62) were challenged for 72 h with 
irradiated (2500 rads, XR) autologous PBMCs (105 per well) in the absence or presence of either 
WT1-Pepmix or WT1-84. Cells were pulsed with [3H] thymidine for an additional 18 h and then 
harvested. T cells only (none) were used as a negative control. HLA-DR mAbs were added to the 
wells containing PBMCs 20 min before the addition of T cells to confirm that the response was 
restricted to the HLA-DR molecule. (A): the proliferative activity of TCL-52 mixed with irradiated 
autologous PBMCs pulsed with the WT1-Pepmix or WT1-84 peptide. (B): the proliferative activity 
of TCL-62 mixed with irradiated autologous PBMCs pulsed with the WT1-Pepmix or WT1-84. Data 
represent the mean of two different experiments performed in duplicate. Error bars indicate the SD.  
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Figure  4.4.  Proliferative activity of the T-cell line 57 generated against the WT1-Pepmix. 
T cells (25x104 per well) from a healthy donor were challenged for 72 h with irradiated (2500 rads, 
XR) autologous PBMCs (105 per well) in the absence or presence of either WT1-Pepmix or WT1-84. 
Cells were pulsed with [3H] thymidine for an additional 18 h and then harvested. T cells only (none) 
were used as a negative control. Data represent the average of two different experiments performed in 
duplicate. Error bars indicate the SD. 
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Figure  4.5.  Effect of blocking antibodies on the proliferative responses of TCL-57.  
T cells (25x104 per well) from a healthy donor were challenged for 72 h with irradiated (2500 rads, 
XR) autologous PBMCs (105 per well) in the absence or presence of WT1-Pepmix. In order to assess 
T cell restriction, HLA-ABC, HLA-DR, HLA-DQ and HLA-DP azide-free mAbs were added to the 
corresponding wells containing PBMCs 20 min before the addition of T cells. T cells only (none) 
were used as a negative control. Cells were pulsed with [3H] thymidine for an additional 18 h and 
then harvested. Data represent the average of two experiments performed in duplicate. Error bars 
indicate the SD. 
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Figure  4.6.  Flow cytometry analysis of CD8, CD4, CD25 and FOXP3 expression in the TCL-
57.  
 (A): 95% T cells are CD4+ T cells. (B): 16.8% of CD4+ T cells co-express CD25 and FOXP3 
molecules.  
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4.3.2. Generation of specific responses against WT1-Pepmix using dynabeads  
The dynabeads T cell expander was used to activate the TCL-57 after several rounds 
of antigen-specific re-stimulations with autologous-APCs (DCs or monocytes) 
pulsed with the Pepmix. The dynabeads are polystyrene beads coated with 
monoclonal antibodies against the CD3 and CD28 cell surface molecules. The beads 
were used because the T cells were poorly proliferating which may have been due to 
the age of the T-cell cultures.  
 
After the 9th stimulation, the T cells were divided into two fractions. One of these 
fractions was re-stimulated with autologous monocytes loaded with the WT1-
Pepmix and the other fraction was re-stimulated with the dynabeads. After two more 
rounds of stimulation, the cells were tested in a proliferation assay to evaluate the 
efficiency of bead-stimulation. Although the T cells stimulated with monocytes 
showed a specific proliferative response against WT1 pepmix, a very high 
proliferative capacity (7.5 fold) was recorded for T cells stimulated with the 
dynabeads when challenged with PBMCs pulsed with the Pepmix (Figure  4.7). The 
result demonstrated that the dynabeads T cell expander was very efficient in 
activating the exhausted T cells after several rounds of antigen-specific re-
stimulation.  
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Figure  4.7.  The efficiency of the dynabead T cell expander in activating exhausted T cells.  
T cells (25x104 per well), either re-stimulated with monocytes pulsed with WT1-Pepmix (TC-M) or 
with dynabeads (TC-B), were challenged for 72 h with irradiated (2500 rads, XR) autologous PBMCs 
(105 per well) in the absence or presence of WT1-Pepmix. T cells only (none) were used as a negative 
control. Cells were pulsed with [3H] thymidine for an additional 18 h and then harvested. Error bars 
(±SD) represent duplicate wells from one experiment. 
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4.3.3. Identification of a novel WT1-60 peptide recognized by TCL-57 T cells 
The specificity of TCL-57 was further investigated as this T cell line showed no 
response towards the WT1-84 peptide. The TCL-57 (activated with dynabeads) was 
screened by proliferation assay against individual 110 WT1-Pepmix peptides using a 
microscale WT1 peptide set, a 96-well plate that contains a single WT1 peptide of 
the 110-Pepmix peptides in each well (Figure  4.8A). In this proliferation assay, five 
peptides designated WT1-60237-251, WT1-61241-255, WT1-79313-327, WT1-80317-331 and 
WT1-96381-395 induced strong proliferative activity (ranging from 4.7 to 8.3 fold) of 
the TCL-57 cells (Figure  4.8B). The rest of the peptides did not induce any 
significant proliferative activity. These five peptides were ordered and specificity of 
the TCL-57 was again tested by challenging T cells against each one of the 
individual-test peptides in a proliferation assay. As shown in Figure  4.9, the peptide 
WT1-60237-251 (TMNQMNLGATLKGVA) induced the strongest T cell proliferative 
response. WT1-60 peptide induced a 10 fold increase in proliferative activity of 
TCL-57. In addition, the proliferative response of T cells to WT1-60 was 3.3 times 
higher than that against the Pepmix. 
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Figure  4.8.  Screening of TCL-57 specificity using a microscale WT1 peptide set.  
The proliferative activity of TCL-57 against PBMCs loaded with WT1-Pepmix or with individual 
peptide was tested to determine which single peptides induced responses to the WT1-Pepmix. T cells 
(15.000 cells/well) were challenged for 72 h with irradiated (2500 rads, XR) autologous PBMCs 
(500.000 cells/well) in a microscale plate. Cells were pulsed with [3H] thymidine for an additional 
18h and then harvested. (A) Shows the location of the WT1-Pepmix peptides in the 96-well plates. 
Each well of the plates contains a single peptide of the 110-peptide set. N, the peptide did not induce 
any proliferative activity of the TCL-57; P, the peptide induced a significant proliferative activity of 
the TCL-57. (B) Shows the proliferation of the TCL-57 from the same screening experiment against   
PBMCs loaded with WT1-Pepmix or with individual peptide that induced responses to the peptide 
pools. T cells only (none) were used as negative control. Error bars (±SD) represent duplicate wells 
from one experiment. 
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Figure  4.9.  Proliferative activity of TCL-57 against the peptides WT1-60, WT1-61, WT1-79, 
WT1-80 and WT1-96 only.  
This figure demonstrates that among the five peptides only one peptide (WT1-60) induced the highest 
proliferative activity of TCL 57. T cells (25x104 cells/well) were challenged for 72 h with 
irradiated (2500 rads, XR) autologous PBMCs (105 per well cells/well). Cells were 
pulsed with [3H] thymidine for an additional 18 h and then harvested. T cells only 
(none) were used as negative control. Error bars (±SD) represent duplicate wells 
from two experiments. 
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4.3.4. Generation of TCL-57 derived T cell clones using the WT1-60 peptide 
and analysis of their HLA-restriction  
Three attempts were performed to clone the TCL-57 T cells using a standard 
limiting dilution assay. T cells were seeded at 1, 2 and 5 cells/well against HLA-
matched allogeneic LCLs loaded with the WT1-60 peptide in the presence of IL-2 
and a pool of allogeneic PBMCs which was used as a feeder. Despite these three 
attempts to clone the T cells, no clones were obtained using this method. Therefore, 
another method was utilized to generate clones specific to the WT1-60 peptide. 
Because the dynabead CD3/CD28 T cell expander efficiently activated the poorly 
proliferating T cells, the beads were used to clone the T cells. The T cells were 
seeded at 5 cells/well in 96-well V-bottomed plates in the presence of the dynabeads 
and IL-2. The V-bottomed plates were used since no feeder cells were added.  Using 
this method, 6 clones were obtained and were tested for their specificity using a 
proliferation assay against autologous PBMCs pulsed with or without the WT1-
derived peptide. The attempts performed to clone the TCL-57 are summarized in 
Table  4.2. Figure  4.10 demonstrates that two clones, TCC-15 and TCC-19, were 
specific to WT1-60 peptide.  
 
To define more precisely the HLA-DR restriction, HLA-DR–matched allogeneic 
LCLs sharing the DR-04 (LCL-11) or DRB1*0701 (LCL-18) with the TCC clones 
were used. Moreover, an HLA-DR*07–restricted epitope, hTRT672-686 
(RPGLLGASVLGLDDI), derived from human telomerase reverse transcriptase 
(Schroers et al., 2002) sequence was included as a negative control.  Both clones, 
TCC-19 and TCC-15, did not show any proliferative response to LCL-18 loaded 
with WT1-60 peptide, ruling out the involvement of the DRB1*0701 in this 
presentation. However, LCL-11 sharing different HLA-DRB1*04 suballele 
(DRB1*0401) with the clones, induced a specific proliferative activity against the 
WT1-60 peptide, showing the requirement for DRB1*04 restriction in this process 
(Figure 4.11A and B). In addition, HLA-DR mAb blocked the T cell response 
showing the requirement for HLA-DR molecule in the presentation of WT1-60 
peptide to both T cell clones (Figure 4.11A and B).  
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Table  4.2. Results of the attempts to clone the TCL-57.  
 
Stimulators 
 
 
attempts 
 
feeders 
 
IL-2 
(IU/mL) 
 
Plates  
 
Seeding density 
(cells/well) 
       
1 
 
2 
 
5 
 
HLA-matched 
allogeneic  
LCLs 
 
 
3  
 
allogeneic 
PBMCs 
 
130 
 
U-
bottomed  
 
N 
 
N 
 
N 
 
Dynabead 
CD3/CD28 T 
cell expander 
 
 
1 
 
Without  
feeders  
 
130 
 
V-
bottomed 
 
ND 
 
ND 
 
Y 
 
N No clones were obtained  
ND Not done 
Y Clones were obtained 
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Figure  4.10.  Proliferative activity of T cell clones generated from TCL-57.  
The TCL-57 was cloned using the dynabead CD3/CD28 T cell expander. 6 clones were obtained and 
tested for their specificity against autologous PBMCs pulsed with (blue colour) or without WT1 
derived peptide (green colour) in a proliferation assay.  
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Figure  4.11.  Proliferative activity of TCC-15 and TCC-19 T cell clones.  
TCC-15 (A) or TCC-19 (B) T cells (25x104 per well) from a healthy donor were challenged for 72 h 
with irradiated (2500 rads, XR) autologous T-APCs (105 per well) or allogeneic LCLs in the absence 
or presence of either WT1-Pepmix or WT1-60. T-APCs pulsed with or without hTert peptide (HLA-
DR7-restricted epitope) was included as a positive control. To assess for T cell restriction, HLA-
ABC, HLA-DR, HLA-DQ and HLA-DP mAbs were added to the corresponding wells containing T-
APCs 20 min before the addition of T cells. Cells were pulsed with [3H] thymidine for an additional 
18 h and then harvested. T cells only (none) were used as a negative control. Data represent the 
average of two different experiments performed in duplicate. Error bars indicate the SD. 
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4.3.5. Evaluation of the cytokine profile of the TCL-57 T cell line and its 
derivative clones  
Cytokines generated during an immune response dictate the outcome of this 
response. Hence, the cytokine profile generated by the TCL-57 cell line and clones 
was evaluated by enzyme-linked immunosorbent assays (ELISAs). The released 
cytokines were determined from cell culture supernatants of T cell cultured for 48 
hours with irradiated autologous PBMCs or T-APCs pulsed with WT1-Pepmix or 
WT1-60 peptide. Autologous PBMCs were used to test the cytokine released by the 
T cell line. Because no more autologous PBMCs were left, the T-APCs were used to 
test the cytokine released by the T cell clone. Before using the T-APCs in this assay, 
these cells were tested and compared with the PBMCs in a proliferation assay which 
showed that the T-APCs were highly effeicint in activating T cells.  
 
A similar cytokine production pattern was found between the line and the two 
clones.  However, the cytokines produced by the clones should identify the type of 
the immune response if a different pattern was seen. The T cell line secreted IL-4, 
IL-5 and GM-CSF specifically to WT1-60 and WT1-pepmix, and small amounts of 
TGF-β1, IL-10 and IFN-γ. This clearly indicates a T helper 2 (Th2) polarized 
immune response. For the clones, a similar cytokine production pattern was found 
although an increase in IFN-γ production was found upon stimulation with pepmix 
or WT1-60 which was more prominent in TCC-15. Figure  4.12 and Figure  4.13 
show the cytokine profile of the T cell line and clones, respectively.  
 
4.3.6. Proliferative activity of TCC-15 clone against HLA-DR-matched 
leukemic cells 
The proliferative activity of the clone TCC-15 only was tested against PBMCs 
obtained from WT1-expressing AML and ALL patients because the TCC-19 cell 
number was too low. The expression of WT1 mRNA in leukaemia samples was 
examined using conventional and quantitative RT-PCR (Table  4.3). Because the 
HLA-DR was the restriction element for the clones, its expression was evaluated by 
FACS analysis. All the examined leukemic samples expressed HLA-DR, although at 
different levels (Table  4.3). In addition, Table  4.3 shows the percentage of leukemic 
blasts in the sample used.   PBMCs from DR0701-1302 matched for DR0701 AML 
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(AML-28), DR0701-0406 fully matched ALL (ALL-21) and HLA-DR0301-0405 
allelic positive ALL (ALL- 16) were used. The DR non-matched 1104-1605, but 
WT1-expressing AML (AML-27) was used as a negative control. As shown in 
Figure  4.14, the TCC-15 clone did not recognize any of the leukemic cells used.  
The data indicates that WT1-60 peptide might be either not naturally processed by 
the leukemic cells or only very low levels of this peptide is presented but it is 
insufficient to be recognized by anti-WT1 specific T cells.  
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Figure  4.12.  Cytokine productions by the TCL-57 T-cell line.  
The cytokines were quantified by ELISAs using cytokine-specific capture antibodies. The released 
cytokines were determined from cell culture supernatants of T cell cultured for 48 hours with 
irradiated autologous PBMCs pulsed with WT1-Pepmix or WT1-60 peptide. The cytokines level was 
determined twice. Values represent the mean of the two experiments performed in duplicate. Error 
bars indicate the SD.  
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Figure  4.13.  Cytokine production by the T cell clones TCC-15 and TCC-19.  
The cytokines were quantified by ELISAs using cytokine-specific capture antibodies. The released 
cytokines were determined from cell culture supernatants of T cell cultured for 48 hours with 
irradiated autologous T-APCs pulsed with WT1-Pepmix or WT1-60 peptide. (A) Cytokine 
production by the T cell clone TCC-15. The cytokine levels were determined twice for TCC-15.  Data 
represent the mean of two different experiments performed in duplicate. Error bars indicate the SD. 
(B) Cytokine production by the T cell clone TCC-19. The cytokine levels were determined only once 
for TCC-19. Data represent the mean of duplicate wells from one experiment. Error bars indicate the 
SD. 
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Table  4.3.  Patients information. 
 
Patients 
% 
Blasts1 
 
HLA-
DRB1* 
 
QRT-PCR2  
 
RT-PCR3 
 
% HLA-
DR/MFI4 
 
Status5 
 
Subtypes 
AML-27 81 1104,1605 7950 +++ 60/200 new M4 
AML-28 61 0701,1302 1800 + ND new M4 
ALL-16 NA 0301,0405 8780 ++ 20/211 new T-cell 
ALL-21 83 0701,0406 333 + 72/667 new Pre B-cell 
 
1  % blasts were determined routinely by the hematopathology laboratory 
 
2  Quantitative real-time PCR data for the expression level of WT1 which normalized from 
K562 on 1000  
3 Conventional RT-PCR data for the expression of WT1 
4  % positive for HLA-DR molecule/mean of fluorescence intensity (MFA) as determined by 
FACS analysis 
5 New indicates that samples were taken at first diagnosis.   
NA=not available 
ND= not done 
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Figure  4.14.  Evaluation of proliferation of TCC-15 against different HLA-matched leukemias. 
 Proliferative activity of TCC-15 against PBMCs from DR0701 matched AML (AML-28), non-
matched (AML-27), DR0701-0406 matched (ALL-21) and HLA-DR04 allelic positive (ALL- 16) 
patients. T cells (25x104 per well) were challenged for 72 h with irradiated (2500 rads, XR) PBMCs 
(105 per well) from AML and ALL patients. Cells were pulsed with [3H] thymidine for an additional 
18 h and then harvested. T cells only and T cells challenged with irradiated autologous T-APCs in the 
absence or presence of the WT1-60 peptide served as negative and positive controls, respectively. 
Data represent the mean of two different experiments performed in duplicate. Error bars indicate the 
SD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 140 
4.4. Discussion 
We have previously identified novel human anti-WT1 Tregs cell line and clones 
using a pool of overlapping peptides spanning the entire WT1 sequence. The T-cell 
line and clones specifically recognized a WT1-333-347 (RYFKLSHLQMHSRKH) 
peptide designated as WT1-84 in an HLA-DRB1*0402–restricted-manner (Lehe et 
al., 2008). In this study, the same methodology was used to generate antigen-specific 
CD4+ T cells with specific proliferative responses to the previously identified 
peptide in 2 out of 3 donors. In this, TCL-52 and TCL-62 generated T cell lines from 
two donors who share the same HLA-DR-allele (HLA-DR-*0402) with the donor 
used in the previous study recognized the WT1-84 epitope. However, the TCL-57 T 
cell line generated from a donor with an HLA-DR-*0406 allele failed to recognize 
the previously identified epitope but rather recognized another peptide WT1-60237-
251(TMNQMNLGATLKGVA) designated (WT1-60). 
  
The WT1-60 peptide was able to induce a specific proliferative response in the 
generated T cell line and clones against peptide-pulsed autologous APCs. However, 
no significant proliferation of the T -cell clone was recorded against leukemic cell 
samples of three patients expressing the WT1 antigen as well as the HLA-DR 
molecule. Furthermore, the WT1-60 peptide was able to induce a specific 
proliferative cross-reactivity in the T cell clones after challenging with LCL-11 
sharing the HLA-DR04 allele with the clones. No proliferative response of the T cell 
clones was recorded against LCL-18 (HLA-DR0701 homozygous donor). Therefore, 
the WT1-60 peptide seems to be presented through the HLA-DR04 molecule. 
Because AML-28 donor shares the HLA-DR*0701 with the clones, no proliferative 
response of the T cell clone was recorded against this leukemic cells.  The failure of 
the T cell clone to recognize ALL-16, although expressing high levels of WT1 
antigen and shares the HLA-DR04 allele with the clones might be due to the 
differences in the sub-allelic level or to low HLA-DR expression. However, the 
fully-matched HLA-DR ALL sample (ALL-21) did not induce any proliferative 
response in the T cell clone. In this, 72% of the ALL-21 cells express the HLA-DR 
molecule, however leukemic cells from this patient did not express high levels of the 
WT1 antigen and this may account for the T cell unresponsiveness. Another, 
explanation for non-recognition of this epitope by the leukemic cells is that the 
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peptide may not be naturally processed  or may be below the threshold required to 
trigger T-cell recognition and effector function in addition to the inhibitory effect of 
the leukemic cells (Dermime et al., 2002). 
 
The generated T cell line and clones exerted a Th2 cytokine profile (IL-5, IL-4) in 
response to the WT1-60 peptide. It has been shown that the affinity of the antigen 
for TCR and the antigen dose can influence the differentiation of Th1 and Th2 cells 
(Constant and Bottomly, 1997).  Th2 cells are generated only in the presence of a 
low dose of an antigen, and a weak TCR signal is needed for their generation (Tao et 
al., 1997). In this study, only 10 µg/mL of the 110 Pepmix including the WT1237-251 
peptide were used to prime the T cells. Therefore, the antigen dose and peptide 
competition in the case of the WT1-Pepmix may contribute to the generation of a 
Th2 helper cell type.  In addition, high concentration of IL-2 (260 IU/mL) was used 
for the T-cell generation. High dose of IL-2 has been shown to increase the 
frequency of Tregs in cancer patients (Ahmadzadeh and Rosenberg, 2006). It is 
possible that the presence of high dose of IL-2 in the T-cell cultures played a role in 
the polarization of T cells to Th2 phenotype as it has been described in other systems 
(Cote-Sierra et al., 2004).  
 
A recent study by Durinovic-Bello and colleagues (Durinovic-Bello et al., 2006) 
showed that human Th2 cells that exert a down-regulatory Treg phenotype also 
express the Foxp3 molecule. However, Foxp3 has also been shown to be expressed 
transiently in activated non-Tregs, whereas it is stably expressed in Tregs (Wang et 
al., 2007). In the present study, 16.8% of the generated TCL-57 T cell line expressed 
Foxp3 and exerted a CD4+CD25+Foxp3+ Treg phenotype. This percentage is higher 
than the percentage of native Treg isolated from peripheral blood, which is usually 
does not exceed 5% of CD4+ T cells in normal adult individuals. A preliminary 
result showed that the T cell clones expressed higher Foxp3 molecule than the TCL-
57 T cell line. However, the expression of Foxp3 and other Treg-related markers 
such as GITR, CTLA-4 and CD127 in the T cell clone (TCC-15) should be further 
examined to confirm the Treg phenotype. It is well known that Tregs suppress 
effector T cells by inhibiting activation, proliferation, differentiation, and effector 
function (Sakaguchi et al., 2009, Askenasy et al., 2008, Spadafora-Ferreira et al., 
2007). Therefore, the generated clone should be tested for its ability to inhibit 
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immune responses in functional assays to confirm the suppressive effect of these T 
cells. 
  
The use of anti-CD3 and anti-CD28 monoclonal antibodies to expand and clone 
antigen-specific T cells has been previously reported (Riddell and Greenberg, 1990, 
Trickett and Kwan, 2003).  This method has also been described to rapidly expand 
antigen-specific T cells for potential clinical applications (Thompson et al., 2003, 
Garlie et al., 1999, Laport et al., 2003) . In the present work this methodology was 
used to activate and expand the exhausted T cell line (TCL-57) using beads coated 
with anti-CD3/anti-CD28 monoclonal antibodies. This method was very efficient 
not only in activating the T cells but also in enhancing the process of T cell cloning. 
In this, the T cell line and clones retained their specificity to both Pepmix and WT1-
60 peptide following two rounds of re-stimulations with the beads. Therefore, this 
method allowed the activation and expansion of CD4+ T cells without altering their 
antigenic specificity.  In addition, this method dramatically reduces the number of 
antigen presenting cells required for re-stimulation.  
 
In conclusion, antigen-specific CD4+ T cells were detected using a pool of 
overlapping peptides spanning the entire sequence of the WT1 antigen. These cells 
showed very high and specific proliferation response to the WT1-60237-251 peptide 
and exerted a Th2 cytokines (IL-5, IL-4) profile. Therefore, the generated CD4+ T 
cells can be considered as a WT1-60-specific Th2 T cell type. Further investigations 
are needed to examine whether these cells are of theTh2 like-Treg type. If these cells 
were confirmed to be Tregs, leukemic PBMCs should be tested to verify whether 
this population exists in leukaemia patients as they may then contribute to the 
inhibition of specific T cell anti-WT1 responses in such patients similar to that 
described in our previous study (Lehe et al., 2008). 
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5. IMMUNOGENICITY OF M-PHASE 
PHOSPHOPROTEIN 11 AND PROTEINASE-3 IN 
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5.1. Introduction 
Despite major advances in molecular biology and targeted therapy of leukaemia, 
current treatment strategies induce adverse side effects and fail to achieve and 
maintain remission in many patients. In acute myeloid leukaemia (AML), the most 
deadly form of leukaemia (Bozzone, 2009), the majority of adult patients younger 
than 60 years achieve a complete remission following consolidation therapy. 
However, only approximately 30 to 40% maintain durable remission (Tallman et al., 
2005). Furthermore,  the complete remission rate  and  duration attained by older 
AML patients is less, with an overall survival rate of 20 to 40%  (Tallman et al., 
2005). Therefore, there is an urgent need for the development of leukaemia-targeted 
immunotherapy designed to eliminate residual leukemic cells thus enhancing the 
graft-versus-leukaemia (GVL) effect observed after allogeneic hematopoietic stem 
cell transplantation (HSCT) and/or prolonging a complete remission achieved by 
chemotherapy (Guglielmelli et al., 2007, Boon and Old, 1997).  
 
The WT1 antigen represents a crucial target for tumour immunotherapy. However, 
cancer cells frequently escape T-cell recognition by losing or down-regulating the 
expression of the targeted-tumour antigen (Begley and Ribas, 2008). Therefore, 
immunotherapeutic approaches based on targeting epitopes derived from more than 
one antigen may be more effective in inducing anti-tumour immune responses.  
 
5.2. Aim 
There is an urgent need for the development of leukaemia-targeted 
immunotherapeutic approaches using defined leukaemia-associated antigens (LAA) 
that are preferentially expressed by most leukaemia subtypes and absent or 
minimally expressed in vital tissues. Although various antigenic epitopes derived 
from leukaemia antigens have been identified, progress in targeting specific 
immunotherapeutic approaches depends in the recognition of a wider range of 
leukaemia antigens. The aim of the study was to identify potential CD8+ cytotoxic T 
lymphocyte (CTL) epitopes in the leukaemia-associated antigens PR-3 and MPP11 
that bind to the most common class I molecule, HLA-A*0201 molecule, and 
provoke specific cytotoxic T lymphocyte responses. This would allow the use of 
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these peptides in leukaemia immunotherapy by either expanding ex vivo tumour-
reactive specific CTLs for adoptive T-cell immunotherapy or actively inducing 
leukaemia antigen-specific T–cell immunity in vivo by vaccinating patients with 
well defined leukaemia-associated antigens. Forty samples from AML and ALL 
patients were also screened for MPP11 positivity. 
 
5.3. Results 
5.3.1. MPP11 antigen screening in leukaemia patients and normal donors 
The mRNA expression pattern of the MPP11 antigen was evaluated in PBMCs of 
patients with AML (n=20), ALL (n=20) and in PBMCs of healthy volunteers (n=28) 
using conventional RT-PCR. This screening was performed for two purposes. The 
first purpose was to compare the MPP11 gene expression level in acute leukaemia 
patients and in normal donors. The second purpose was to be able to select the HLA-
A*0201+ leukaemia donors expressing the MPP11 gene to be used (if needed) as 
targets for T cells generated against the MPP11 peptides.   
 
Total RNA was extracted from the PBMCs of patients and healthy donors and 
reverse transcriptized into cDNA using Moloney murine leukaemia virus. The 
extraction and reverse transcription methods are described in Chapter 2 section 2.13 
and 2.14, respectively. The conventional RT-PCR was performed as described in 
Chapter 2 section 2.15. The amplification product of the house keeping gene β-actin 
served as control of cDNA quality. RNA isolated from K562 cell line, which 
expresses MPP11, served as a positive control.  Distilled water served as a negative 
control. The expression of the MPP11 gene was classified into one of the following 
categories: - , no detectable mRNA expression; +, low expression; ++, moderate 
expression; +++, high expression. The intensity of the positive bands determined the 
level of antigen expression.  
 
The results show that 16/20 (80%) of AML patients and 17/20 (85%) of ALL 
patients expressed the MPP11 gene. In total, the MPP11 was expressed in 33 out of 
40 (82.5%) acute leukaemia patients and in 9/28 (32%) normal donors. The level of 
the expression of the MPP11 antigen was generally higher in acute leukaemia 
patients compared to low levels of expression in normal donors. Results are shown 
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in Figure  5.1 and Table  5.1. As shown in Table  5.1, there was no clear relation 
between MPP11 expression levels and the blast number (the percentage of blast 
varies between 1 and 99%).  
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16/20 (80%) AML patients express the MPP11 gene 
 
 
   MPP11  
 
-actin  
 
17/20 (85%) ALL patient express the MPP11 gene 
 
 
   MPP11 
 
 
-actin  
 
9/28 (32%) normal donors  express the MPP11 
 
 
   MPP11 
 
 
-actin 
 
 
Figure  5.1. RT-PCR analysis of MPP11 gene expression in PBMCs from AML, ALL patients 
and normal donors. 
80% of AML patients and 85% of ALL patients expressed the MPP11 antigen, whereas only 32% of 
the normal donors expressed the MPP11 antigen.  
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Table  5.1.  Clinical features of leukaemia patients with MPP11 gene expression 
 
Subtypes1 
 
Patients # 
 
Status2 
 
% Blast3 
 
MPP11 expression 
 
 
M0 
 
AML 3 
 
New 
 
84 
 
 ++ 
M1 AML 1 New 61  - 
M2 AML 5 New   1  + 
 AML 7 New 61  + 
 AML 8 New  20  ++ 
 AML 19 New 23  +++ 
 AML 29 Rel  Post chemo 81  ++ 
M4 E0 AML 13 2nd Rel post allo BMT 10  ++ 
 AML 36 New 12  + 
M4 AML 25 New 52  + 
 AML 27 New 81  + 
 AML 28 New 61  ++ 
M5a AML 2 New NR - 
 AML 12 New  79  - 
M5 AML 11 New 80  + 
 AML 16 New 4  +++ 
 AML 24 New 50  ++ 
 AML 31 New 13  - 
 AML 34  Rel Post allo BMT 80  +++ 
M6 AML 20 New 65  +++ 
     
Pre T-cell ALL 26 New 99 ++ 
T-cell ALL 1 Rel 6 + 
 ALL 2 Rel  Post-BMT  87 + 
 ALL 3 Rel 87 + 
 ALL 13 New 75 + 
 ALL 16 New NR +++ 
 ALL 18 New 94 ++ 
 ALL 22 New 47 - 
 ALL 23 New 84 ++ 
Pre B-cell ALL 4 New 55 ++ 
 ALL 5 New 56 ++ 
 ALL 20 New 5 - 
 ALL 21 New 83 ++ 
 ALL 27 New 59 ++ 
 ALL 28 New 88 ++ 
 ALL 29 New 2 ++ 
 ALL 36 Rel on chemo NR ++ 
B-cell ALL 10 New 59 - 
BP / Biclonal ALL 7 New 89 + 
NR ALL 24 Rel 61 +++ 
 
New, newly diagnosed; Rel, relapsed; - , no detectable mRNA expression; +, low expression; ++, 
moderate  expression; +++, high expression  
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5.3.2. Selection of potential CTL epitopes derived from MPP11 and PR3 
proteins 
The candidate epitopes derived from MPP11 and PR-3 were obtained using internet-
based prediction programs. The selected peptides were synthesized and tested for 
their capacity to bind to the HLA-A*0201 molecule and/or generate cytotoxic T 
lymphocyte responses. Potential CTL epitopes derived from MPP11 antigen were 
predicted using the SYFPEITHI and BIMAS epitope prediction programs available 
at www.syfpeithi.de and www-bimas.cit.nih.gov, respectively. In each of the 
programs website, the amino acid sequences of the MPP11 (Figure  5.2) were 
entered. The HLA-A*0201 was selected for the MHC type and 9-mer was selected 
for the length of the peptides. Subsequently, the results from the database displayed 
numerous 9-mer peptides along with their positions and their predicted binding 
scores. Peptides qualified as positive if the score ranked ≥22 using the SYFPEITHI 
software or ≥100 using the BIMAS software. Four native peptides derived from 
MPP11 protein were selected. Although these peptides recorded a theoretically low 
binding affinity to the HLA-A*0201 molecule using the BIMAS software, they 
showed high binding affinity to the same molecule by the SYFPEITHI software.  
Peptides binding scores were ranging from 22 to 25 according to SYFPEITHI and 
from 79 to 4 according to BIMAS. In addition to the predicted peptides, tyrosine 
amino acid substitution in the P1 position of the first predicted epitope MPPN-1 
(QLLIKAVNL) was also carried out. The binding score of the modified epitope, 
MPPY-1 (YLLIKAVNL), was enhanced from 25 to 27 as assessed by the 
SYFPEITHI server and from 79 to 364 as evaluated by the BIMAS server. The 
sequences of the peptides as well as their binding scores are presented in Table  5.2.  
 
Potential PR3-derived candidate sequences predicted to bind to the HLA-A*0201 
molecule were obtained using three different epitope prediction programs 
(SYFPEITHI, BIMAS and RANKPEP). The amino acid sequences of PR-3 (Figure 
 5.3) were entered into the computer programs, the MHC type and the length of the 
peptides were selected and potential candidate epitopes were displayed on the 
database. Two 9-mer peptides (PR-9 and PR-129) were selected as potential 
epitopes for the generation of cytotoxic T lymphocyte responses. The PR-9 peptide 
was selected as having the highest probability of binding based on the proposed 
SYFPEITHI algorithm. On the other hand, PR-129 had the highest score using 
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BIMAS and RANKPEP algorithms. In addition to the two selected peptides, PR-169 
peptide-the previously described PR-1 epitope (Molldrem et al., 1996) was selected 
to serve as a positive control. The predicted binding scores by different computer 
programs for the 3 different PR3 peptides are listed in Table  5.3. 
 
The standard T2 binding assay, illustrated in Figure  2.1 was used to evaluate the 
ability of MPP11 and PR-3 candidate peptides to bind and stabilize HLA-A*0201 
molecule using the well-characterized A2-binding peptides WT1-187 and PR-169 as 
positive controls. The human processing-defective T2 cell line express empty HLA 
class I molecules.  The binding assay is based on the stabilization of HLA class I 
molecules on the cell surface by the addition of peptides exogenously. The T2 cells 
are incubated with peptides overnight and if the peptide binds to the HLA-A*0201, 
the surface expression will be stabilized and there will be an upregulation of this 
molecule. Changes in its expression were assessed by staining HLA-A*0201 and 
quantifying the fluorescence intensity by flow cytometry analysis. The peptides are 
assumed to bind if their fluorescence ratio is greater than 1. All T2 binding assays 
were done in duplicate. Figure  5.4 and Figure  5.5 show the flow cytometric analyses 
of T2 cells following overnight incubation with 30 µM of either MPP-11 or PR-3 
derived peptides, respectively.  
 
As shown in Figure  5.6, MPP-3 and MPP-4 peptides (Fluorescence Index [FI] =1.1 
and 2.5, respectively) stably bind to the HLA*A-0201molecule. The affinity of 
MPP-4 peptide to the molecule was comparable with that observed for the positive 
control WT1-187 epitope (FI =2.6). 187N is a WT1 derivative peptide known to 
highly bind to the HLA-A*0201 molecule (Oka et al., 2000). Because of their high 
binding affinities, MPP-3 and MPP-4 peptides were selected for the generation of 
peptide-specific T lymphocyte lines. On the other hand, the peptides MPP-1N, 
MPP1-Y, and MPP-2 were excluded from testing for immunogenicity since they did 
not show any binding or only very weak binding to the HLA-A*0201 molecule.  
 
Regarding PR3 peptides, the PR-129 peptide up-regulated the HLA-A*0201 
molecule and showed high affinity to this molecule (FI=1.9) compared to the 
positive control PR-169 peptide (FI=2.5). However, the PR-9 peptide had a low 
binding affinity to the HLA-A*0201 molecule (FI=0.6). The results of the T2 
binding assay for the PR3 peptides are shown in Figure 5.7.
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DVSRCAHRAR PGAIMLLLPS AADGRGTAIT HALTSASTLC QVEPVGRWFE 
 
AFVKRRNRNA SASFQELEDK KELSEESEDE ELQLEEFPML KTLDPKDWKN 
 
QDHYAVLGLG HVRYKATQRQ IKAAHKAMVL KHHPDKRKAA GEPIKEGDND 
 
YFTCITKAYE MLSDPVKRRA FNSVDPTFDN SVPSKSEAKD NFFEVFTPVF 
 
ERNSRWSNKK NVPKLGDMNS SFEDVDIFYS FWYNFDSWRE FSYLDEEEKE 
 
KAECRDERRW  IEKQNGATRA QRKKEEMNRI RTLVDNAYSC DPRIKKFKEE 
 
EKAKKEAEKK AKAEAKRKEQ EAKEKQRQAE LEAARLAKEK EEEEVRQQAL 
 
LAKKEKDIQK KAIKKERQKL RNSCKIEEIN EQIRKEKEEA EARMRQASKN 
 
TEKSTGGGGN GSKNWSEDDL QLLIKAVNLF PARTNSRWEV IANYMNIHSS 
 
SGVKRTAKDV IGKAKSLQKL DPHQKDDINK KAFDKFKKEH GVVPQADNAT 
 
PSERFEGPYT DFTPWTTEEQ KLLEQALKTY PVNTPERWEK IAEAVPGRTK 
 
KDCMKRYKEL  VEMVKAKKAA QEQVLNASRA KK  
 
Figure  5.2.  MPP11 Protein sequence. 
 
 
 
MAHRPPSPAL ASVLLALLLS GAARAAEIVG GHEAQPHSRP YMASLQMRGN 
 
IHPSFVLTAA HCLRDIPQRL VNVVLGAHNV RTQEPTQQHF SVAQVFLNNY 
 
PGSHFCGGTL DAENKLNDIL LIQLSSPANL QCLAMGWGRV QELNVTVVTF 
 
FCRPHNICTF VPRRKAGICF GDSGGPLICD GIIQGIDSFV IWGCATRLFP 
 
DFFTRVALYV DWIRSTLRRV EAKGRP   
 
Figure  5.3.  PR-3 protein sequence. 
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Table  5.2.  Peptide Sequences derived from MPP11 and their binding prediction to 
HLA- A*0201 molecule  
 
Given name 
 
 
Start 
position 
 
Sequence 
 
BIMAS* 
Score 
 
 
SYFPEITHI** 
Score 
 
MPP-1N 
 
421 
 
QLLIKAVNL 
 
79 
 
 
25 
 
MPP-1Y Y-422 YLLIKAVNL 364 27 
 
MPP-2 419 DLQLLIKAV 12 24 
 
MPP-3 13 AIMLLLPSA 6 
 
23 
 
MPP-4 37 STLCQVEPV 4 22 
 
 
 
 
 
Table  5.3.  Peptide Sequences derived from PR3 and their binding prediction to 
HLA- A*0201   molecule 
 
Given name 
 
start 
position 
 
Sequence 
 
BIMAS* 
Score 
 
SYFPEITHI** 
Score 
 
RANKPEP*** 
Score 
 
PR-169  
 
169 
 
VLQELNVTV 
 
484.7 
 
28 
 
72.8% 
 
PR-129  129 NLSASVATV 159.9 28 90.35% 
 
PR-9  9 ALASVLLAL 49.1 30 86.84% 
 
 
* The BIMAS scoring system is based on the calculation of the theoretical half-life of the 
MHC class I/peptide complex, which is a measure peptide-binding affinity. Peptides qualified as 
positive if the score was ≥100.  
 
** The SYFPEITHI scoring system is based on the presence of certain amino acids in certain 
position along the MHC-binding groove. Optimal anchor residues are valued at 10 points, unusual 
anchors are given 6-8 points and preferred residues are worth 1-4 points. Amino acids with negative 
effect on the bining affinity score between -1 and -3.  The maximum score for HLA-A*0201 is 36. 
Peptides qualified as positive if the score ranked ≥22. 
 
*** The RANKPEP scoring system includes information on the score of the peptide and the % 
optimum score of the predicted peptide relative to that of a sequence that yields the maximum score 
with selected profile. Peptides qualified as positive if the % optimum was ≥50%. 
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T2 WT1-187N 
 
 
 
 
MPP-1N MPP-1Y 
 
 
 
 
 
 
MPP-2 MPP-3 
 
 
MPP-4 
 
 
 
Figure  5.4.  Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells cultured 
overnight in the absence or in the presence of 30 µM of WT1-187N or each MPP11-derived peptide.  
The WT1-187N peptide was used as a positive control. Following incubation with the peptides, the 
T2 cells were stained with HLA-A2 specific monoclonal antibody (BB7.2) and analyzed by flow 
cytometry. *Average of median fluorescence intensities of duplicate experiments of T2 binding 
assay. 
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PR-129 PR-9 
 
 
 
 
Figure  5.5. Flow cytometric analysis of HLA-A2 molecules expressed by T2 cells cultured 
overnight in the absence or in the presence of 30 µM of each PR-3-derived peptide.  
The PR-169 peptide was used as a positive control. Following incubation with the peptides, the T2 
cells were stained with HLA-A2 specific monoclonal antibody (BB7.2) and analyzed by flow 
cytometry. *Average of median fluorescence intensities of duplicate experiments of T2 binding 
assay. 
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Figure  5.6. The binding ability of MPP11-derived peptides to the HLA-A*0201 molecule as 
measured by the T2 peptide-binding assay.  
WT1-187N, a well-characterized A2-binding peptide, served as a positive control. MPP-3 and MPP-4 
peptides stably bind to the HLA-A*0201 as demonstrated by stabilization of surface HLA-A2. The 
peptides MPP-1N, MPP-2 and the modified peptide MPP-1Y showed no binding to HLA-A*0201 
and thereby were not used to generate CTLs. Each value represents the average of duplicate assays 
and error bars indicate the SD. 
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Figure  5.7. The binding ability of PR-3 derived peptides to the HLA-A*0201 molecules as 
measured by the T2 binding assay.  
PR-169 is a well-characterized A2-binding peptide that is used as a positive control. PR-129 peptide 
has a high binding affinity whereas PR-9 has a very low binding affinity to the HLA-A*0201 
molecule. Each value represents the average of duplicate assays and error bars indicate the SD. 
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5.3.3. Generation of MPP11 specific T lymphocyte lines by T2 cells 
The ability of the MPP11-derived peptides to induce specific cytotoxic T 
lymphocytes (CTLs) was tested. PBMCs obtained from two HLA-A*0201 positive 
healthy volunteers designated as BC-21 and BC-32 were utilized to generate CTLs 
specific to the selected peptides.  The responder cells were CD8+ T cells purified by 
MACS negative selection as described in Materials and Methods section 2.6.1. The 
purified CD8+ T cells were then stimulated in vitro with T2 cells. The choice of T2 
cells as APCs was made to reduce the number of PBMCs used and was based on 
previous studies (Houbiers et al., 1993, Molldrem et al., 1996, Oka et al., 2000). The 
T2 cells were pulsed with MPP-4, MPP-3 or WT1-126N peptide and used to prime 
and activate the purified CD8+ T cells every 7-10 days. The T cell line generated 
against the WT1-126N peptide was used as a control. The generated T cell lines 
were tested against different HLA-A*0201+ targets in the presence or absence of 
autologous peptide using a Chromium Release Assay and an ELISPOT assay after 3 
to 8 rounds of stimulations. 
 
The specificity of in vitro primed CTLs was first tested for specific IFN-γ release to 
stimulation with the corresponding peptides using an ELISPOT assay. The T cell 
lines (MPP-3, MPP-4 and WT1-126N) generated from both donors (BC-21 and BC-
32) did not produce antigen specific IFN-γ spots when stimulated with T2-loaded 
peptide (Figure  5.8 and Figure  5.9). In addition, autologous PBMCs un-pulsed or 
peptide-pulsed, K562 and K562-A2.1 were used to test the specificity of the T cell 
lines generated from BC-21 donor. K562 is a leukaemia cell line expressing MPP11 
antigen and K562-A2.1 is the same cell line but transfected with the HLA-A*0201 
molecule. As shown in Figure  5.8, no antigen specific IFN-γ spots were formed 
when the three BC-21-T cell lines were challenged with targets other than T2 cells.  
 
The next step in monitoring CD8+ T cell responses to MPP11-derived peptides was 
to test the cytotoxic activity of the generated T cell lines in a standard Cr51-release 
assay. Consistent with the results obtained with the ELISPOT assay; the T cell lines 
generated from the two different donors (BC-21 and BC-32) did not elicit any 
peptide-specific cytotoxic responses. The T cell lines generated from BC-21 donor 
were challenged with T2 cells or LCL-21 pulsed with no peptide or with each 
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peptide at different E:T ratio starting from 50:1. As shown in Figure  5.10, Figure 
 5.11 and Figure  5.12, the MPP-3, the MPP-4 and the WT1-126N T cell lines did not 
recognize peptide-pulsed T2 or LCL-21 targets cells. The T cell lines generated from 
the other donor (BC-32) were challenged with T2 cells or LCL-32 pulsed with no 
peptide or with each peptide at different E:T ratio starting from 100:1. In these 
cytotoxic experiments, K562 and K562-A2.1 were used as targets too. The three 
tested T cell lines did not show any peptide-specific cytotoxic responses toward 
peptide-pulsed T2, LCL-32 as well as K562-A2.1 targets cells (Figure  5.13, Figure 
 5.14 and Figure  5.15). 
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Figure  5.8. Non-specific IFN- release of BC-21 CTLs generated by T2 cells against the MPP-
3, MPP-4 and WT1-126N peptides using an IFN-γ- ELISPOT assay. 
The T cell lines were established from BC-21, an HLA-A0201+ donor, and tested following three to 
eight rounds of in vitro T cell stimulations. Targets were autologous PBMCs T2 cells, K562 and 
K562-A2.1. The PBMCs and T2 cells were pulsed with either no peptide or with peptide.  
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Figure 5.8. Continued 
The background observed when T cells alone were used is shown. Non-specific IFN- release is 
shown for T cell line generated against the MPP-3 peptide (A). Non-specific IFN- release is shown 
for T cell line generated against the MPP-4 peptide (B). Non-specific IFN- release is shown for T 
cell line generated against the WT1-126N peptide (C). Results are expressed as IFN- γ positive cells 
per 20.000 CD8+ T cells and are the mean of triplicate assays (±SD).  
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Figure  5.9. Non-specific IFN- release of BC-32 CTLs generated by T2 cells  against the MPP-
3, MPP-4 and WT1-126N peptides using an IFN-γ- ELISPOT assay. 
The T cell lines were established from BC-32, an HLA-A0201+ donor, and tested following three to 
eight rounds of in vitro T cell stimulations. Targets were T2 cells pulsed with either no peptide or 
with peptide. The background observed when T cells alone were used is shown. Non-specific IFN- 
release is shown for T cell line generated against the MPP-3 peptide (A). Non-specific IFN- release 
is shown for T cell line generated against the MPP-4 peptide (B). Non-specific IFN- release is 
shown for T cell line generated against the WT1-126N peptide (C). Results are expressed as IFN- γ 
positive cells per 20.000 CD8+ T cells and are the mean of triplicate assays (±SD).  
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Figure  5.10. Non-specific lysis by BC-21 CTLs generated by T2 cells against MPP-3 peptide as 
tested using a standard chromium release assay.  
The effector cells were MPP-3 T cell line generated from an HLA-A0201+ donor, BC-21, by T2 cells. 
The T cell line was tested following three to eight rounds of in vitro T cell stimulations. Target cells 
were pulsed with either no peptide (dark blue symbol) or with MPP-3 peptide (pink symbol). The 
MPP-3 T cell line was stimulated with T2 cells (A), and with autologous LCL-21 (B). The data are 
presented as the percentage specific lysis at the indicated E:T ratios and represents the average of 
three experiments. Error bars indicate the SD.  
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Figure  5.11. Non-specific lysis by BC-21 CTLs generated by T2 cells against MPP-4 peptide as 
tested using a standard chromium release assay.  
The effector cells were MPP-4 T cell line generated from an HLA-A0201+ donor, BC-21, by T2 cells. 
The T cell line was tested following three to eight rounds of in vitro T cell stimulations. Target cells 
were pulsed with either no peptide (dark blue symbol) or with MPP-4 peptide (pink symbol). The 
MPP-4 T cell line was stimulated with T2 cells (A), and with autologous LCL-21 (B). The data are 
presented as the percentage specific lysis at the indicated E:T ratios and represents the average of 
three experiments. Error bars indicate the SD.  
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Figure  5.12. Non-specific lysis by BC-21 CTLs generated by T2 cells against WT1-126N 
peptide as tested using a standard chromium release assay.  
The effector cells were WT1-126N T cell line generated from an HLA-A0201+ donor, BC-21, by T2 
cells. The T cell line was tested following three to eight rounds of in vitro T cell stimulations. Target 
cells were pulsed with either no peptide (dark blue symbol) or with WT1-126N peptide (pink 
symbol). The WT1-126N T cell line was stimulated with T2 cells (A), and with autologous LCL-21 
(B). The data are presented as the percentage specific lysis at the indicated E:T ratios and represents 
the average of three experiments. Error bars indicate the SD.  
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Figure  5.13. Non-specific lysis by BC-32 CTLs generated by T2 cells against MPP-3 peptide as 
tested using a standard chromium release assay.  
The effector cells were MPP-3 T cell line generated from an HLA-A0201+ donor, BC-32, by T2 cells. 
The T cell line was tested following three to eight rounds of in vitro T cell stimulations. Target cells 
were pulsed with either no peptide (dark blue symbol) or with MPP-3 peptide (pink symbol). The 
MPP-3 T cell line was stimulated with T2 cells (A), with autologous LCL-32 (B) and with K562-
A2.1. (C). The data are presented as the percentage specific lysis at the indicated E:T ratios and 
represents the average of three experiments. Error bars indicate the SD.  
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Figure  5.14. Non-specific lysis by BC-32 CTLs generated by T2 cells against MPP-4 peptide as 
tested using a standard chromium release assay.  
The effector cells were MPP-4 T cell line generated from an HLA-A0201+ donor, BC-32, by T2 cells. 
The T cell line was tested following three to eight rounds of in vitro T cell stimulations. Target cells 
were pulsed with either no peptide (dark blue symbol) or with MPP-4 peptide (pink symbol). The 
MPP-4 T cell line was stimulated with T2 cells (A), with autologous LCL-32 (B) and with K562-
A2.1. (C). The data are presented as the percentage specific lysis at the indicated E:T ratios and 
represents the average of three experiments. Error bars indicate the SD.  
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Figure  5.15. Non-specific lysis by BC-32 CTLs generated by T2 cells against WT1-126N 
peptide as tested using a standard chromium release assay.  
The effector cells were WT1-126N T cell line generated from an HLA-A0201+ donor, BC-32, by T2 
cells. The T cell line was tested following three to eight rounds of in vitro T cell stimulations. Target 
cells were pulsed with either no peptide (dark blue symbol) or with WT1-126N peptide (pink 
symbol). The WT1-126N T cell line was stimulated with T2 cells (A), with autologous LCL-32 (B) 
and with K562-A2.1. (C). The data are presented as the percentage specific lysis at the indicated E:T 
ratios and represents the average of three experiments. Error bars indicate the SD.  
. 
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5.3.4. Generation of MPP11 specific T lymphocyte lines by DC2d  
The T cell lines generated form the two different donors (BC-21 and BC-32) by T2 
cells showed no specific CD8+ T cell responses to any of the peptides tested 
including the positive control peptide WT1-126N. Therefore, a second protocol for 
the generation of CD8+ T cell lines was then used where peptide-pulsed DC2d (fast 
DC) were used to prime the purified CD8+ T cells and peptide-pulsed monocytes 
were used for subsequent T cell stimulations. The DC2d were generated as described 
in Materials and Methods section 2.5.4.3. PBMCs obtained from four different 
HLA-A*0201 positive healthy volunteers were utilized to generate CTLs specific to 
the selected peptides.  The four donors were designated as BC-21, BC-32, BC-37 
and BC-41. The PBMCs from each donor were used as the source of the responder 
cells and antigen presenting cells. The responder cells were CD8+ T cells purified by 
MACS negative selection and stimulated in vitro with antigen presenting cells-
loaded peptide for 7-10 days.    
 
To investigate whether the MPP11 synthetic peptides could stimulate peptide-
specific CTLs,  the generated T cell lines were tested against different HLA-
A*0201+ targets in the presence or absence of autologous peptide using a Chromium 
Release Assay and an ELISPOT assay after 3 to 8 rounds of stimulations. 
 
5.3.5. CD8+ T cell responses to MPP11- derived peptides  
5.3.5.1. MPP-4 CTL s produced specific IFN-γ 
After the third round of stimulation, the specificity of in vitro primed CTLs was first 
tested for specific IFN-γ release to stimulation with the corresponding peptides using 
an ELISPOT assay. The BC-21 CTLs generated against the MPP-4 peptide 
produced specific IFN-γ spots when stimulated with T2-loaded peptide whereas 
non-specific production was seen in case of CTLs generated from the same donor 
against MPP-3 as shown in Figure  5.16A and B. The anti-MPP-3 and anti-MPP-4 T 
cell lines generated from the three other donors (BC-32, BC-37 and BC-41) were 
also tested. However, these T cell lines did not produce any specific IFN-γ spots 
when challenged with either MPP-3 or MPP-4 peptides (Figure  5.17, Figure  5.18 
and Figure  5.19). The specificity of BC-32 and BC-37 T cell lines was tested by 
challenging the T cells from each donor with T2 cells and autologous LCLs 
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unpulsed or pulsed with their corresponding peptide (Figure  5.17A and B and Figure 
 5.18A and B).  The specificity of BC-41 T cell lines was tested using unloaded or 
peptide-loaded T2 cells Figure  5.19A and B. 
 
Because CD8+ T cells are known to utilize cytotoxic factors such as granzyme B 
and/or perforin to induce killing of their target cells, the BC-21 MPP-4-CTL was 
therefore tested for the release of granzyme B and/or perforin. The test was 
performed after 5 rounds of stimulation. MPP-4 pulsed T2 and autologous LCLs 
were used as stimulators. No specific production of granzyme B and/or perforin to 
the peptide MPP-4 was observed due to very high background responses seen when 
BC-21 T cells alone were used in the assay (Figure  5.20 A and B).  Although 
specific IFN- release was seen with the MPP-4 T cell line generated from BC-21 
donor only, the MPP-4 T cell lines generated from BC-32, BC-37 and BC-41 were 
also tested for the release of granzyme B and/or perforin. MPP-4 pulsed T2 or K562-
A2.1 cells were used as stimulators. As shown in Figure  5.21, Figure  5.22 and 
Figure  5.23, the three T cell lines did not produce any specific granzyme B or 
perforin spots when challenging with APCs loaded with MPP-4 peptide. 
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Figure  5.16. Specificity of BC-21 CTLs generated by DC2d against the MPP-3 and MPP-4 
peptides using an IFN-γ- ELISPOT assay.  
The T cell lines were established from BC-21, an HLA-A0201+ donor, and tested following three to 
eight rounds of in vitro T cell stimulations. Targets were T2 cells pulsed with either no peptide or 
with peptide. The background observed when T cells alone were used is shown. Results are expressed 
as IFN- γ positive cells per 20.000 CD8+ T cells and are the mean of triplicate assays (±SD). MPP-4-
CTLs released IFN- upon re-stimulation with T2 cells pulsed with MPP-4 peptide (A). T cell line 
generated against the MPP-3 peptide released more IFN- upon re-stimulation with T2 cells alone 
(B).  
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Figure  5.17.  Non-specific IFN- release of BC-32 CTLs generated by DC2d cells against the 
MPP-4 and the MPP-3 peptides using an IFN-γ- ELISPOT assay. 
The T cell lines were established from BC-32, an HLA-A0201+ donor, and tested following three to 
eight rounds of in vitro T cell stimulations. Targets were T2 cells and LCL-32 pulsed with either no 
peptide or with peptide. The background observed when T cells alone were used is shown. Non-
specific IFN- release is shown for T cell line generated against the MPP-4 peptide (A). Non-specific 
IFN- release is shown for T cell line generated against the MPP-3 peptide (B). Results are expressed 
as IFN- γ positive cells per 20.000 CD8+ T cells and are the mean of triplicate assays (±SD).  
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Figure  5.18. Non-specific IFN- release of BC-37 CTLs generated by DC2d cells against the 
MPP-4 and the MPP-3 peptides using an IFN-γ- ELISPOT assay. 
The T cell lines were established from BC-37, an HLA-A0201+ donor, and tested following three to 
eight rounds of in vitro T cell stimulations. Targets were T2 cells and LCL-37 pulsed with either no 
peptide or with peptide. The background observed when T cells alone were used is shown. Non-
specific IFN- release is shown for T cell line generated against the MPP-4 peptide (A). Non-specific 
IFN- release is shown for T cell line generated against the MPP-3 peptide (B). Results are expressed 
as IFN- γ positive cells per 20.000 CD8+ T cells and are the mean of triplicate assays (±SD).  
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Figure  5.19. Non-specific IFN- release of BC-41 CTLs generated by DC2d cells against the 
MPP-4 and the MPP-3 peptides using an IFN-γ- ELISPOT assay. 
The T cell lines were established from BC-41, an HLA-A0201+ donor, and tested following three to 
eight rounds of in vitro T cell stimulations. Targets were T2 cells pulsed with either no peptide or 
with peptide. The background observed when T cells alone were used is shown. Non-specific IFN- 
release is shown for T cell line generated against the MPP-4 peptide (A). Non-specific IFN- release 
is shown for T cell line generated against the MPP-3 peptide (B). Results are expressed as IFN- γ 
positive cells per 20.000 CD8+ T cells and are the mean of duplicate assays (±SD).  
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Figure  5.20. Specificity of BC-21 CTLs generated by DC2d against the MPP-4 peptides using 
granzyme B and perforin ELISPOT assay.  
The T cell lines were established from BC-21, an HLA-A0201+ donor, and tested following five to 
eight rounds of in vitro T cell stimulations. Targets were T2 cells and autologous LCL-21 cells pulsed 
with either no peptide or with MPP-4 peptide. Results are expressed as granzyme B (A) or perforin 
(B) positive cells per 10.000 CD8+ T cells and are the mean of duplicate assays (±SD). T cell line 
MPP-4 released high granzyme B and perforin when T cells alone were used and when no peptide 
was used.  
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Figure  5.21. Non-specific granzyme B and perforin release by BC-32 CTLs generated by DC2d 
cells against the MPP-4 peptides using an ELISPOT assay. 
The anti-MPP-4 T cell line was established from BC-32, an HLA-A0201+ donor, and tested following 
five to eight rounds of in vitro T cell stimulations. Targets were K562-A2.1 cells pulsed with either 
no MPP-4 peptide or with the peptide. The background observed when T cells alone were used is 
shown. (A) Shows non-specific granzyme B release for BC-32 MPP-4 T cell line. (B) Shows non-
specific perforin release for BC-32 MPP-4 T cell line. Results are expressed as granzyme B or 
perforin positive cells per 10.000 CD8+ T cells and are the mean of duplicate assays (±SD).  
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Figure  5.22. Non-specific granzyme B and perforin release of BC-37 CTLs generated by DC2d 
cells against the MPP-4 peptides using an ELISPOT assay. 
The anti-MPP-4 T cell line was established from BC-37, an HLA-A0201+ donor, and tested following 
five to eight rounds of in vitro T cell stimulations. Targets were T2 cells pulsed with either no MPP-4 
peptide or with the peptide. The background observed when T cells alone were used is shown. (A) 
Shows non-specific granzyme B release for BC-37 MPP-4 T cell line. (B) Shows non-specific 
perforin release for BC-37 MPP-4 T cell line. Results are expressed as granzyme B or perforin 
positive cells per 20.000 CD8+ T cells and are the mean of duplicate assays (±SD).  
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Figure  5.23. Non-specific granzyme B and perforin release of BC-41 CTLs generated by DC2d 
cells against the MPP-4 peptides using an ELISPOT assay. 
The anti-MPP-4 T cell line was established from BC-41, an HLA-A0201+ donor, and tested following 
five to eight rounds of in vitro T cell stimulations. Targets were K562-A2.1 cells pulsed with either 
no MPP-4 peptide or with the peptide. The background observed when T cells alone were used is 
shown. (A) Shows non-specific granzyme B release for BC-41 MPP-4 T cell line. (B) Shows non-
specific perforin release for BC-41 MPP-4 T cell line. Results are expressed as granzyme B or 
perforin positive cells per 10.000 CD8+ T cells and are the mean of duplicate assays (±SD).  
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5.3.5.2. MPP-4 CTLs specifically lysed MPP-4-pulsed target cells   
The expanded anti-MPP-3 and anti-MPP-4 T cell lines generated from the four 
HLA-A*0201 donors were tested for their specificity against T2 cells and 
autologous LCL using a chromium release assay. Specific lysis of 16.4% against the 
T2 cells loaded with MPP-4 peptide compared to 0.25% in the absence of the 
peptide was recorded for TCL-21 MPP-4 at an effector to target ratio (E:T) of 50:1 
(Figure  5.24A). 34.3% specific lysis for the same T cell line was recorded against 
autologous LCL (LCL-21) loaded with the MPP-4 peptide compared to 6.5% against 
autologous LCL in the absence of the peptide at E: T ratio of 50:1 (Figure  5.24B). 
The cytotoxic activity of MPP-4 T cell line against K562-A2.1 was also measured. 
K562-A2.1 is a leukaemia cell line expressing MPP11 and transfected with the 
HLA-A*0201 molecule. At an E:T ratio of 50:1, MPP-4 CTLs exerted a lytic 
activity of 13% against this leukaemia cell line. Whereas only 3.65% lysis towards 
the wild type K-562 (lacking the HLA-A2 expression) was recorded at the same E: 
T ratio (Figure  5.24C).  
 
In accordance with the ELISPOT results, only the MPP-4 T cell line generated from 
BC-21 showed peptide specificity while T cell lines generated from the other three 
donors (BC-32, BC-37 and BC-41) could not lyse different HLA-A2.1+ target cells 
loaded with the MPP-4 peptide (Figure  5.25, Figure  5.26 and Figure  5.27). Non-
specific lysis was recorded for the TCL-32 MPP-4 challenged with unpulsed or 
peptide pulsed T2 cells (Figure  5.25A) and LCL-32 (Figure  5.25B). Non-specific 
lysis was recoreded by the same T cell line against K-562 and K562-A2.1 (Figure 
 5.25C). Very low level of lysis (2.8% only) by TCL-37 MPP-4 of peptide-loaded 
LCL-37 was recorded (Figure  5.26). The TCL-41 MPP-4 failed to recognize 
peptide-loaded LCL-41 (Figure  5.27A) as well as K562-A2.1 (Figure  5.27B).  
 
Once more the results of the ELISPOT are consistent with the cytotoxic findings. 
Herein, all of the four T cell lines generated against the MPP-3 peptide did not show 
any specific cytotoxic activity (Figure  5.28, Figure  5.29, Figure  5.30 and Figure 
 5.31). The TCL-21 MPP-3 failed to recognize peptide-loaded T2 cells (Figure 
 5.28A) as well as peptide-loaded autologous LCL (Figure  5.28B). The TCL-32 
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MPP-3 failed to recognize the peptide-loaded T2 cells (Figure  5.29A) and showed 
no lytic activity against unpulsed or peptide-pulsed autologous LCL (Figure  5.29B).  
The same thing was recorded for the TCL-37 MPP-3 when challenged with 
autologous LCL (Figure  5.30).  The TCL-41 MPP-3 did not recognize peptide-
pulsed LCL-41 (Figure  5.31A) as well as K562-A2.1 (Figure  5.31B).  
 
5.3.5.3. Cloning of MPP-4 CTLs 
The TCL-21 MPP-4 that showed specificity to the MPP-4 peptide was cloned at 1, 2 
and 5 cells/well against the T2 loaded peptide and a pool of allogeneic PBMCs in 
the presence of IL-2 and IL-15 using a standard limiting dilution assay. In order to 
obtain an optimal expansion, anti-CD3 antibody (OKT3) was added. 200 T cell 
clones were generated. These clones were screened for their specificity against the 
MPP-4 peptide using the cytotoxic chromium release assay. The T2 cells were either 
unpulsed or pulsed with MPP-4 peptide. Unfortunately, none of the clones showed 
specific lytic activity for the MPP-4 peptide.  Therefore, another attempt was done to 
clone the T cell line in the presence of IL-2 only (without the addition of either IL-
15 or OKT3), however, the generated T cell clones (9 clones) died at an early stage. 
Moreover, the specific cytotoxicity of the generated MPP-4 T cell lines was only 
seen with the line generated from the BC-21 donor. We were not successful in 
generating specific T cell lines against the MPP-4 peptide using a further three 
HLA-A*0201 positive donors.  
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Figure  5.24. Recognition of HLA-A0201+ target cells by BC-21 T cell line generated by DC2d 
against MPP-4 peptide as tested using a standard chromium release assay.  
The MPP-4 T cell line generated from normal HLA-A0201+ donor, BC-21, was used as effector cells.  
(A) Target cells were T2 cells pulsed with either no peptide (dark blue symbol) or with MPP-4 
peptide (pink symbol). (B) Target cells were autologous LCL-21 pulsed with either no peptide (dark 
blue symbol) or with MPP-4 peptide (pink symbol). (C) Target cells were K562 (dark blue symbol) 
and K562-A2.1 (pink symbol). The data are presented as the percentage specific lysis at the indicated 
E:T ratios and represents the average of the two experiment and error bars indicate the SD.  
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Figure  5.25. Non-specific lysis by BC-32 T cell line generated by DC2d against MPP-4 peptide 
as tested using a standard chromium release assay.  
The MPP-4 T cell line generated from normal HLA-A0201+ donor, BC-32, were used as effector 
cells. (A) Target cells were T2 cells pulsed with either no peptide (dark blue symbol) or with MPP-4 
peptide (pink symbol). (B) Target cells were autologous LCL-32 pulsed with either no peptide (dark 
blue symbol) or with MPP-4 peptide (pink symbol). (C) Target cells were K562 (dark blue symbol) 
and K562-A2.1 (pink symbol). The data are presented as the percentage specific lysis at the indicated 
E:T ratios and represents the average of the two experiment and error bars indicate the SD. 
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Figure  5.26. Non-specific lysis by BC-37 T cell line generated by DC2d against MPP-4 peptide 
as tested using a standard chromium release assay.  
The MPP-4 T cell line generated from normal HLA-A0201+ donor, BC-37, were used as effector 
cells. Target cells were autologous LCL-37 pulsed with either no peptide (dark blue symbol) or with 
MPP-4 peptide (pink symbol). The data are presented as the percentage specific lysis at the indicated 
E:T ratios and represents the average of the two experiment and error bars indicate the SD. 
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Figure  5.27. Non-specific lysis by BC-41 T cell line generated by DC2d against MPP-4 peptide 
as tested using a standard chromium release assay.  
The MPP-4 T cell line generated from normal HLA-A0201+ donor, BC-41, were used as effector 
cells. (A) Target cells were autologous LCL-41 pulsed with either no peptide (dark blue symbol) or 
with MPP-4 peptide (pink symbol). (B) Target cells were K562 (dark blue symbol) and K562-A2.1 
(pink symbol). The data are presented as the percentage specific lysis at the indicated E:T ratios and 
represents the average of the two experiment and error bars indicate the SD. 
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Figure  5.28. Non-specific lysis by BC-21 T cell line generated by DC2d against MPP-3 peptide 
as tested using a standard chromium release assay.  
The MPP-3 T cell line generated from a normal HLA-A0201+ donor, BC-21, were used as effector 
cells. (A) Target cells were T2 cells pulsed with either no peptide (dark blue symbol) or with MPP-4 
peptide (pink symbol). (B) Target cells were autologous LCL-21 pulsed with either no peptide (dark 
blue symbol) or with MPP-4 peptide (pink symbol). The data are presented as the percentage specific 
lysis at the indicated E:T ratios and represents the average of the two experiments and error bars 
indicate the SD. 
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Figure  5.29.  Non-specific lysis by BC-32 T cell line generated by DC2d against MPP-3 peptide 
as tested using a standard chromium release assay.  
The MPP-3 T cell line generated from a normal HLA-A0201+ donor, BC-32 was used as effector 
cells. The T cells were stimulated with T2 cells (A) and with autologous LCL-32 (B). Target cells 
pulsed with no peptide are represented by dark blue symbol, whereas target cells pulsed with MPP-3 
peptide are represented by pink symbol. The data are presented as the percentage specific lysis at the 
indicated E:T ratios and represents the average of the two experiments and error bars indicate the SD. 
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Figure  5.30.  Non-specific lysis by BC-37 T cell line generated by DC2d against MPP-3 peptide 
as tested using a standard chromium release assay.  
The MPP-3 T cell line generated from a normal HLA-A0201+ donor was used as effector cells. The T 
cells were stimulated with autologous LCL-37. LCL-37 pulsed with no peptide are represented by 
dark blue symbol, whereas LCL-37 pulsed with MPP-3 peptide are represented by pink symbol. The 
data are presented as the percentage specific lysis at the indicated E:T ratios and represents the 
average of the two experiments and error bars indicate the SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 187 
A
0
1
2
3
4
5
50:1 25:1 12.5:1 6.25:1
E:T ratio
%
 L
ys
is LCL41
LCL41-MPP-3
B
0
0.5
1
1.5
2
2.5
50:1 25:1 12.5:1 6.25:1
E:T ratio
%
 L
ys
is K562
K562-A2.1
%
 L
ys
is
%
 L
ys
is
 
Figure  5.31.  Non-specific lysis by BC-41 T cell line generated by DC2d against MPP-3 peptide 
as tested using a standard chromium release assay.  
The MPP-3 T cell line generated from a normal HLA-A0201+ donor, BC-41, was used as effector 
cells. (A) Target cells were T2 cells pulsed with either no peptide (dark blue symbol) or with MPP-3 
peptide (pink symbol). (B) Target cells were K562 (dark blue symbol) and K562-A2.1 (pink symbol). 
The data are presented as the percentage specific lysis at the indicated E:T ratios and represents the 
average of the two experiments and error bars indicate the SD. 
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5.3.6. Generation of PR3 specific T lymphocyte lines 
The ability of the PR3-derived peptides to induce specific cytotoxic T lymphocytes 
(CTLs) was tested. PBMCs obtained from three different HLA-A*0201 positive 
healthy volunteers were utilized to generate CTLs specific to the selected peptides.  
The three donors were designated as BC-32, BC-37 and BC-41. The PBMCs from 
each donor were used as the source of the responder cells and antigen presenting 
cells. The responder cells were CD8+ T cells purified by MACS negative selection 
and stimulated in vitro with antigen presenting cells-loaded peptide for 7-10 days.   
The protocol used for the generation of CD8+ T cell lines utilized peptide-pulsed 
DC2d (fast DC) to prime the purified CD8+ T cells and peptide-pulsed monocytes 
for subsequent T cell stimulations. The DC2d were generated as described in 
Materials and Methods section 2.5.4.3.  
 
To investigate whether the PR3 synthetic peptides could stimulate peptide-specific 
CTLs,  the generated T cell lines were tested against different HLA-A*0201+ targets 
in the presence or absence of autologous peptide using a Chromium Release Assay 
and an ELISPOT assay after 3 to 8 rounds of stimulations. 
 
5.3.7. CD8+ T cell responses to PR3-derived peptides  
5.3.7.1. IFN-γ and granzyme B production by PR3 T cell lines 
After the fourth round of stimulation, the specificity of the in vitro primed CTLs was 
tested first for IFN-γ release to stimulation with the corresponding peptides using an 
ELISPOT assay. All the generated BC-32-CTL lines were able to produce IFN-γ 
against autologous targets regardless of the presence or absence of the corresponding 
peptide.  No specific IFN-γ production was recorded for the two CTLs generated 
against the PR-129 and PR-9 test peptides (Figure  5.32A and B). However, the CTL 
line generated with the PR-169 positive control peptide produced IFN-γ after 
stimulation with autologous LCLs loaded with the PR-169 peptide (Figure  5.32C). 
Interestingly, when monocytes were used as stimulators, IFN- γ specific production 
by the anti-PR169 CTL were observed in the presence of peptide and only when IL-
2 (10 ng/ml) was added  (Figure  5.32C).  
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The specificity of the T cell lines generated from the two other donors, BC-37 and 
BC-41, was also tested in IFN-ELISPOT assays. Targets used to test BC-37 T 
cell lines were T2 cells and autologous LCL pulsed with either no peptide or with 
corresponding PR-3-peptide.  K562-A2.1 cells, loaded with either no peptide or with 
corresponding PR-3-peptide, were used to test BC-41 T cell lines. As shown in 
Figure  5.33 and Figure  5.34, none of the generated PR-3-T cell lines produced 
specific IFN-γ spots when challenged with peptide-loaded target cells including the 
positive control PR-169.  
 
The next ELISPOT assay was to test whether the generated PR3-T cell lines produce 
specific granzyme B. K562-A2.1 and T2 cells loaded with each peptide were used as 
stimulators in this ELISPOT assay. No granzyme B production was recorded for the 
BC-37-CTLs, BC-32-CTLs as well as BC-41-CTLs generated against the PR-9 and 
PR-129 test peptides (Figure  5.35A and B), (Figure  5.36A and B) and (Figure  5.37A 
and B). However, the control peptide PR-169-CTL generated from BC-37, BC-32 
and BC-41 produced granzyme B after stimulation with T2 or K562-A2.1 loaded 
with the PR-169 peptide (Figure  5.35C, Figure  5.36C and Figure  5.37C ).   
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Figure  5.32. ELISPOT assay for IFN- production by BC-32 T cell lines generated by DC2d 
cells against peptides derived from the PR-3 antigen.  
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Figure 5.32.  Continued  
The T cell lines were established from a healthy HLA-A*0201+ donor, BC-32, and tested following 
four to eight rounds of in vitro T cell stimulations. T cell line generated against PR-169 peptide was 
included as a positive control. Targets were LCL-32 and autologous monocytes pulsed with either no 
peptide or with peptide. Monocytes were pulsed with each peptide in the presence or absence of IL-2. 
T cell lines generated against PR-129 (A) and PR-9 (B) did not produce more spots of IFN- when 
stimulated with target cells pulsed with the corresponding peptide. The positive control PR-169 
produces more IFN- spots when stimulated with LCL-pulsed peptide and monocyte-pulsed peptide 
in the presence of IL-2 (C). The background observed when T cells alone were used is shown. 
Results are expressed as IFN- γ positive cells per 50.000 CD8+ T cells and are the mean of duplicate 
assays (±SD). Mo= Monocytes. 
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Figure  5.33. ELISPOT assay for IFN- production by BC-37 T cell lines generated by DC2d 
cells against peptides derived from the PR-3 antigen.  
The T cell lines were established from a healthy HLA-A*0201+ donor, BC-37, and tested following 
four to eight rounds of in vitro T cell stimulations. T cell line generated against PR-169 peptide was 
included as a positive control. Targets were T2 cells and LCL-37 pulsed with either no peptide or 
with peptide. The T cell lines generated against PR-129 (A), PR-9 (B) and PR-169 (C) did not 
produce more spots of IFN- when stimulated with target cells pulsed with the corresponding peptide. 
The background observed when T cells alone were used is shown. Results are expressed as IFN- γ 
positive cells per 50.000 CD8+ T cells and are the mean of duplicate assays (±SD).  
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Figure  5.34. ELISPOT assay for IFN- production by BC-41 T cell lines generated by DC2d 
cells against peptides derived from the PR-3 antigen. 
The T cell lines were established from a healthy HLA-A*0201+ donor, BC-41, and tested following 
four to eight rounds of in vitro T cell stimulations. T cell line generated against PR-169 peptide was 
included as a positive control. Targets were T2 cells and LCL-37 pulsed with either no peptide or 
with peptide. The T cell lines generated against PR-129 (A), PR-9 (B) and PR-169 (C) did not 
produce more spots of IFN- when stimulated with target cells pulsed with the corresponding peptide. 
The background observed when T cells alone were used is shown. Results are expressed as IFN- γ 
positive cells per 10.000 CD8+ T cells and are the mean of duplicate assays (±SD).  
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Figure  5.35. ELISPOT assay for granzyme B production by BC-37 T cell lines generated by 
DC2d cells against the peptides derived from PR-3 antigen.  
The T cell lines were established from a healthy HLA-A*0201+ donor, BC-37, and tested following 
three to eight rounds of in vitro T cell stimulations. T cell line generated against PR-169 peptide was 
included as a positive control. Targets were T2 pulsed with either no peptide or with peptide.   T cell 
lines generated against PR-129 (A) and PR-9 (B) did not produce more spots of granzyme B when 
stimulated with T2 cells pulsed with the corresponding peptide. The positive control PR-169 
produces more granzyme B spots when stimulated with T2-pulsed peptide (C). The background 
observed when T cells alone were used is shown. Results are expressed as granzyme B positive cells 
per 20.000 CD8+ T cells and are the mean of duplicate assays (±SD).  
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Figure  5.36. ELISPOT assay for granzyme B production by BC-32 T cell lines generated by 
DC2d cells against the peptides derived from PR-3 antigen.  
The T cell lines were established from a healthy HLA-A*0201+ donor, BC-32, and tested following 
three to eight rounds of in vitro T cell stimulations. T cell line generated against PR-169 peptide was 
included as a positive control. Targets were K562-A2.1 cells pulsed with either no peptide or with 
peptide. T cell lines generated against PR-129 (A) and PR-9 (B) did not produce more spots of 
granzyme B when stimulated with K562-A2.1 cells pulsed with the corresponding peptide. The 
positive control PR-169 produces more granzyme B spots when stimulated with K562-A2.1-pulsed 
peptide (C). The background observed when T cells alone were used is shown. Results are expressed 
as granzyme B positive cells per 10.000 CD8+ T cells and are the mean of duplicate assays (±SD). 
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Figure  5.37. ELISPOT assay for granzyme B production by BC-41 T cell lines generated by 
DC2d cells against the peptides derived from PR-3 antigen.  
The T cell lines were established from a healthy HLA-A*0201+ donor, BC-41, and tested following 
three to eight rounds of in vitro T cell stimulations. T cell line generated against PR-169 peptide was 
included as a positive control. Targets were K562-A2.1 cells pulsed with either no peptide or with 
peptide. T cell lines generated against PR-129 (A) and PR-9 (B) did not produce more spots of 
granzyme B when stimulated with K562-A2.1 cells pulsed with the corresponding peptide.  
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Figure 5.37.  Continued  
The positive control PR-169 produces more granzyme B spots when stimulated with K562-A2.1-
pulsed peptide (C). The background observed when T cells alone were used is shown. Results are 
expressed as granzyme B positive cells per 10.000 CD8+ T cells and are the mean of duplicate assays 
(±SD). 
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5.3.7.2. Cytotoxic activity of anti-PR3 CTLs  
The next step in monitoring CD8+ T cell responses to PR3-derived peptides was to 
test the cytotoxic activity of the generated T cell lines in a standard Cr51-release 
assay. T2 cells or autologous LCLs were pulsed with no peptide or with each peptide 
and used as targets at different E:T ratio. Among the three HLA-A*0201 donors 
used to generate anti-PR-3 CTLs, peptide-specific cytotoxic responses were only 
demonstrated with a T cell line generated from one donor i.e. BC-32. Consistent 
with the results obtained with the ELISPOT assay; the T cell line generated against 
the previously identified epitope PR-169 showed peptide-specific cytotoxic 
responses, whereas the T cell lines generated from the same donor against the PR-9 
and PR-129 test peptides did not elicit any peptide-specific cytotoxic responses. The 
PR-129-T cell line peptide did not recognize peptide-pulsed T2 and LCL-32 targets 
cells (Figure 5.17A and B). Similarly, the PR-9-T cell line peptide tested against T2 
cells and LCL-32 did not recognize peptide-pulsed target cells (Figure  5.39A and 
B). The PR-169-CTL line recorded a specific lysis of 51% against T2 cells loaded 
with PR-169 peptide compared to 6% in the absence of the peptide at E:T ratio 25:1 
(Figure  5.40A). In addition, 10% specific lysis was demonstrated for the same CTL 
line against LCL-32 pulsed-peptide and only 4% lysis against LCL-32 in the 
absence of the peptide (Figure  5.40 A &B).  
 
The specificity of the T cell lines generated from BC-37 donor was also examined 
using cytotoxicity assays. However, none of the generated CTL lines showed a 
specific activity against peptide-loaded LCL-37 including the positive control PR-
169 peptide (Figure  5.41A, B and C). The cytotoxic activity of the T cell lines 
generated from BC-41 could not be tested due to low cell number.  
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Figure  5.38. Non-specific lysis by BC-32 T cell line generated by DC2d against PR-129 peptide 
as tested using a standard chromium release assay.  
The PR-129 T cell line generated from normal HLA-A0201+ donor, BC-32, was used as effector 
cells. Target cells were T2 cells and LCL-32 pulsed with either no peptide (dark blue symbol) or with 
PR-129 peptide (pink symbol). The PR-129 T cell line was stimulated with T2 cells (A) and with 
LCL-32 (B). The data are presented as the percentage specific lysis at the indicated E:T ratios and 
represents the average of the two experiments and error bars indicate the SD. 
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Figure  5.39. Non-specific lysis by BC-32 T cell line generated by DC2d against PR-9 peptide as 
tested using a standard chromium release assay.  
The PR-9 T cell line generated from normal HLA-A0201+ donor, BC-32, was used as effector cells. 
Target cells were T2 cells and LCL-32 pulsed with either no peptide (dark blue symbol) or with PR-9 
peptide (pink symbol). The PR-9 T cell line was stimulated with T2 cells (A) and with LCL-32 (B). 
The data are presented as the percentage specific lysis at the indicated E:T ratios and represents the 
average of the two experiments and error bars indicate the SD. 
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Figure  5.40.  Recognition of peptide pulse target cells by BC-32 T cell line generated by DC2d 
against PR-169 peptide as tested using a standard chromium release assay.  
The PR-169 T cell line generated from normal HLA-A0201+ donor, BC-32, was used as effector 
cells.  Target cells were autologous T2 cells and LCL-32 pulsed with either no peptide (dark blue 
symbol) or with PR-169 peptide (pink symbol). (A) Shows the cytotoxic activity of PR-169 cell line 
against peptide-pulsed T2. (B) Shows the cytotoxic activity of PR-169 cell line against peptide-pulsed 
LCL-32. The data are presented as the percentage specific lysis at the indicated E:T ratios and 
represents the average of the two experiments and error bars indicate the SD. 
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Figure  5.41. Non-specific lysis by BC-37 T cell lines generated by DC2d against the PR-3 
peptides as tested using a standard chromium release assay.  
The three T cell lines, PR-129, PR-9 and PR-169, were generated from a normal HLA-A0201+ donor, 
BC-37. The PR-169 T cell line was included as a positive control.  The T cells were used as effector 
cells. Target cells were LCL-37 pulsed with either no peptide (dark blue symbol) or with 
corresponding peptide (pink symbol). (A) Shows non-specific lysis of the T cell line generated 
against the PR-129 peptide. (B) Shows non-specific lysis of the T cell line generated against the PR-9 
peptide. (C) Shows non-specific lysis of the T cell line generated against the PR-169 peptide.  
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Figure 5.41. Continued  
The data are presented as the percentage specific lysis at the indicated E:T ratios and represents the 
average of the two experiments and error bars indicate the SD. 
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5.4. Discussion 
CD8+ cytotoxic T lymphocytes (CTLs) recognize endogenously processed peptides 
consisting of 8-11 amino acids, most commonly 9 amino acids long, presented on 
the cell surface of target cells in the context of major histocompatibility complex 
(MHC) class I molecules. These cells are believed to play an important role in 
identifying and eliminating tumour cells (Melief and Kast, 1995). To date, several 
CD8+ T cell epitopes derived from leukaemia antigens have been identified, some of 
them have been investigated in clinical trials (Heslop et al., 2003, Qazilbash et al., 
2004, Schmitt et al., 2008). Importantly, the graft versus leukaemia (GVL) effect 
often seen after  allogeneic HSCT  has been found to be mediated mostly by donor-
derived CD8+ T cells recognizing peptides derived from leukaemia antigens and/or 
minor histocompatibility antigens (mHAs) presented on recipient cells (Schetelig et 
al., 2005, Wu and Ritz, 2006, Appelbaum, 2001).   Overexpressed antigens such as 
WT1, PR-3 and MUC1 represent possible targets of specific GVL reactions (Kapp et 
al., 2009, Molldrem et al., 2000, Rezvani et al., 2003).  
 
This study investigated the potential of CD8+ T cell epitopes derived from the 
leukaemia associated antigens MPP11 and PR-3 using a reverse immunological 
approach. Previous studies have reported the existence of a humoral response 
against MPP11 protein as well as the overexpression of this protein in patients with 
myeloid leukaemias (Greiner et al., 2003, Greiner et al., 2004, Schmitt et al., 2006). 
However, the identification of CD8+ T-cell epitopes derived from the MPP11 
protein is a crucial contribution to the field of leukaemia immunotherapy. Although 
the antigenic epitope PR-1 has already been identified (Molldrem et al., 1996); PR-3 
seems to be a rich source of peptide epitopes that can elicit a specific CTL response. 
Therefore, additional A*0201-restricted epitopes capable of inducing CTL responses 
were searched for within known databases, and tested.  
 
The reverse immunological approach permitted the identification of class I as well 
as class II candidate epitopes derived from known tumour antigens on the basis of 
HLA-binding motifs (Stevanovic, 2002, Paschen et al., 2004). Using this approach, 
numerous epitopes could be identified in leukaemia (Molldrem et al., 1996, Oka et 
al., 2000, Greiner et al., 2005, Asemissen et al., 2006) as well as in solid tumours 
(Alves et al., 2003, Ayyoub et al., 2002, Fujie et al., 1999, Kawashima et al., 1998, 
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Kessler et al., 2001, Neumann et al., 2005).  The amino acid sequences derived from 
MPP11 and PR-3 proteins were examined for the presence of peptides containing 
binding motifs for one of the most frequent class I alleles, A*0201 allele using 
computer-based epitope prediction programs. Four MPP11-derived peptides were 
identified which were predicted to bind with high affinity to HLA-A*0201 
molecule. The peptides were named MPP-1N, MPP-2, MPP-3 and MPP-4. The 
actual binding capacity of the selected peptides was tested using T2 binding assay.  
The MPP11- derived peptides MPP-3 and MPP-4 recorded binding scores lower 
than MPP-1N, and MPP2 scores as determined by the SYFPEITHI software. 
However, in the actual T2 binding assay, MPP-3 and MPP-4 were found to have 
higher binding affinities compared to the two other peptides. This was probably due 
to a very poor dissolution of the MPP-1N and MPP-2 peptides since more 
hydrophobic amino acids are contained within their sequence. In addition to the four 
predicted peptides, the amino acid sequence of the highest scoring peptide i.e., MPP-
1N (QLLIKAVNL) was modified. Studies (Tourdot et al., 2000, Valmori et al., 
1998, Al Qudaihi et al., 2009) have shown that introducing a tyrosine amino acid 
residue at the first position (P1Y) of a peptide enhances epitope immunogenicity. 
Therefore, a tyrosine amino acid residue was introduced in P1 of the MPP-1N 
peptide in order to boost its binding affinity and /or immunogenicity. The 
modification of the MPP-1N peptide enhanced the binding affinity of the modified 
MPP-1Y peptide using the algorithm prediction but in the actual binding assay, the 
analogue peptide could not stabilize the HLA-A*0201 molecule which again may be 
due to its poor dissolution.  
 
Inconsistent with other groups (Molldrem et al., 1996, Oka et al., 2000, Houbiers et 
al., 1993) who have succeeded in identifying CD8+ T-cell epitopes using a simple 
method that employs T2 cells as antigen-presenting cells, specific immune responses 
could not be generated using this method to both MPP11-derived peptides as well as 
the WT1-126N peptide which was included as a positive control.  Since MPP11 and 
WT1 are self-proteins, the majority of high avidity CD8+ T cells might have been 
deleted during thymic maturation (Starr et al., 2003). Thus it is more difficult to 
generate cytotoxic T cell responses from the remaining low avidity-naïve precursors 
because their activation required more stringent costimulatory requirements 
(Janeway and Bottomly, 1994, Swain et al., 1996). DCs as antigen-presenting cells 
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were therefore used for the generation of anti-MPP11 CTL immune responses.  DCs 
are known as the professional antigen presenting cells because of their unique ability 
to stimulate naïve T-cell responses (Banchereau and Steinman, 1998). However, 
following priming of naïve T cells (usually two rounds of T cell stimulation) other 
good APCs such as monocytes and T-APCs could be used for T cell expaniosn. The 
conventional protocol for generating monocyte-derived DCs include 7-9 days of 
culture, however, Dauer et al., (2003) described a rapid protocol for the generation 
of mature DCs from monocytes within only two days of in vitro culture.  Such cells, 
termed as FastDC or DC2d, were found to be capable of inducing tumour-specific 
CD8+ T cell responses as effectively as DCs generated according to the conventional 
7-day method (Dauer et al., 2005, Ho et al., 2006).  Moreover, CTL lines primed 
with DC2d expanded more effectively and showed greater lytic activity than lines 
stimulated with DC7d (Dauer et al., 2005, Ho et al., 2006). Using DC2d as antigen 
presenting cells to prime T cell responses, antigen-specific responses by CTL-21 
generated against MPP-4 peptide were detected via cytokine production and 
cytotoxic assays. MPP-4-CTLs selectively recognized peptide-loaded T2 cells and 
responded by releasing IFN- in an ELISPOT assay (Fig. 5.3A). These T cells 
specifically killed T2 cells and autologous LCLs when loaded with the MPP-4 
peptide suggesting recognition was selective to the MPP-4 peptide (Fig. 5.4 A&B).  
Moreover, they were capable of recognizing the leukaemia cell lines K562-A2.1 
expressing MPP11 protein (Fig. 5.4 C). Even though, T2 cells were not efficient at 
priming and generating specific-CD8+ T cell immunity, however these cells were 
very useful as targets when conducting functional assays such as cytotoxicity and 
ELISPOT. 
 
Four healthy HLA-A*0201 positive individuals were used to generate MPP-4-
specific CTLs; however, specific responses could only be observed in one CTL line 
established from one donor, i.e., BC 21. The failure to obtain specific CTL 
responses to tumour antigens in all four donors tested has been observed previously 
and it has been suggested to be due to the low frequency of peptide-specific CD8+ T 
cell precursors in healthy individuals (Ohminami et al., 2000). The MPP-4 CTL line 
was cloned before testing its capability of recognizing fresh A*0201-positive 
leukemic cells that overexpressed MPP11 protein. Unfortunately, no MPP-4-specific 
clones could be generated. Although leukaemia samples were screened for the 
 207 
MPP11 gene expression, the results were not used as no specific clones against 
MPP-4 were generated. Standard techniques for cloning T cells employ stimulation 
with antigen loaded-APCs in the presence of IL-2 and allogeneic feeder cells in 
limiting dilution cultures followed by repeated re-stimulations to maintain growth 
and specificity. In the first attempt, the MPP-4 T cell line was cloned by stimulation 
with peptide pulsed-T2 cells in the presence of allogeneic feeder cells, IL-2, IL-15 
and anti-CD3 monoclonal antibody (OKT3). Interleukin-2 is the cytokine frequently 
used to promote the survival and  expansion of cultured T cells (Smith, 1988). IL-2 
and IL-15 share the β-chain and the common γ chain receptor (IL-2/IL-15 Rβγc), but 
each cytokine has its unique α-chain receptor (Carson et al., 1994, Grabstein et al., 
1994). IL-15 was initially identified by its capability to promote the development of 
NK cells and the survival of CD8+ memory T cells in vivo (Colucci et al., 2003, 
Zhang et al., 1998). However, it has been reported that anti-tumour-CTLs expanded 
and survived for relatively long time periods in vitro in the presence of IL-15 
whereas CTLs maintained in IL-2 died at earlier stages (Lu et al., 2002). 
Furthermore, IL-15-maintained CTLs retained their effector function as cytotoxic 
cells and did not switch into memory cells (Lu et al., 2002). For TCR triggering, 
OKT3 was used as  reported  previously (Ho et al., 2006). Because all of the 
generated clones were not specific, another attempt to clone the line was conducted 
but without the addition of either IL-15 or anti-CD3 monoclonal antibody. This time 
the generated clones were few and died at an early stage perhaps because of old T 
cell culture.  
 
Two PR-3 peptides (PR-129 and PR-9) that contained anchor motifs required for the 
binding to the class I-A*0201 molecule were identified. However, both peptides 
were incapable of inducing specific CD8+ T cell responses. Although the PR-129 
peptide displayed high binding affinity to the HLA-A*0201 molecule, there were no 
precursor T cells with appropriate T cell receptors (TCRs) reactive to these peptides. 
This result implied again that peptide binding capacity to the HLA molecule was not 
the only factor that determines its immunogenicity. The positive control PR-169 
peptide was effective in inducing specific responses as measured by the ELISPOT as 
well as in cytotoxicity assays in two (BC 32 and BC 37) out of four HLA-A*0201 
positive donors. The demonstration that the positive control PR-169 peptide was 
effective in inducing specific cytotoxic activity and specific cytokine production 
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indicated that the stimulation system used in the present study was optimum for 
generation of cytotoxic T cells. Previous studies have reported the overexpression of 
PR-3 protein in patients with myeloid leukaemias (Muller-Berat et al., 1994, Yong et 
al., 2008). In this study, the leukaemic samples were not screened for the PR-3 
expression. There was no need to select leukaemia samples that express PR-3 
antigen since no specific T cell responses were recorded against PR-9 and PR-129 
peptides.  
 
In summary, the data suggested that CD8+ T cells reactive with the MPP-4 peptide 
could be generated from the T cell repertoire of HLA-A0201+ healthy individuals. 
More importantly, these CTLs were able to specifically lyse the K562-A2.1 
leukemic cells naturally expressing the MPP11 antigen. The study also demonstrated 
that both PR-129 and PR-9 peptides were non-immunogenic. 
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6. GENERAL DISCUSSION 
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A major obstacle facing cancer vaccines is tolerance to self-tumour antigens which 
can prevent the development of effective anti-tumour CTL responses. Different 
approaches have been tested to circumvent this problem (Bellantuono et al., 2002, 
Gao et al., 2000, Xue et al., 2005). Among these, modified peptide ligands known as 
heteroclitic peptides have been used to improve the reactivity of T cells specific for 
tumour antigens by enhancing their affinity to HLA molecules or TCR. These 
peptide ligands are analogues of native tumour antigens generated by single or 
double amino acid substitutions at certain MHC anchor positions. A number of 
peptide analogues derived from melanoma associated antigens and leukaemia 
antigens capable of recognizing native epitopes with enhanced immunogenicity have 
been described (Tsuboi et al., 2002, Pinilla-Ibarz et al., 2005, Valmori et al., 1998, 
Bae et al., 2004a, Bae et al., 2004b, Parkhurst et al., 1996). Tsuboi et al (2002) 
reported that a modified HLA-A*2402-restricted WT1 peptide exhibited a higher 
binding affinity and elicited WT1-specific CTLs more effectively than the natural 
WT1 peptide. Bae et al (2004a, , 2004b) identified a novel HLA-A*0201-restricted 
epitope derived from CD33 and showed that analogues to the native sequence 
displayed enhanced affinity and immunogenicity. Indeed, the modification approach 
has been used to enhance immunogenicity of epitopes not only derived from self 
antigens but also derived from the leukaemia-specific antigen BCR-ABL. In this, 
HLA-A*0201-restricted epitopes derived from BCR-ABL junctional region have 
been improved in terms of their binding capacity and immunogenicity by modifying 
their sequences (Pinilla-Ibarz et al., 2005). Based on these findings, analogues 
derived from WT1 and BCR-ABL have been tested in vaccination trials in which 
clinical responses to the vaccines have been reported (Maslak et al., 2008, Oka et al., 
2004).  
 
In this study, an analogue to a previously identified epitope, Db126 
(RMFPNAPYL), derived from the WT1 antigen has been identified. The analogue 
126Y (YMFPNAPYL) was designed using a single amino acid substitution strategy 
initially described by Tourdot et al (Tourdot et al., 2000). This strategy consists of 
replacing the amino acid at position 1 of HLA-A*0201-associated peptides with a 
tyrosine residue (Y). Although vaccination trials using the native Db126 peptide 
have demonstrated some immunological effect (Rezvani et al., 2008, Mailander et 
al., 2004, Keilholz et al., 2006), the use of an analogue peptide might enhance the 
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vaccine potency as it may induce biological responses superior to that induced by 
the native sequence. Therefore, the purpose of developing this analogue was to test 
whether it would elicit potent CD8+ CTL responses more efficiently than the native 
peptide and whether it would be capable of recognizing its native sequence.  Data 
presented in chapter 3 showed that modification in the sequence of the wild type 
epitope improved its binding to the HLA-A*0201 molecule and enhanced its 
immunogenicity. Importantly, CTLs generated with the modified 126Y peptide 
lysed HLA-matched WT1+ AML cells more efficiently than CTLs generated with 
the native epitope. Similar results supporting our findings have been reported by the 
Scheinberg group (Pinilla-Ibarz et al., 2006). They showed that the WT1A1 
analogue (the same as 126Y analogue) generated more potent CD8 CTL responses 
and was able to recognize and lyse WT1+ CML cell lines. In a subsequent study, the 
same group identified an HLA-DR-restricted epitope (WT1-122A1, 
SGQAYMFPNAPYLPSCLES) spanning the WT1 amino acids 122-140 and showed 
that inclusion of the heteroclitic peptide WT1A1/126Y within the sequence of the 
helper peptide induces a robust CD4 and CD8 T cell response (May et al., 2007). In 
addition, the modified WT1-122A1 epitope was more potent in inducing cytotoxic 
CD8+ CTL responses than the native sequence, WT1-122A (May et al., 2007). 
These results along with results presented in this thesis demonstrate that the 
analogue 126Y epitope is able to cross-react with its native sequence and it is more 
efficient than the native epitope in inducing anti-WT1 responses. All together these 
data should open the door for a potential immunotherapeutic approach utilizing 
WT1-126Y peptide analogue to target malignant tumour cells in HLA-matched 
leukaemia and possibly in other WT1-expressing tumours.  
 
The ability of the 126Y peptide analogue to induce reliable immune responses in 
vivo has been tested by the Scheinberg group via a recently conducted  pilot study 
using multivalent-WT1 peptides to vaccinate patients with AML, mesothelioma and 
non-small cell lung cancer (Maslak et al., 2010, Krug et al., 2010). The vaccine 
consisted of the analogue peptide WT1A1/126Y and three class II peptides including 
the modified WT1-122A1. A total of ten AML patients in complete remission (CR) 
following chemotherapy who had measurable WT1 transcript were enrolled. Patients 
received the four WT1 peptides plus the immune adjuvant montanide and GM-CSF. 
In this trial, robust CD4 and CD8 T-cell immune responses were observed to the 
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WT1 peptides in high proportion of patients with minimal toxicity. Importantly, the 
WT1-122A1 heteroclitic peptide was more efficient in inducing anti-126N immune 
responses than its native sequences (Maslak et al., 2010). Data from this trial 
suggested that it is possible to induce effector cells capable of recognizing WT1-
expressing malignant cells in vitro. However, further clinical trials that evaluate the 
clinical effectiveness of this vaccine as a post-remission therapy for leukaemia 
patients are needed.  
 
Despite the promise of using heteroclitic peptides as a strategy to break tolerance to 
the WT1 antigen, the mono-therapy vaccine alone will not be able to achieve robust 
and persistent anti-tumour responses that will prevent relapse. For the best clinical 
benefit it will probably be necessary to combine multiple therapeutic interventions 
which include blockade of host-negative immunoregulatory mechanisms 
(checkpoints) such as CTLA-4, PD-1 and most importantly regulatory T cells 
(Tregs). Tregs have been shown to play an important role in modulating both natural 
and adoptive immune responses in cancer patients. It has been demonstrated that 
Tregs directly suppress the anti-tumour immune responses in cancer patients (Beyer 
and Schultze, 2006, Ghebeh et al., 2008), and depletion of this T-cell population 
resulted in an enhancement of vaccine-mediated anti-tumour immunity in cancer 
patients (Dannull et al., 2005, Mahnke et al., 2007). Furthermore, Tregs have been 
shown to be inversely related to the outcome of several human malignancies 
(Salama et al., 2009, Heimberger et al., 2008). Importantly, fully functional Tregs 
specific for LAGE1 and ARTC1 were demonstrated in melanoma patients (Wang et 
al., 2004, Wang et al., 2005a). Greiner et al (2006) investigated the influence of the 
expression levels of several LAAs on the clinical outcome of patients with AML. 
High expression of three LAAs was found to be associated with favourable clinical 
outcome, inducing strong CD8+ CTL responses. However, there was no correlation 
with the clinical outcome nor induction of natural anti-WT1 CD8+ CTL response in 
these patients (Greiner et al., 2006). In line with this, Nishikawa et al (2005) has 
shown the existence of tumour-specific Tregs, which actively suppress antigen-
specific anti-tumour immunity in cancer patients. Another study by Nadal and 
colleagues suggested that Tregs exert an inhibitory effect on graft versus leukaemia 
and this was associated with relapse after allogeneic stem cell transplantation (Nadal 
et al., 2007). Importantly, it has been shown that anti-WT1 responses can be largely 
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affected by the presence of CD4+CD25+ Tregs in which depletion of this T-cell 
population was necessary for the generation of an effective WT1-specific CTL 
responses (Asemissen et al., 2006). Moreover, our group has identified a human 
HLA-DRB1*0402–restricted CD4+CD25+FOXP3+ Tregs population specific for the 
WT1 antigen and showed that this antigen is a novel target for leukaemia-specific 
CD4+ Tregs (Lehe et al., 2008). In this study, we have generated Tregs cell lines and 
clones using a pool of 110 15-mer overlapping peptides across the entire WT1 
protein. These T-cell lines and clones specifically recognized a WT1333-347-derived 
peptide (RYFKLSHLQMHSRKH) designated WT1-84 in an HLA-DRB1*0402–
restricted manner. The Treg clones were able to recognize HLA-DRB1*04–matched 
fresh leukemic cells expressing the WT1 antigen and were able to significantly 
inhibit the proliferative activity of allogeneic T cells. We also detected anti–WT1-84 
Tregs in HLA-DR4+ AML patients. Furthermore, we have shown that the presence 
of Tregs strongly inhibited the induction of anti–WT1-126 CD8+ CTL responses 
(Lehe et al., 2008). Therefore, the existence of such tumour-specific Tregs can 
actively suppress the WT1-specific anti-tumour immunity in cancer patients as 
shown in other systems (Nishikawa et al., 2005). In addition to our previous 
findings, a novel MHC class II epitope derived from WT1 antigen and presented by 
DRB1*04 (WT1-60237-251, TMNQMNLGATLKGVA) was identified in this 
presented study. This peptide was recognized by CD4+ T cells obtained from a 
healthy HLA-DRB1*0406,0701 donor. The anti-WT1-60- peptide T-cell line was 
generated using the same methodology and conditions used to generate the anti-
WT1-84 Tregs. Moreover, the cytokines secreted by these cells was of a Th2 
cytokine profile similar to that of generated Tregs. WT1-60 may thus represent 
another target for Tregs. However, these T cells should be further examined for the 
presence of Treg markers, to confirm the Treg-phenotype, and for their suppressor 
effect, to confirm Treg function. 
 
Current interests in cancer immunotherapy should be focused on determining the 
therapeutic implications of Treg cells ‘‘regulating the regulators.’’ Interestingly, 
elimination of Tregs by IL-2 conjugated to diphtheria toxin (ONTAK) enhanced 
vaccine-mediated anti-tumour immunity in cancer patients (Dannull et al., 2005, 
Mahnke et al., 2007). However, targeting the CD25 molecule may eliminate Tregs, 
leading to an increase in the susceptibility to autoimmunity, and it can also deplete 
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activated CD25+ effector cells, which may be important for clearance of cancer and 
infection (Curtin et al., 2008). Therefore, studies should be tailored toward 
developing selective depletion strategies directed against Treg-related markers. 
Alternatively, triggering of TLR8 or OX40, and potentially blocking adenosine, 
might improve the chances of neutralizing Tregs immunosuppression in cancer 
patients (Colombo and Piconese, 2007).  
 
Although the WT1 antigen represents an ultimate target for tumour immunotherapy, 
targeting a single tumour antigen may result in tumour immune escape by losing or 
down-regulating the expression of the parent protein. Therefore, immunotherapeutic 
approaches targeting more than one antigen may be more effective in inducing anti-
tumour immune responses. In this respect, Rezvani et al (2008)  showed that a 
combined peptide vaccine consisting of PR-1 (VLQELNVTV) and WT1-126 
(RMFPNAPYL) peptides was safe and could elicit immunologic responses 
associated with a reduction in WT1 mRNA expression in patients with myeloid 
leukaemia. In line with this strategy, the work presented in chapter 5 focused on the 
identification of novel potential multi-antigenic epitopes, derived from two potential 
antigens (MPP11 and PR-3), that are presented in the context of HLA-A*0201 
molecule and recognized by T cells. The data showed that CTLs directed against the 
MPP-4 (STLCQVEPV) peptide derived from the MPP11 antigen could be generated 
form peripheral blood mononuclear cells of an HLA-A*0201 normal donor. These 
findings strongly suggest that MPP-4-specific T cells should be further investigated 
as they may be used for the development of an efficient T-cell based leukaemia 
immunotherapy. MPP-4 specific T cells could be expanded ex vivo for adoptive 
transfer to leukaemia patients or MPP-4 peptide may be utilized in vaccination trials 
as a single agent or in combination with epitopes derived from other antigens such 
as WT1.  
 
Collectively, data presented in this thesis expanded our knowledge of improving T-
cell based immunotherapeutic approaches against leukaemia by demonstrating the 
concept of introducing a modified epitope within a self tumour antigen and by 
identifying a novel epitope derived from the MPP11 antigen. Indeed the 
commentary by Justin Kline on our study of the WT1-126 peptide modification 
“altering tumour antigens may be the next logical step to take on the road to 
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improving cancer immunotherapy” supports such strategy (Kline, 2009). Epitope-
modification represents a promising approach for improving current strategies in 
immunotherapy for cancer patients.  However, tumour immunotherapy should focus 
on the development of strategies that will further increase the immunogenicity of 
self-epitopes and decrease tolerance. In addition, such approaches should be 
incorporated into strategies that specifically deplete or inhibit Tregs in cancer 
patients as the existence of this T cell population may contribute to the impairment 
of anti-tumour responses and to the limited success of cancer immunotherapy in 
humans.  
 
In order to develop immunotherapeutic strategies for a broad range of cancer bearing 
patients, future studies will investigate whether WT1, MPP11 and PR-3 antigens 
containing potential epitopes presented by common HLA alleles other than HLA-
A*0201. Modifications in the sequence of PR-169 and/or MPP-4 epitopes using the 
same approach used to promote WT1 peptides and generation of T cell responses 
using the wild type PR-169 and MPP-4 peptides and their analogues should be also 
investigated.  
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Abstract
The Wilms tumor antigen 1 (WT1) antigen is over-expressed in human leukemias, making it an attractive target for
immunotherapy. Most WT1-specific Cytotoxic T Lymphocytes (CTLs) described so far displayed low avidity, limiting its
function. To improve the immunogenicity of CTL epitopes, we replaced the first-amino-acid of two known immunogenic
WT1-peptides (126 and 187) with a tyrosine. This modification enhances 126Y analogue-binding ability, triggers significant
number of IFN-g-producing T cells (P¼ 0.0003), induces CTL that cross-react with the wild-type peptide, exerts a
significant lytic activity against peptide-loaded-targets (P¼ 0.0006) and HLA-A0201-matched-leukemic cells (P¼ 0.0014).
These data support peptide modification as a feasible approach for the development of a leukemia-vaccine.
Keywords: WT1 Db126 analogue, CD8þ CTL, AML, peptide modification, dendritic cells, immunotherapy
Introduction
Cytotoxic T Lymphocytes (CTLs) recognise tumor
antigens in the form of short peptides (CTL
epitopes) presented by MHC class I molecules on
the cell surface of an antigen presenting cell [1]. In
the last few years, a large number of tumor antigens
and their corresponding CTL epitopes have been
identified in several hematological malignancies and
solid tumors [1,2]. The Wilms tumor antigen 1
(WT1), a gene that has been shown to be responsible
for the childhood renal cancer [3], performs an
oncogenic function in various types of leukemia [4]
and solid tumors [5]. This antigen has been shown to
serve as marker for disease burden [6–9]. It is
overexpressed in acute myelocytic and lymphocytic
leukemia, chronic myelocytic leukemia and also in
various types of solid tumors including lung and
breast cancer [10–12]. For this reason, it has been
considered as an attractive target for immunother-
apy. Because WT1 has been shown to be expressed
at low levels in some normal cells such as CD34þ
stem cells [13,14], many of the potential CTL
epitopes against this antigen may be absent or sub-
optimal. This is mainly due to clonal deletion of
high-avidity CTLs during maturation of the im-
mune system [15]. To this end, different groups
introduced modifications in the sequence of these
‘sub-optimal’ peptides to improve their binding to
HLA class I molecules and to increase their
immunogenicity [16–19]. For example, substitution
of amino acid residues pointing to the T cell
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receptor has been shown to enhance epitope
immunogenicity [20,21]. Some of these modified
peptides have been effectively used to vaccinate
cancer patients [22], to improve the detection
of anti-tumor immunity [19], or to reverse the
irresponsiveness of T lymphocytes to wild-type
tumor antigens [21]. Indeed, vaccination of cancer
patients with WT1-modified peptides induced
WT1-specific CTLs and resulted in tumor
regression [23].
It has been demonstrated that WT1 specific CTLs
isolated from leukemia patients exert a low-avidity
response [24,25]. In the present study, we explored
the feasibility of using an approach that enhances
the immunogenicity of these low-avidity restricted-
peptides without altering their antigenic specificity
[26]. This approach consists of replacing the first
amino acid of the epitope by a tyrosine (P1Y).
The advantage of this approach is that the P1Y
variants are able to efficiently trigger in vivo wild-type
peptide-specific CTLs which also recognised the
naturally occurring epitope [26]. We have carried out
the Y amino acid substitution in the sequence of the
126 and 187 WT1-derived peptides. We have
selected these two peptides as they were reported to
be presented by the most common HLA allele
(HLA-A0201 present in 50% of the population)
and exert specific lysis against WT1-expressing
leukemia cells [27].
Our study demonstrated that the replacement of
the first amino acid of WT1–126 with tyrosine
(126Y) enhanced its binding to HLA-A0201 mole-
cule and increased the CTL lytic activity not only to
the 126Y epitope but also to the wild-type 126N
counterpart. This modification also enhanced the
frequency of the IFN-g producing T cells and
increased the CTL lytic activity against HLA-
A0201-matched leukemic cells. Interestingly, we
found that the primed T cells generated against this
modified peptide can cross-react with the wild-type
peptide.
Materials and methods
Cell lines
The T2 and K562 cell lines were purchased from
ATCC (Manassas, VA). B-lymphoblastoid cell Lines
(LCL) were established by transformation of B cells
using Epstein–Barr virus using standard techniques
[28]. The T2, LCL and K562 cells were maintained
in complete medium (CM) consisting of RPMI 1640
medium (Sigma, MO) supplemented with 10% FCS
(Cambrex Bio Science, MD), 2 mM L-glutamine,
100 IU/mL penicillin and 100 mg/mL streptomycin
(Sigma).
Peptides
A Y amino acid substitution in the sequence of the
following WT1 peptides was carried out: Peptide 126
(wild type 126N¼RMFPNAPYL, analogue
126Y¼YMFPNAPYL), and peptide 187 (wild type
187N¼SLGEQQYSV, analogue 187Y¼YLGE
QQYSV). The peptides were synthesised and
HPLC-purified to 90% purity by Alta Bioscience,
Birmingham, UK.
Prediction of peptide-binding to the HLA-A*0201
molecule and in vitro binding ability of the peptides using
the T2 binding assay
We first compared the predictive binding ability of
the wild-type (126N and 187N) peptides with their
corresponding analogues (126Y and 187Y) to the
HLA-A*0201 molecule using a computer-based
epitope prediction program (http://bimas.dcrt.nih.
gov/molbio/hla_bind). Peptide binding capacity to
the HLA-A*0201 molecule was then measured using
the T2 binding assay described previously [29]. T2
cells are a hybrid human cell line which lacks most of
the MHC class I region including the known
transporter proteins for antigenic peptide (TAP)
and proteasome genes. They contain the gene
HLA-A*0201, but express very low levels of cell-
surface HLA-A*0201 and are unable to present
endogenous antigens [30]. Stable HLA-A2.1 expres-
sion in T2 cells is observed only when peptides that
are capable of binding to and stabilising the cell
surface expression of the HLA-A2.1 molecule are
added exogenously. T2 cells were washed three times
in serum-free CM and suspended at 106 cells/mL.
Cells (106 cells/well) were incubated for 18 h in
serum-free CM containing different concentrations
of peptides and 1 mg/mL b2-microglobulin (Sigma).
The cells were washed twice with cold PBS contain-
ing 2% FCS and incubated for 30 min at 48C with
anti-HLA-A2.1 BB7.2 monoclonal antibody conju-
gated to FITC ((AbD Serotec, NC). The cells were
washed three times and fixed with 4% paraformalde-
hyde. The level of HLA-A2 expression was analysed
using FACS Scan (Becton & Dickinson, Immuno-
cytometry Systems, CA). HLA-A2 expression was
quantified as fluorescence index according to the
following formula: fluorescence index¼ (mean fluor-
escence intensity with peptide (mean fluorescence
intensity without peptide)/mean fluorescence
intensity without peptide.
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) from
patients with leukemia and healthy donors were
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isolated from blood samples by density gradient
centrifugation over Ficoll–Paque PLUS (Amersham
Biosciences AB, Uppsala, Sweden). Written in-
formed consent was obtained from patients and
donors prior to sample collection. The cells were
aliquoted and cryopreserved in 90% FCS þ 10%
DMSO according to pre-established procedures.
The HLA typing of these samples were carried out
at the Immunopathology Laboratory (King Faisal
Specialist Hospital and Research Centre) and HLA-
A*0201þ subjects were selected. The patients and
donor information are presented in Table I.
Generation of autologous monocytes derived dendritic cells
Monocytes (CD14þ cells) were isolated from
PBMCs of a healthy donor, designated as BC-32,
using MACS human Monocytes Isolation kit II
(Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. The
CD14þ cells were adhered and cultured in 24-well
plates in X-vivo 15 medium (BioWhittaker, MD)
supplemented with 2 mM L-glutamine (DC-med-
ium) in the presence of 50 ng/mL rhIL-4 and
100 ng/mL rhGM-CSF (R&D Systems, MN).
20 ng/mL rhTNF-a, (R&D Systems), 10 ng/mL
rhIL-1b (eBioscience, CA) and 25 mg/mL Poly I:C
(Sigma) were added on day 6 and mature dendritic
cells (DCs) were harvested on day 8.
Generation of anti-WT1 126N and 126Y peptide
specific CTLs
CD8þ T lymphocytes were separated from PBMCs
obtained from healthy HLA-A2-positive donors
using MACS Cell Isolation Kits according to
manufacturer’s protocols. CD8þ T lymphocytes
were stimulated in vitro with the 126N or 126Y
peptides loaded on DCs. Briefly, the DCs growing in
X-vivo 15 medium were washed once in the same
medium and incubated with the peptides at concen-
tration of 50 mM/mL and 5 mg/mL b2-microglobulin
for 2 h at 378C. The peptide loaded DCs were then
X irradiated (2500 rads), washed once and added to
the CD8þ T lymphocytes at 5:1 T lymphocytes:
DCs ratio. IL-7 (20 ng/mL) and IL-12 (100 pg/mL)
were added to each culture. The cells were incubated
in 2 mL DC-medium þ 10% heat inactivated human
AB serum (Sigma) in 24-well plates. After 7 days of
co-culture, a similar second stimulation was per-
formed, and on the following day, IL-2 (20 IU/mL)
was added (the cultured cells were maintained by
weekly stimulation with peptide-loaded DCs and
feeding with IL-2 the next day). Two T cell lines
against the two different peptides were generated.
Responder T lymphocytes were tested for cytotoxic
activity (Chromium Release Assay) and IFN-g
production (ELISPOT Assay) against different tar-
gets. Cross-reactivity between the peptides was also
tested to determine if the analogue peptide 126Y is
able to induce immune response against the native
126N peptide.
Quantitative real time RT-PCR for WT1 expression in
patients’ leukemic cells
Total RNA was isolated from PBMC-32, AML-27
and AML-28 samples (see Table I) and treated with
DNase1 (Invitrogen, CA). For cDNA synthesis, 1 mg
RNA using oligo-dT-primers and M-MLV RT
(Invitrogen) were used in a total volume of 25 mL.
The WT1 mRNA expression was quantified using
Light Cycler FastStart DNA master SYBR Green 1
kit (Roche, Mannheim, Germany) in a Light Cycler
(Roche). PBGD was used as house-keeping gene.
2 mL cDNA from the K562 cells was used to
generate standard curves [31] in 5-log steps for
WT1 and PBGD. Amplification was conducted in a
total volume of 20 mL for 40 cycles/10 sec at 958C, 4
sec/648C and 35 sec/728C. Samples were run in
triplicates and their relative expression was deter-
mined by normalising the expression of each target to
PBGD and then comparing this to the normalised
expression in a reference sample (K562) to calculate
a fold-change-value. Forward primer: TTCATC
AAACAGGAGCCGAGC and reverse primer:
Table I. Information for patients and donors used in the study.
Donor/patient samples HLA-A type % Blasts* QRT-PCR WT 1 mRNA{ Status{ FAB-typex
PBMCC-32 A0201, 29 NA 60 NA NA
AML-27 25, 29 81 7950 New M4
AML-28 A0201, 26 61 1800 New M4
*% blasts were determined routinely by the hematopathology laboratory.
{Quantative real-time PCR data for the expression level of WTl which normalised from K562 set on 1000.
{New indicates that samples were taken at first diagnosis.
xFrench–American–British classification.
Na, not applicable.
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GGTGCGAGGGCGTGTGA were used for WT1.
For PBGD, forward primer: CATGTCTGG
TAACGGCAATG and reverse primer: TCTTCT
CCAGGGCATGTTCAA were used.
Chromium release assay
Target cells were removed from culture, washed in
RPMI1640 serum-free medium, re-suspended in a
minimal volume of RPMI1640 and incubated with
51Cr (100 mCi) per target for 90 min. Target cells
labelled with peptide were concurrently incubated
with the appropriate peptide at 50 mM/mL. The
target cells were then washed and placed in 96 V-
bottomed wells at 103 cells/100 mL/well. The effector
T cells were washed, and added in triplicate at
varying quantities to the target cells, to give varying
effector to target ratios (E:T ratios) in a final volume
of 200 mL/well. The plates were spun for 5 min
(300g) and incubated for 4 h at 378C before 100 mL
supernatants were removed and transferred to 1450
Microbeta Plus Wallac plates (Wallac, Turku, Fin-
land). 150 mL scintillation fluid, Optiphase HiSafe 2
(Wallac) was added to each well and the plates were
heat-sealed using a Microsealer system (Wallac).
Chromium release was assessed by a liquid scintilla-
tion counter (Wallac). Target cells were also in-
cubated with 0.2% Tween 20 or medium alone to
assess the maximum and minimal (spontaneous)
release of the chromium respectively. Spontaneous
release was never exceeding 20% of the maxi-
mum release. Percent specific lysis was calculated as:
% Specific lysis ¼ðexperimental release
 spontaneous releaseÞ
=ðmaximal release
 spontaneous releaseÞ  100:
In some experiments blocking antibody
(10 mg/mL) anti-class I ABC (AbD Serotec, NC)
was added to target cells before adding T cells.
ELISPOT assay
An ELISPOT assay for IFN-g production by the
generated T cell lines was performed using an IFN-g
kit (Mabtech, OH) according to the manufacturer’s
protocol. 20 000 T cells/well and 2000 cells/well of
different stimulators were seeded in Multiscreen 96-
well plates (Millipore, MA) pre-coated overnight
(48C) with catching-antibody (1-D1K). After 40 h
incubation (378C, 5% CO2), cells were removed and
after washing, Biotinylated-IFN-g antibody was
added for 3 h at room temperature (RT). After
washing, Streptavidin ALP was added to each
well and incubated at RT for 2 h. After washing,
100 mL/well of BCIP/NBT substrate (Sigma) was
added to each well and incubated at RT until colour
developed according to the manufacturer’s instruc-
tions. Spots were counted using an automated
ELISPOT reader (AID, Strasberg, Germany). Anti-
gen-specific T cell frequencies were considered to be
increased when they were at least two-fold higher
than in the control wells.
Statistical analysis
Comparative analysis was performed by the Student t
test. A P value less than or equal to 0.05 was deemed
to be significant in all experiments.
Results
Identification of peptides predicted to highly bind to
the HLA-A0201 molecule
HLA-A0201 is one of the most common allele in the
whole population. Thus, we aimed to identify
peptides with enhanced binding to HLA-A0201
that can be recognised by the T cell receptors. This
approach may afford peptides that would induce
CTL recognising modified peptides with stronger
affinity compared with CTL induced with unmodi-
fied peptides. To this end, we modified the two WT1
peptides, which are known to be HLA-A0201
restricted peptides [27], by substituting the amino
acid at position 1 with tyrosine (Y). The binding of
the wild-type peptides (126N and 187N) was
compared with their corresponding analogues
(126Y and 187Y) to the HLA-A0201 molecule using
a computer-based epitope prediction program
(http://bimas.dcrt.nih.gov/molbio/hla_bind/). Our
data (Figure 1) demonstrated that this tyrosine
Figure 1. Prediction of the wild-type (WT1-126N, WT1-187N)
and the modified (WT1-126Y, WT1-187Y) peptides and their
binding affinities to the HLA-A02 01 molecule as predicted by the
computer-based epitope prediction program (http://bimas.dcrt.
nih.gov/molbio/hla_bind/).
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modification resulted in 4.6-fold increase in the
estimated half-time of disassociation of the modified
peptides to HLA-A0201 compared with their native
counterparts.
The computer-based epitope prediction program
has only 60–80% predictive accuracy. Therefore, we
directly measured the strength of the interaction
between these peptides and the HLA-A0201 mole-
cules using the T2 binding assay described above.
We observed enhanced binding of the 126Y analogue
peptide compared to the wild-type 126N peptide at
all doses tested (Figure 2A). Although 50 mM of the
126N peptide is needed to achieve a 2.5 fluorescence
index, only 15 mM of the 126Y peptide was able to
reach the 2.5 fluorescence index. However, modifi-
cation of the 187 peptide (187Y) did not enhance its
binding ability and stabilisation of the HLA-A0201
molecules (Figure 2B). These data show a selective
enhancement of peptide binding to HLA-A0201
after modification, thus give us a good model to test
the effect of this process on the function of T cell
generated.
Enhanced cytotoxicity of CTL generated against
WT1-126Y
Because only the 126Y analogue peptide but not
the 187Y peptide showed a high binding affinity to
the HLA-A0201 molecule compared to their
peptides counterparts, we tested the effect of
tyrosine modification of the WT-126 peptide on
its ability to induce specific CTL compared with its
wild-type peptide. We used an optimised T-cell
activation protocol, with CD14þ monocytes-derived
DC as antigen presenting cells, and purified CD8þ
T cells to investigate whether the new synthetic
WT1 (126Y) analogue could stimulate peptide-
specific CTLs. After three to five rounds of
stimulations, the generated T cell lines were tested
against the T2 cells in the presence or absence of
autologous peptide using a Chromium Release
Assay and an IFN-g ELISPOT assay. Cross-
reactivity between the two peptides was also tested
to determine if the analogue peptide 126Y is able
to induce immune response to the native peptide
(126N).
The lysis activity of the T cell lines generated
against 126N and 126Y are presented in Figure 3(A)
and (B), respectively. Specific lysis was recorded
against the T2 cells for both T cell lines raised against
the 126N peptide and its 126Y analogue, because
there was no T cell response against the T2 cells in
the absence of the peptides. However, a significantly
(P¼ 0.0006) higher lytic activity was recorded when
the T cell line raised against the 126Y modified
peptide was used (Figure 3A versus Figure 3B).
Interestingly, we found cross reactivity of each T cell
line with the opposite peptide. In this, the T cell line
generated against the wild-type 126N peptide was
able to equally lyse the T2 cells loaded with the 126N
or the 126Y. Similar results were obtained for the T
cell line generated against the analogue 126N
peptide. To confirm that the T cells response
generated against both the wild-type 126N and the
126Y peptides is restricted to the HLA-A0201
molecule, an HLA blocking assay was performed.
Blocking of the HLA-ABC resulted in a strong
inhibition of the cytotoxic activity of both T cell lines
against peptide-loaded T2 cells [Figure 3(C)].
However, the isotype control did not inhibit the
cytotoxic activity of this T cell lines. These data show
that the tyrosine modification of the WT1-126
peptide, which enhanced their binding to HLA-
A0201, can increase its lytic activity not only to the
126Y epitope, but also to the wild-type 126N
counterpart.
Figure 2. HLA-A0201 epitope enhancement of the WT1-126N wild-type peptide by an amino acid substitution (Y) at position 1 (126Y)
analogue peptide (A) and no enhancement in the case of peptide 187Y (B) as measured by the T2 stabilisation. The assay was conducted as
described in Materials and methods section. The HLA-A0201 expression by the T2 cells was quantified as fluorescence index according to
the following formula: fluorescence index¼ (mean fluorescence intensity with peptide – mean fluorescence intensity without peptide)/mean
fluorescence intensity without peptide.
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WT1-126Y peptide increased the frequency of IFN-g
producing T cells
The 126N and the 126Y T cell lines were tested for
the frequency of IFN-g producing T cells after three
rounds of in vitro stimulation using an ELISPOT
assay. Both T cell lines produced specific IFN-g in
response to stimulation with autologous LCL loaded
with their corresponding peptide (Figure 4). How-
ever, the T cell line generated with the analogue
126Y peptide exerted a significantly higher number
(P¼ 0.0003) of IFN-g producing T cells compared
with that generated against the 126N wild-type
peptide (Figure 4). These data demonstrate that
modification of the WT1-126 peptide can increase
the frequency of IFN-g producing T cells and thus
making them better effector cells.
Evaluation of WT1 expression and lytic activity of
anti-WT1 T cell lines against HLA-A0201-matched
leukemic cells
Given the above, we tested the feasibility of using this
modification approach of the WT1-126 peptide to
generate CTLs that effectively kill HLA-A0201-
matched leukemic cells. We first examined the expres-
sion of the WT1 mRNA in fresh AML cells (AML-27
and AML-28) using Q-RT-PCR. K562 cells, known to
express high levels ofWT1 [31] were used as a positive-
control. PBMC-32 from a normal donor served as a
negative control. Higher levels of WT1 expression
were observed in AML samples (Table I). The lytic
activity of the two T cell lines generated against the
126N and 126Y peptides were then measured against
PBMCs from HLA-A0201-matched (AML-28) and
Figure 3. Cytotoxicity assay with T cells from a healthy HLA-A0201 donor after multiple stimulations in vitro. T cells were stimulated in vitro
following the protocol described in Material and methods section with the peptides. (A) Specific lysis of the 126N T cell line and its cross-
reactivity with the analogue 126Y peptide. (B) Specific lysis of the 126Y T cell line and its cross-reactivity with the wild-type 126N peptide.
(C) Inhibition of lytic activity after blocking with anti-ABC antibody showing the restriction response to the HLA-A0201 molecule. Ab was
added to the wells containing T2 cells 20 min before the addition of T cells. P value between A and B¼0.0006.
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non-HLA-A0201 matched (AML-27) AML patients.
Specific lytic activity was recorded for both T cell
lines against the AML-28 cells expressing the
HLA-A0201 molecule (Figure 5). However, both
T cell lines failed to recognise non-HLA-A0201
AML-27 although they express high levels of WT1
(Figure 5). Interestingly, the T cell line generated
with the analogue 126Y peptide exerted a signifi-
cantly higher lytic activity (P¼ 0.0014) compared
with that generated against the 126N wild-type
peptide (Figure 5). Altogether, the modified WT1-
126Y enhanced its binding to HLA-A0201, in-
creased the frequency of IFN-g producing T cells,
and boosted the lytic activity against HLA-matched
leukemia cells. Thus, modification of the WT1-126
peptide provides a potential approach for the devel-
opment of leukemia vaccine.
Discussion
Most tumor associated antigens which have been
identified so far are derived from self-antigens.
Immunological tolerance can prevent the develop-
ment of immune responses against such self-anti-
gens. Therefore, most self/tumor antigens used in
clinical trials so far showed poor immunogenicity. To
circumvent the problem of tolerance, Stauss
et al. [32,33] developed an allo-restricted CTL
against leukemia. In this approach, T cells from
HLA-A0201þ donors were stimulated with peptide-
loaded HLA-A0201-matched APCs. This allows the
generation of high-avidity allo-restricted CTLs
against an HLAA0201 WT1-derived epitope. Inter-
estingly, the generated CTLs specifically lysed
WT1þ, HLA-A0201-matched leukemia cells. More
importantly, only the high-avidity CTLs were able to
eliminate the progenitors of CFU-GM and BFU-
GM from CD34þ CML samples, whereas normal
CD34þ progenitors/stem cells were spared [32,33].
However, as allogeneic APCs usually provoke domi-
nant CTL responses against allogeneic epitopes, the
isolation of HLA-A0201-WT1 peptide-specific allo-
geneic CTLs was unsuccessful in many cases.
Another drawback of this strategy is the difficultly
in applying such an approach in the clinical settings.
A more promising approach has been recently
developed by the same group, which rely on
introducing the WT1-specific TCR into autologous
T cells for possible future clinical applications [34].
Because the WT1 is a self-protein expressed at low
levels in some normal cells [35,36], many of the
potential CTL epitopes from this antigen may be
absent or ‘sub-optimal’. This is due to clonal deletion
of high-avidity CTLs during maturation of the
immune system. Therefore, the induction of anti-
tumor immune responses frequently needs to be
addressed against those ‘sub-optimal’ CTL epitopes
to enhance their immunogenicity, frequency and
hence their therapeutic potential. In addition, natu-
rally arising CD25þCD4þ regulatory T cells (Tregs),
play an important role in the maintenance of
immunologic self-tolerance [37]. Although this T
cell population plays a key role in regulating the
immune response to self antigen, it has been shown
recently that Tregs can directly suppress the anti-
tumor immune responses in cancer patients [38–41].
Indeed, another group demonstrated that the
depletion of this T cell population resulted in
an enhancement of vaccine-mediated anti-tumor
Figure 4. Specific production of IFN-g by the two T cell lines
generated against the wild type 126N and its analogue 126Y
peptides as measured by an ELISPOT assay. T cells (26 104 cell/
well) were stimulated with 26103 cell/well autologous
LCL+peptide for 40 h in anti-IFN-g pre-coated wells before
development of the spots. T cells incubated without stimulators
(T cell only) served as a baseline.
Figure 5. Cytotoxicity assay showing the lytic activity of the 126N
and 126Y T cell lines against HLA-A0201-matched (AML-28)
and non-matched AML-27 cells. T cells were used after three
rounds of stimulations.
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immunity in cancer patients [42]. Furthermore, a
recent study showed that such response can be
largely affected by the presence of CD4þCD25þ
Tregs and depletion of this T cell population was
necessary for the generation of an effective WT1-
specific cytotoxic response [43].
It is known that the immunogenicity of antigenic
peptides is dependent on their binding affinity to
MHC class I molecules; stability of the peptide-
MHC complexes; and the avidity of the TCR
binding to the peptide complex [44]. Indeed, it has
been found that the poor immunogenicity of some
self/tumor antigens is due to the instability of the
peptide-MHC complex rather than low affinity of T
cell receptors to peptide-MHC complexes [44].
Therefore, many studies have put emphasis on
introduced a peptide modification to improve the
binding of self antigenic peptides to their correspond-
ing MHC class I molecules and consequently
enhance the immunogenicity of these peptides [45–
51]. In the present study, we have applied a strategy
used by others and shown to enhance the immu-
nogenicity of low-avidity HLA-A0201-restricted
peptides without altering their antigenic specificity
[26]. This approach consists of substituting the first
amino acid of the epitope with a tyrosine (Y). The
importance of this approach is that the resulting
peptide analogues are able to efficiently trigger
in vivo wild-type peptide-specific CTLs which also
recognised the naturally occurring epitope [26]. We
have carried out the Y amino acid substitution in
the sequence of the two known HLA-A0201-
restricted Db126 and WH187 WT1-derived
peptides [27]. Using a computer-based epitope
prediction program, the 126Y and 187Y analogue
peptides were predicted to bind 4.6-fold more to the
HLA-A0201 molecule compared to their native
126N and 187N counterparts. However, a signifi-
cant enhancement of the actual binding ability was
only recorded for the 126Y peptide analogue when
we used the T2 binding assay. Therefore, we
generated CTLs lines against the wild-type 126N
and its 126Y peptide analogue. Although both
peptides were able to induce specific cytotoxic
immune response against autologous peptide-loaded
T2 cells, the CTL line generated with the 126Y
peptide showed a higher and significant lytic activity
compared with the CTL line generated with the
126N wild-type peptide. Interestingly, CTL gener-
ated against the 126Y analogue peptide was able to
lyse the T2 cells target when loaded with the wild-
type peptide. Therefore, modification of the 126
peptide resulted in enhancement of its immuno-
genicity without altering its antigenic specificity.
Another important finding is the significant high
lytic activity observed for the 126Y CTL line against
HLA-A0201-matched leukemic cells expressing the
WT1 antigen. These data confirm that T cells
generated against the 126Y analogue peptide cross-
react also with the naturally processed 126N native
peptide. Our results suggest that stimulation
with the 126Y peptide analogue induced CTLs
with a high TCR avidity. Finally, the high lytic
activity provoked by the 126Y CTL may be also
attributed to the significant high number of anti-126
T cells in this T cell line as demonstrated by g-IFN
production.
During the course of our study, Pinilla-Ibarz et al.
[52] reported on a similar study that uses the same
strategy to modify several HLA-A0201 WT1-derived
peptides including the 126N, 187N and their
analogues described in the present work. Although,
this group did not find any difference in the binding
affinity between the 2 126N and 126Y peptides, they
reported that stimulation with the 126Y peptide
analogue was able to generate an earlier and stronger
specific CTL than that generated with the 126N
wild-type peptide. Consistent with our findings the
126Y CTL line was able to recognise the 126N wild-
type peptide on the target cells and specifically lyse
HLA-A0201-matched leukemia cells expressing the
WT1 antigen. Another group has introduced a
tyrosine modification in position two of a 9-mer
WT1-derived peptide which is known to bind to the
HLA-A2402 molecule and showed a better binding
affinity and elicitation of higher lytic activity [53].
Moreover, the modified peptide has been used to
vaccinate cancer patients where a clear correlation
was observed between an increase in the frequencies
of WT1-specific CTL after vaccination and clinical
responses [23].
In conclusion, our study and others’ [23,52,53]
shed light on the importance of peptide modification
as a new approach in elucidating a better immune
response, needed to combat cancer. On the basis of
these findings, leukemia patients could be clinically
tried for vaccination with the current WT1-126Y
peptide analogue or adoptively treated with ex vivo
anti-WT1-126Y T cells to specifically enhance the
graft-versus-leukemia effect and anti-WT1 CTL
frequency, which are known to be very low in these
patients.
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Abstract
Compelling evidences indicate a key role for regulatory T cells
(Treg) on the host response to cancer. The Wilms’ tumor
antigen (WT1) is overexpressed in several human leukemias
and thus considered as promising target for development of
leukemia vaccine. However, recent studies indicated that the
generation of effective WT1-specific cytotoxic T cells can be
largely affected by the presence of Tregs. We have generated
T-cell lines and clones that specifically recognized a WT1-84
(RYFKLSHLQMHSRKH) peptide in an HLA-DRB1*0402–
restricted manner. Importantly, they recognized HLA-
DRB1*04–matched fresh leukemic cells expressing the WT1
antigen. These clones exerted a T helper 2 cytokine profile,
had a CD4+CD25+Foxp3+GITR+CD127 Treg phenotype, and
significantly inhibited the proliferative activity of allogeneic T
cells independently of cell contact. Priming of alloreactive T
cells in the presence of Tregs strongly inhibited the expansion
of natural killer (NK), NK T, and CD8+ T cells and had an
inhibitory effect on NK/NK T cytotoxic activity but not on
CD8+ T cells. Furthermore, priming of T cells with the WT1-126
HLA-A0201–restricted peptide in the presence of Tregs strongly
inhibited the induction of anti–WT1-126 CD8+ CTL responses
as evidenced by both very low cytotoxic activity and IFN-;
production. Moreover, these Treg clones specifically produced
granzyme B and selectively induced apoptosis in WT1-84–
pulsed autologous antigen-presenting cells but not in apopto-
tic-resistant DR4-matched leukemic cells. Importantly, we
have also detected anti–WT1-84 interleukin-5+/granzyme B+/
Foxp3+ CD4+ Tregs in five of eight HLA-DR4
+ acute myeloid
leukemia patients. Collectively, our in vitro and in vivo
findings strongly suggest important implications for the
clinical manipulation of Tregs in cancer patients. [Cancer Res
2008;68(15):6350–9]
Introduction
The Wilms’ tumor (WT1) gene exerts an oncogenic function in
various types of leukemias (1). It is also overexpressed in several
solid tumors (2), and therefore, it has been considered as an
attractive target for cancer immunotherapy. Specific anti-WT1
immune responses have been described in which CD8+ cytotoxic T
cells (3, 4) have been generated in vitro . However, a recent study
showed that such response can be largely affected by the presence
of CD4+CD25+ regulatory T cells (Treg) in which depletion of this
T-cell population was necessary for the generation of an effective
WT1-specific cytotoxic response (3).
It has been shown recently that Tregs directly suppress the
antitumor immune responses in cancer patients (5, 6), and
depletion of this T-cell population resulted in an enhancement of
vaccine-mediated antitumor immunity in cancer patients (7). This
highlights the role of Tregs in modulating both natural and adoptive
immune responses in cancer patients. Tregs may directly modulate
the CD8+ T-cell response (8) or alternatively promote tolerization of
CD8+ T cells by preventing the licensing of antigen-presenting cells
(APC) by CD4+ T helper cells (9). It has became clear that CD8+ T
cells generated in the absence of CD4+ T cells help may have a
normal primary response; however, their cytotoxic memory
response is severely weakened (10). A recent study by Greiner
and colleagues (11) investigated the influence of the expression
levels of several leukemia-associated antigens (LAA) on the clinical
outcome of patients with acute myeloid leukemia (AML). High
expression of three LAAs, which was found to be associated with
favorable clinical outcome, induced strong CD8+ T-cell responses.
However, there was no correlation with the clinical outcome nor
induction of natural detectable anti-WT1 CD8+ T-cell response in
these patients (11). In line with this, a recent study has shown the
existence of tumor-specific Tregs, which actively suppress antigen-
specific antitumor immunity in cancer patients (12). Furthermore,
fully functional Tregs specific for LAGE1 (13) and ARTC1 (14) were
shown in melanoma patients. Another study by Nadal and
colleagues (15) suggested that Tregs exert an inhibitory effect on
graft versus leukemia and this was associated with relapse after
allogeneic stem cell transplantation.
To this end, we asked whether an anti-WT1 Treg population exist
in leukemia patients, which may contribute to the impairment of
anti-WT1 responses. We have identified a human HLA-DRB1*0402–
restricted CD4+ Treg population and showed that the WT1 is a
novel target for leukemia-specific CD4+ Tregs.
Materials and Methods
Patients and donors. Peripheral blood mononuclear cells (PBMC) from
leukemia patients and healthy donors were isolated by density gradient
centrifugation. This study was conducted in accordance with Helsinki
Declaration and all patients and donors signed a consent form approved by
the Research Ethics Committee of King Faisal Specialist Hospital and
Research Center (KFSH&RC). The study was approved by the KFSH&RC
Research Advisory Council (RAC#2030006). Patient and donor information
is listed in Supplementary Data 1.
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
Requests for reprints: Said Dermime, Tumor Immunology Section, King Faisal
Specialist Hospital and Research Centre, MBC 03, P. O. Box 3354, Riyadh 11211, Saudi
Arabia. Phone: 966-1-442-4552; Fax: 966-1-442-7858; E-mail: Sdermime@kfshrc.edu.sa
or sdermime@gmail.com.
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Peptides. A pool of 110 peptides derived from the WT1 protein desig-
nated as WT1-Pepmix and a microscale WT1 peptide set containing each
peptide in a single well were obtained from JPT Peptide Technologies (Jerini
AG, GmbH; Supplementary Data 2). The WT1333-347 (RYFKLSHLQMHSRKH),
WT1-84, HPV3373-87 (ASDLRTIQQLLMGTV) HLA-DR*0402–restricted pep-
tide (16), and the WT1-db126 (RMFPNAPYL) HLA-A0201–restricted peptide
(4) were synthesized and high-performance liquid chromatography purified
to z90% purity by Alta Bioscience.
Cell lines. B-lymphoblastoid cell lines (LCL) were established by
transformation of B cells using EBV using standard techniques (17). K562
and T2 cell lines were purchased from the American Type Culture
Collection. All cell lines were maintained in RPMI 1640 (Sigma)
supplemented with 10% FCS (Cambrex Bio Science), 2 mmol/L L-glutamine,
100 IU/mL penicillin, and 100 mg/mL streptomycin (Sigma).
Generation of autologous monocyte-derived dendritic cells. CD14+
cells were isolated from PBMCs of three healthy donors, designated as BC-
29, BC-52, and BC-62, using MACS Monocytes Isolation kit (Miltenyi Biotec)
according to the manufacturer’s instructions. CD14+ cells were adhered and
cultured in 24-well plates in X-VIVO 15 medium supplemented with
2 mmol/L L-glutamine [dendritic cell (DC) medium] in the presence of
50 ng/mL recombinant human interleukin (rhIL)-4 and 100 ng/mL
recombinant human granulocyte macrophage colony-stimulating factor
(GM-CSF; R&D Systems). Recombinant human tumor necrosis factor-a
(20 ng/mL; R&D Systems), 10 ng/mL rhIL-1h (eBioscience), and 25 Ag/mL
polyinosinic acid:poly-CMP (Sigma) were added on day 6 and mature DCs
were harvested on day 8.
Generation of anti–WT1-specific Tregs and clones. Irradiated DCs
(3,000 rads) were pulsed with 10 Ag/mL WT1-Pepmix in DC medium and
incubated for 4 h at 37jC, 5% CO2. DCs were cocultured with autologous
PBMCs at a 10:1 T-cell to DC ratio. DC medium containing 10 ng/mL rhIL-7,
20 pg/mL rhIL-12 (R&D Systems), and 10% heat-inactivated human
serum (Sigma) was used. T cells were restimulated at weekly intervals
and 260 IU/mL rhIL-2 was added 2 d after each restimulation. Three of
three anti–WT1-Pepmix-specific T-cell lines were obtained after the fourth
restimulation. Anti–WT1-Pepmix T-cell clones were generated as described
before (18). T cells were screened for their peptide specificity against the
microscale WT1 peptide set.
Proliferation and 51Cr cytotoxicity assay. T-cell proliferation was
assessed by [3H]thymidine incorporation as described before (18). Briefly,
T cells were cocultured with X-irradiated PBMCs, LCLs (Fantigens), or
leukemic cells at different ratios in DC medium containing 10% human
serum for 3 d. [3H]thymidine (1 ACi/well; Amersham) was added for the last
18 h. [3H]thymidine uptake was measured using a 1450 Micro Beta PLUS
liquid scintillation counter (Wallac). In some experiments, the following
blocking antibodies (50–100 Ag/mL) were used: anti-ABC (AbD Serotec),
anti–HLA-DR (BD Biosciences), anti–HLA-DP, and anti–HLA-DQ (Leinco
Technologies). Mouse isotypes were used as controls. Cytotoxic activity was
measured by a standard 51Cr release assay as described before (18).
ELISA. Supernatants from 48-h T-cell cultures were harvested, and ELISA
for the human IFN-g, IL-4, IL-5, IL-10, and GM-CSF ELISA kits (Mabtech)
and transforming growth factor (TGF)-h1 and TGF-h2 matched antibody
pairs (R&D Systems) was performed according to the manufacturer’s
instructions.
Flow cytometry. T cells were phenotypically analyzed using the human
Treg staining kit (eBioscience) according to the manufacturer’s instructions
and also stained with CTLA-4-PE (Dako Corp.), CD127-RPE, and GITR-APC
(eBioscience). The T-cell receptor (TCR) Vh profile was determined using
the IOTest Beta Mark, TCR Vh Repertoire kit (Beckman Coulter). Cells were
analyzed using FACScan (Becton Dickinson).
Immunostaining. Immunostaining on cytospins was carried out as
described previously (19). Anti-Foxp3 antibody (eBioscience), anti-CD3
antibody (Dako), and anti-WT1 antibody (Dako) were used. Isotype-
matched controls for all antibodies were used. The staining was evaluated
by two independent scientists.
Reverse transcription-PCR for Foxp3 expression. Total RNA was
isolated using RNeasy Micro kit (Qiagen). The forward primer CAGCTGCC-
CACACTGCCCCTAG and the reverse primer CAGTGCCATTTTCCCAGC-
CAG were used for Foxp3. The PCR conditions were 95jC/3 min, 35 cycles
of 95jC/1 min, 67jC/40 s, and 72jC/1 min. The h-actin forward primer
ATCTGGCACCACACCTTCTACAATGAGCTGCG and the reverse primer
CGTCATACTCCTGCTTGCTGATCCACATCTGC were used as a control.
PCR products were separated by electrophoresis on a 1% agarose gel
(Sigma).
Quantitative real-time reverse transcription-PCR for WT1 expres-
sion. Total RNA was isolated as above and treated with DNase1
(Invitrogen). For cDNA synthesis, 1 Ag RNA using oligo(dT) primers and
Moloney murine leukemia virus reverse transcriptase (Invitrogen) was used
in a total volume of 25 AL. The WT1 mRNA expression was quantified using
LightCycler FastStart DNA Master SYBR Green 1 kit (Roche) in a
LightCycler (Roche). Porphobilinogen deaminase (PBGD) was used as
housekeeping gene. cDNA (2 AL) from K562 was used to generate standard
curves (20). Amplification was conducted in a total volume of 20 AL for
40 cycles/10 s at 95jC, 4 s/64jC, and 35 s/72jC. The forward primer
TTCATCAAACAGGAGCCGAGC and the reverse primer GTGCGAGGG-
CGTGTGA were used for WT1. For PBGD, the forward primer CATGTC-
TGGTAACGGCAATG and the reverse primer TCTTCTCCAGGGCATGTTCAA
were used.
Treg suppression assays and Transwell experiments. To examine the
suppressive effect of the Treg clones on the induction of T helper
alloresponses, a standard mixed lymphocyte reaction (MLR) was carried
out as described before (21). Briefly, fresh BC-29 PBMCs (105 per well,
responders) were cultured in DC medium containing 10% human serum for
5 d with XR, 3,000 rads allogeneic PBMCs (105 per well, stimulators) with
different concentrations of Tregs + autologous LCL FWT1-84 peptide. The
proliferative activity was determined as before. For some experiments,
neutralizing antibodies against TGF-h1/h2, IL-4, IL-5 (R&D Systems), IL-10
(Biosource), and GM-CSF (Biolegend) were added in the assay at an
optimum final concentration of 5 Ag/mL. The effect of Treg inhibition on
nonirradiated autologous LCL was also examined. Transwell experiments
were performed in 24-well plates with pore size of 0.4 Am (Corning Costar).
BC-29 PBMCs (0.75  106 per well, responders) were cultured in the outer
wells of 24-well plates in DC medium containing 10% human serum and
XR, 3,000 rads allogeneic (BC-8) PBMCs (1.5  106 per well, stimulators).
Treg clones (0.15  106 cells per well) were added into the inner wells of
autologous LCL F WT1-84 peptide. After 4 d in culture, the cells in the
outer wells were harvested and transferred to 96-well plates and the
proliferative activity was determined as before.
The suppressive effect of Tregs on the induction of alloreactive and anti–
WT1-specific cytotoxic responses was examined. For alloreactive CTLs, BC-
29 PBMCs (2  106 per well, responders) were cultured in DC medium
containing 10% human serum for 7 d with XR, 7,500 rads allogeneic LCL
(0.5  106 cells per well, stimulators) in 24-well plates F 0.5  106 cells per
well TCC 29.B.42 Treg clone + WT1-84 peptide. This procedure was used for
the generation of anti-WT1 CTLs, except that autologous DC pulsed with
the WT1-126 (RMFPNAPYL) HLA-A0201–restricted peptide (4) was used.
IL-2 (25 units/mL) was added on day 4 and a similar stimulation was
repeated after 7 d. Several stimulations were carried out without addition of
the Tregs every 7 d. Flow cytometry analysis was used to determine the CD8,
CD56, and CD8/CD56 cell population in the culture. CD8 T cells were
purified using MACS human CD8-negative selection kit (Miltenyi Biotec).
Cytotoxic and IFN-g production activity were determined by 51Cr release
and enzyme-linked immunospot (ELISPOT) assays, respectively.
ELISPOT assay. ELISPOT assay was performed using IFN-g, granzyme B,
and perforin kits (Mabtech). Autologous LCLs or AML cells were used as
stimulators. Tregs (10
3 cells per well) and stimulators (2  104 cells per well)
were seeded in Multiscreen 96-well plates (Millipore) precoated with
catching antibody. After 40 h of incubation, cells were removed and plates
were processed according to the manufacturer’s instructions. Spots were
counted using an automated ELISPOT reader (AID). Antigen-specific T-cell
frequencies were considered to be increased when they were at least 2-fold
higher than in the control wells.
Apoptosis assay. An apoptosis assay was carried out using Vybrant
Apoptosis Assay Kit #2 (Invitrogen). Tregs (2  104) and target cells (2  104)
were incubated in DC medium + 10% human serum for 24 h. Targets were
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gated after staining with monoclonal antibodies (mAb) to CD19-PE, CD40-
PE, and CD33-PE (BD Biosciences) for LCL, DCs, and AML, respectively.
Apoptosis was measured by flow cytometry assessment of phosphatidylser-
ine externalization cells stained with Alexa Fluor 488 Annexin V in
combination with propidium iodide.
Intracellular cytokine staining and determination of anti–WT1-84/
Foxp3+ Treg frequencies in AML patients. PBMCs (2  106/mL) were
cultured in DC medium + 10% human serum + 125 units IL-2 for 48 h F
WT1-84 peptide. Brefeldin A (eBioscience) was added at 5 Ag/mL in the last
12 h of culture. Cells were surface stained with anti-CD4 antibody (BD
Biosciences) followed by fixation/permeabilization using eBioscience buffer.
Cells were intracellularly stained with anti–granzyme B, anti–IL-5 anti-
bodies (BD Biosciences), and anti-Foxp3 antibody (eBioscience) and
analyzed using FACScan as above.
Results
Generation of T-cell lines and clones against the WT1-
Pepmix and analysis of their HLA restriction. PBMCs from three
healthy individuals, BC-29, BC-52, and BC-62 (Supplementary
Data 1), sharing the HLA-DRB1*0402 molecule, were stimulated
repeatedly with autologous DCs pulsed with WT1-Pepmix.
Corresponding T-cell lines designated TCL 29, TCL 52, and TCL
62 with specific proliferative activity against autologous WT1-
Pepmix–pulsed LCLs were generated (Fig. 1A). The TCL 29 line,
which gave high proliferative activity, was cloned by limiting
dilution, and 48 clones were obtained and screened by proliferation
assay against autologous LCL FWT1-Pepmix. Eight clones showed
specific proliferative activity against the WT1-pepmix. Four clones
(TCC 29.B.9, TCC 29.B.16, TCC 29.B.19, and TCC 29.B.42), which
showed the highest and most stable proliferative activity (Fig. 1A),
were selected and expanded for further analysis. TCL 29 was then
screened by proliferation assay against the individual 110 WT1-
Pepmix peptides. A peptide designated WT1-84 with the WT1333-347
RYFKLSHLQMHSRKH sequence induced the strongest specific
proliferative activity of TCL 29 (Fig. 1B). Interestingly, both TCL 52
and TCL 62 lines also showed specific proliferative activity against
the WT1-84 peptide (data not shown). The rest of the peptides
did not induce significant proliferative activity, indicating the
Figure 1. Proliferative activity of T-cell lines and clones generated against the WT1-Pepmix. A, T cells (5  104 per well) from three T-cell lines (TCL 29, TCL 52, TCL
62) and four expanded T-cell clones (TCC 29.B.9, TCC 29.B.16, TCC 29.B.19, and TCC 29.B.42) were challenged for 72 h with irradiated (8,000 rads, XR) autologous
LCL (105 per well) in the absence (gray columns ) or presence (black columns) of WT1-Pepmix. Cells were pulsed with [3H]thymidine for additional 18 h and then
harvested. T cells only (TC ; white columns ) were used as negative control. B, the TCL 29 cells (2.5  104 per well) were mixed with irradiated autologous PBMCs
(5  104 per well) pulsed with the different 110 single WT1 peptides. The culture conditions were the same as described in A. C, representative T-cell clone (TCC
29.B.42) showing the restriction response to the HLA-DR molecule. Experimental conditions were the same as described in A . mAbs were added to the wells containing
LCLs 20 min before the addition of T cells. D, proliferative activity of a representative T-cell clone (TCC 29.B.42) against the HLA-DR0402–matched LCL-19 and
the HLA-DR0701–matched LCL-18 in the absence (gray columns ) or presence (black columns ) of the WT1-84 peptide. Experimental conditions for D were the same as
described in A with the exception that 104 T cells per well were challenged for 72 h with 2  104 per well irradiated LCLs.
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immunodominance of this epitope. All clones had specific
proliferative activity to the WT1-84 peptide and a dose-dependent
response was shown in all clones with the optimal concentration at
40 Amol/L (data not shown). The HLA restriction of the clones was
determined in which anti–HLA-DR mAb was found to significantly
inhibit their proliferative activity, whereas their corresponding
isotypes had no inhibition effect (Fig. 1C). To define more precisely
the HLA-DR restriction, two HLA-DR–matched allogeneic LCLs
sharing the DRB1*0402 (LCL-19) or DRB1*0701 (LCL-18) with the
TCC 29.B.42 clone were used. LCL-18 failed to present the WT1-84
peptide, ruling out the involvement of the DRB1*0701 in this
presentation. However, LCL-19 sharing the DRB1*0402 with the
clone induced a specific proliferative activity against the WT1-84
peptide, showing the requirement of DRB1*0402 restriction in this
process (Fig. 1D). No proliferative response was recorded when LCL
pulsed with a negative control HPV3373-87 HLA-DR*0402–restricted
peptide was used (data not shown). All clones were CD4+ (data not
shown). Because CD4+ T cells can exert a cytotoxic effect (22),
we used 51Cr release assay to examine cytotoxic effect against
autologous LCL FWT1-84. No lytic activity was detected (data not
shown), ruling out this possibility.
Evaluation of the cytokine profile of the T-cell clones.
Cytokines generated during an immune response dictate the
outcome of this response. Hence, we evaluated the cytokine
profile generated by the anti–WT1-84 clones. Various cytokines
released were determined from cell culture supernatants of T cells
cultured for 48 h with irradiated autologous PBMCs or LCL F
WT1-84 or FWT1-Pepmix. All clones secreted very high amounts
of IL-5 and GM-CSF, and high IL-4, specifically to WT1-84 and
WT1-Pepmix, but little or no IL-10, TGF-h1/h2, or IFN-g
(Supplementary Data 3). This clearly shows a T helper 2 (Th2)-
polarized immune response.
Characterization of the phenotypic profile and TCR usage of
the T-cell clones. The cytokine profile of the clones suggested that
they represent a Th2 phenotype. It has been recently shown (23)
that human Th2 cells exert a Treg phenotype in which a generated
Th2 clone also expressed Foxp3, a specific marker for Treg lineages
(24, 25). Foxp3 is also expressed transiently in activated non-Tregs
(26). Therefore, we tested whether TCL 29 and clones express
Foxp3 after long-term culture. Figure 2A shows the presence of
Foxp3 mRNA in TCL 29 and two other clones. Because Tregs are
elevated during pregnancy (27), we used PBMCs from a pregnant
Figure 2. Phenotypic analysis of the TCL 29 T-cell line and the expanded T-cell clones generated against the WT1-Pepmix. A, RNA expression of Foxp3 in the
T-cell line (TCL 29) and clones (TCC 29.B.9 and TCC 29.B.42). PBMCs from a 7-mo pregnant women (PBMC-PR) and LCL-29 were used as a positive and a negative
control. PBMC-29 from which the TCL 29 was generated was used as a baseline. b-Actin acts as a housekeeping gene. Total RNA was isolated from different individual
cell types and analyzed by RT-PCR. B, cytospin immunocytochemical double staining of a representative T-cell clone (TCC 29.B.9) after more than 1 mo in
culture showing (right ) the nuclear expression of the Foxp3 protein (brown) and the membranous expression of the CD3 T-cell marker (blue ). Left, anti–CD3-stained
cells with an isotype Foxp3-matched negative control. Magnification, 520. C and D, FACS analysis of a representative T-cell clone (TCC 29.B.9) showing a Treg
phenotype after more than 1 mo in culture.
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woman as a positive control. Foxp3 expression was further
confirmed at the protein level (Fig. 2B). We further confirmed
the protein expression in these clones by fluorescence-activated
cell sorting (FACS) analysis and found to exert a CD4+CD25+Foxp3+
Treg phenotype (Fig. 2C). Finally, we examined the clones for the
expression of other Treg-related markers. GITR (28, 29) and CTLA-4
(30) molecules are constitutively expressed at high levels in Tregs.
All clones expressed GITR but were negative for CTLA-4 and
CD127, which has been recently used to discriminate between
human regulatory CD127 and activated T cells (Fig. 2D ; ref. 31).
Altogether, these data indicate that the current anti-WT1 clones
are phenotypically Tregs.
The TCR profile of the generated T-cell line and clones was
determined using a TCR Vh kit, which is used to detect the 24 most
common human TCR Vh molecules. All clones shared the same
TCR Vh8 chain (Supplementary Data 4A). We also determined the
frequency of TCR Vh8 in TCL 29 and PBMC-29 from the same
donor. The TCR Vh profile of PBMC-29 scattered between 1% and
8% in which 5% of T cells were TCR Vh8 (Supplementary Data 4B).
The frequency of other two T-cell populations with unknown
Figure 3. Expression of the WT1 antigen
by leukemic cells and proliferative
activity of the anti-WT1 Tregs to different
HLA-DR4–matched leukemias. A, cytospin
immunocytochemical staining of three
representative PBMCs from AML patients
(AML-25, AML-27, and AML-28) showing
the nuclear expression of the WT1 protein
in the leukemic blasts (red). The K562 cell
line was used as a positive control, and
LCL-29 and PBMC-29, from which the
TCL 29 and clones were generated, were
used as negative controls. Cells were
counterstained in instant hematoxylin.
Magnification, 520. B, proliferative
activity of a representative T-cell clone
(TCC 29.B.42) against the HLA-DR04
suballelic positive LCLs (LCL-06, LCL-11,
LCL-10, LCL-25, and LCL-38) in the
absence (gray columns ) or presence
(black columns ) of the WT1-84 peptide.
C, proliferative activity of the TCC 29.B.42
Treg clone against PBMCs from
DR0402-matched (AML-13 and AML-23),
nonmatched (AML-27 and AML-28), and
HLA-DR04 suballelic positive AML
(AML-21, AML-25, and AML-29) patients.
T cells (5  104 per well) were challenged
for 72 h with irradiated (3,000 rads, XR)
PBMCs (105 per well) from AML patients,
incubated for additional 18 h with
[3H]thymidine, and harvested. T cells
challenged with irradiated autologous
PBMC-29 in the absence or presence of
the WT1-84 peptide served as negative
and positive control, respectively.
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specificities was increased (Vh2, 8–21%; Vh3, 7–12%) after seven
rounds of stimulation (Supplementary Data 4C). Interestingly, the
TCR Vh8+ T-cell frequency was enriched to 40% in TCL 29 after
seven rounds of stimulation, indicating the immunodominance of
anti–WT1-84 TCR Vh8+ T-cell population in TCL 29.
Evaluation of WT1 expression and proliferative activity of
anti-WT1 Tregs against DR4-matched healthy and leukemic
cells.We examined the expression of the WT1 mRNA in fresh AML
cells using quantitative reverse transcription-PCR (RT-PCR). WT1
protein expression was also evaluated by immunostaining and
scored by two independent scientists. K562 cells, known to express
high levels of WT1 (20), were used as a positive control. PBMCs
and LCLs from normal donors served as negative controls. Higher
levels of WT1 expression were recorded in AML samples
(Supplementary Data 5). Figure 3A shows immunostaining of
PBMCs from three AML patients indicating different levels of WT1
expression.
Because HLA-DR was the restriction element for the clones
(Fig. 1C), it was important to evaluate its expression in the AML
samples. All AML samples expressed HLA-DR, although at
different levels (Supplementary Data 5). The proliferative activity
of a selective clone was then measured against PBMCs from two
DR0402-matched (AML-13 and AML-23) and two non-DR0402
(AML-27 and AML-28) AML patients. Specific proliferative activity
was recorded for the clone against AML-13 and AML-23 cells
expressing the DR0402 molecule (Fig. 3B). However, this clone
failed to recognize non-DR0402 AML-27 and AML-28 cells,
although they express high levels of WT1 (Fig. 3C). Percentages
of leukemic blasts used in this study are shown in Supplementary
Data 4, column 2. T cells challenged with PBMC-29 F WT1-84
Figure 4. Suppressive function of the TCC 29.B.42 Treg clone. A, top, the proliferative activity of allo-MLR was strongly suppressed by a representative clone TCC
29.B.42 at different clone to allo-PBMCs ratios in which specific activation of the clones with WT1-84 peptide was required for such suppressive activity; middle,
Transwell experiments showing that Tregs cultured in inner wells were able to significantly suppress the proliferative activity of the allo-MLR cells cultured in the outer
wells (ratio was at 1:5); bottom, blocking antibodies to TGF-h1/h2, IL-4, IL-5, IL-10, or GM-CSF did not restore the allo-MLR (ratio was at 1:20). B, top, the suppressive
effect of the TCC 29.B.42 Treg clone on the expansion of alloreactive cytotoxic lymphocytes (inhibition effect of the Tregs on the expansion of NK (CD56), NK T
(CD8/CD56), and CD8 cells after second and fifth stimulation; middle, the cytotoxic activity of purified CD8+ alloreactive T lymphocytes generated in the presence
or absence of Tregs and tested against allogeneic LCL-5 and K562 cells; bottom, the cytotoxic activity of mixed alloreactive T lymphocytes generated in the presence or
absence of Tregs and tested against allogeneic LCL-5 and K562 cells. C, top, the suppressive effect of the TCC 29.B.42 Treg clone on the induction of anti–WT1-126
CTLs; bottom, the suppressive effect of the TCC 29.B.42 Treg clone on the induction of anti–WT1-126 IFN-g–producing T lymphocytes. CTLs were challenged
with irradiated T2 cells in the absence (TC[T2] ) or presence (TC[T2+126 peptide] ) of peptide. T cells only (TC ) were used as negative control.
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served as negative and positive controls. We have also showed
that the WT1-84 peptide was able to induce a specific
proliferative cross-reactivity in the T-cell clones after challenging
with LCLs sharing different HLA-DR04 suballeles: DR-0401 (LCL-
06 and LCL-11), DR-0403 (LCL-10, LCL-25, LCL-33, and LCL-36),
and DR-0405 (LCL-38; Fig. 3B). Therefore, we tested the
proliferative activity of the clones against WT1-expressing PBMCs
from different HLA-DR04 suballelic positive AML patients (AML-
21, AML-25, and AML-29). The clones recognized all AML cells
used (Fig. 3C). We conclude that leukemic cells express relatively
high levels of the WT1 antigen and able to process it to the
WT1-84 peptide, which then presented to Tregs through the HLA-
DR04 molecule.
Evaluation of the inhibition effect of the Treg clones on
alloreactive T helper/cytotoxic lymphocytes and induction of
anti-WT1 CTL responses. To evaluate whether the Treg clones
exert a suppressor function on alloreactive T helper lymphocytes,
we used an allo-MLR (32) as a functional readout. All clones
significantly suppressed the proliferative activity of the allo-MLR
and showed a strong inhibition effect even at 1:100 T-cell to allo-
PBMC ratio (Fig. 4A, top). Specific activation of the clones with
WT1-84 peptide was required for such suppressive activity, as
stimulation with LCL alone did not have a significant effect. To
test whether cell-cell contact was required for such inhibition, we
carried out experiments in Transwell plates. All clones cultured in
inner wells were able to significantly suppress the proliferative
activity of the allo-MLR cells cultured in the outer wells (Fig. 4A,
middle), showing that cell-cell contact was not required for such
inhibition. This inhibition effect was not mediated with TGF-h1/
h2, IL-4, IL-5, IL-10, or GM-CSF, as mAbs to these cytokines did
not restore the allo-MLR (Fig. 4A, bottom). The clones inhibited
also the proliferation of autologous LCL (data not shown),
suggesting the involvement of other soluble factors in such
inhibition.
We next examined the suppressive effect of TCC 29.B.42 Treg
clone on the expansion and function of alloreactive cytotoxic
lymphocytes. The presence of Tregs had a strong inhibition effect on
the expansion of both natural killer (NK; CD56) and NK T (CD8/
CD56) cells in early cultures, whereas a strong inhibition effect on
the expansion of CD8 was recorded in late cultures (Fig. 4B, top).
However, the cytotoxic activity of alloreactive CD8+ CTLs generated
in the presence of Tregs was comparable with that generated in the
absence of Tregs when allogeneic LCL-5 cells were used as a target
(Fig. 4B, middle). Interestingly, NK activity against K562 was
recorded only in mixed alloreactive cells generated in the absence
of Tregs (Fig. 4B, bottom).
Finally, we examined the suppressive effect of TCC 29.B.42 Treg
clone on the induction of anti-WT1 CTL responses. The presence of
Tregs had a strong inhibition effect on the induction of anti–WT1-
126 CD8+ CTL responses as evidenced by both very low cytotoxic
activity (Fig. 4C, top) and IFN-g production (Fig. 4C, bottom)
recorded for the CTL-126 Tregs after challenge with the HLA-A0201
+
T2 cell line as a target.
Production of granzyme B and induction of apoptosis by
the Treg clones. We next sought to determine what other soluble
factors are involved in such inhibition. Granzyme B is produced
by Tregs and induces apoptosis in target cells in a perforin-
independent (33) and perforin-dependent (34) manners. There-
fore, we examined our Treg clones for granzyme B and perforin
production using ELISPOT and intracellular staining assays.
Granzyme B was specifically produced in response to autologous
LCL in the presence of the WT1-84 peptide and also to
stimulation with DR4-matched AML-25 cells but not to non–
DR4-matched AML-27 cells (Fig. 5A). Perforin was not detected
by either assays (data not shown). We further examined the
apoptotic effect of these clones. A specific apoptosis was induced
in autologous DCs and LCL pulsed with WT1-84 peptide but no
apoptotic effect was detected for either DR4-matched AML-25 or
non–DR4-matched AML-27 cells (Fig. 5B). These data show the
capability of Tregs to selectively induce apoptosis in APCs and not
in AML cells.
Determination of anti–WT1-84 Treg frequencies in AML
patients. Our generated Treg clones exerted a CD4
+Foxp3+
phenotype and specifically produced IL-5 and granzyme B in
response to the WT1-84 peptide. Therefore, we have used
intracellular cytokine staining to test for specific granzyme B and
IL-5 production and Foxp3 expression by CD4+ T cells in AML
patients. Of eight HLA-DR-4+ patients (Supplementary Data 1)
Figure 5. Specific production of granzyme B by anti-WT1 Treg clones and
induction of apoptosis in target cells. A, ELISPOT assay for granzyme B
production by three Treg clones. Tregs (10
3 per well) were stimulated with
autologous LCL FWT1-84, HLA-matched AML-25, or nonmatched AML-27
cells (2  104 per well) for 40 h in anti–granzyme B precoated wells before
development of the spots. T cells incubated without stimulators (TC) served as
a baseline. B, proportion of apoptosis induction by TCC 29.B.42 Treg clone after
24 h of incubation with target cells. Apoptosis was determined by FACS using
Annexin V in combination with propidium iodide on CD19 (LCL), CD40 (DCs),
and CD33 (AML) gated cells.
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tested, five patients showed significant increase in granzyme
B/Foxp3 expression and IL-5 production in the presence of the
WT1-84 peptide (Fig. 6). Non–HLA-DR-4 (AML-27 and AML-28)
and HLA-DR-4+ donors (BC-29 and BC-62; Supplementary Data 1)
were negative (data not shown). These findings support our in vitro
data and show the amplification of tumor-specific anti–WT1-84
Tregs in AML patients in HLA-DR4–restricted manner.
Discussion
In this study, we identified novel human anti-WT1 Treg and
clones using a pool of 110 15-mer overlapping peptides across the
entire WT1 protein. These T-cell lines and clones specifically
recognized a WT1333-347 (RYFKLSHLQMHSRKH) peptide designat-
ed WT1-84 in an HLA-DRB1*0402–restricted manner. The T-cell
clones produced GM-CSF, IL-4, and IL-5 in response to the WT1-84
peptide exerting a Th2 cytokine profile. During the course of our
study, Fujiki and colleagues (35) described an anti-WT1 T helper 1
(Th1) T-cell clone restricted to HLA-DRB1*0405 and specific to
a 16-mer WT1332-347 peptide that has an additional amino acid
compared with the 15-mer WT1333-347 epitope described in our
study. It has been shown that the affinity of the antigen for TCR
and the antigen dose can influence the differentiation of Th1 and
Th2 cells (36). Th2 cells are generated only in the presence of a low
dose of an antigen, and a weak TCR signal is needed for their
generation (37). Fujiki and colleagues used high dose (50 Ag/mL)
of the WT1332-347 as a single peptide to prime T cells, whereas only
10 Ag/mL of the 110 Pepmix including the WT1333-347 peptide were
used in the current study. Therefore, the antigen dose and peptide
competition in the case of the WT1-Pepmix may contribute to
the generation of two different T helper cell types. Finally, we used
high concentration of IL-2 (260 IU/mL) for the T-cell generation,
whereas Fujiki and colleagues used only 20 IU/mL in their study.
High dose of IL-2 has been shown to increase the frequency of
Tregs in cancer patients (38) and selectively up-regulate the in vitro
expression of Foxp3 in Tregs. It is possible that the presence of high
dose of IL-2 in our T-cell cultures played a role in the polarization
of T cells to Th2 phenotype as it has been described in other
systems (39) and up-regulated the expression of Foxp3 in this T-cell
population.
A recent study by Durinovic-Bello and colleagues (23) showed
that human Th2 cells that exert a down-regulatory Treg
phenotype also express Foxp3. However, Foxp3 has also been
shown to be expressed transiently in activated non-Tregs, whereas
Figure 6. Intracellular staining and determination of
anti–WT1-84 Foxp3+ Treg frequencies in AML patients.
PBMCs (2  106/mL) were cultured in DC medium as
described in Materials and Methods + 125 units of IL-2 for
48 h FWT1-84 peptide. Brefeldin A was added at 5 Ag/mL
in the last 12 h of culture. Granzyme B-FITC/Foxp3-APC
double-positive cells were analyzed on gated CD4-PE+
cells. IL-5-PE+ cells were analyzed on gated CD4APC+
cells. AML-3, AML-24, AML-25, AML-29, and AML-37
showed significant increase in granzyme B/Foxp3
expression and IL-5 production in response to the WT1-84
peptide. Inserted numbers indicate the percentage of
positive cells within the quadrant or the gate.
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it is stably expressed in Tregs (26). We have shown that the
generated T-cell clones were stably expressing Foxp3 and exerted
a CD4+CD25+Foxp3+ Treg phenotype. Furthermore, the T-cell
clones were examined for the expression of other Treg-related
markers (GITR, CTLA-4, and CD127) and confirmed to be
CD4+CD25+Foxp3+GITR+CD127 antigen-specific Tregs. The lack
of CD127 expression rules out the activation-induced Foxp3
expression. These clones recognize the WT1-84 epitope through
their TCR Vh8 chain. The immunodominance of the anti–WT1-
84/TCR Vh8+ T-cell population in the generated T-cell line may
have had a down-regulatory effect on the generation of Th1 T
cells against other epitopes in the WT1-Pepmix. Importantly,
these Treg clones recognized HLA-DR4–matched leukemic cells
expressing the WT1 antigen, showing the natural processing and
presentation of the WT1-84 epitope. The WT1-84 peptide
described in this study seems to be a promiscuous HLA class
II–restricted T-cell epitope as it has been reported to be
recognized by both HLA-DP5–restricted cytotoxic (22) and HLA-
DR0405–restricted T helper (35) CD4+ T cells.
Demonstration of functional Tregs will reside eventually on their
ability to inhibit immune responses in functional assays (40).
Several molecular and cellular events have been attributed to the
suppressive effect of Tregs (41). The Treg clones described in the
present study were able to significantly inhibit the proliferative
activity of allogeneic T cells independently of cell contact.
Moreover, priming in the presence of anti–WT1-84 Tregs had a
strong inhibition effect on the expansion and cytotoxic activity of
NK and NK T-cell populations. This agrees with the recent study
showing a direct inhibitory effect of Tregs on the generation and
function of NK cells (42). However, the presence of anti–WT1-84
Tregs had a strong inhibition effect on the expansion of alloreactive
CD8 T cells but no effect on their cytotoxic activity. The animal
model study by Edinger and colleagues (43) showing that Tregs
suppress alloantigen-driven expansion of CD8 T cells without
inhibition of their cytotoxic effect supports our observation. More
importantly, we have shown that the presence of Tregs strongly
inhibited the induction of anti–WT1-126 CD8+ CTL responses. The
existence of such tumor-specific Tregs can actively suppress the
WT1-specific antitumor immunity in cancer patients as it has been
shown in other systems (12).
Furthermore, the present Tregs inhibited the proliferation of
LCL, which does not depend on cytokines in their proliferation,
suggesting the involvement of other soluble factors. It has been
shown that production of granzyme B by Tregs results in the
induction of apoptosis in T and B cells in a perforin-independent
fashion (33). The current Tregs specifically produced granzyme B,
but not perforin, in response to the WT1-84 peptide and induced
apoptosis in LCL and DCs, suggesting a direct effect of granzyme
B on the suppressive activity of these Tregs. However, they failed
to induce apoptosis in HLA-matched AML cells, although
granzyme B was produced in response to these cells. It is known
that leukemic cells use several antiapoptotic signals to escape
killing (44). Apoptosis in response to granzyme B involves
activation of caspase-dependent cell death pathways (45).
Blockade in caspase activation pathways is a common feature
in leukemia (46), and this may explain the current resistance of
AML cells to apoptosis. Our findings raise the possibility that
leukemic cells may function as APC to preferentially induce anti–
WT1-specific Tregs and hence down-regulate the patients’ immune
response through induction of apoptosis in APCs, such as DCs
and B cells (34), and/or inhibition of specific and nonspecific
anti-leukemia immune responses. Another important finding is
the detection of anti–WT1-84 IL-5+/granzyme B+/Foxp3+ CD4+
Tregs in five of eight HLA-DR4
+ AML patients. The recent demon-
stration by Zhou and colleagues (47) that tumor-specific Tregs are
amplified in vivo following cancer vaccination supports our data.
Current interests in cancer immunotherapy should be focused
on determining the therapeutic implications of Tregs ‘‘regulating the
regulators.’’ Interestingly, elimination of Tregs by IL-2 conjugated to
diphtheria toxin (ONTAK) enhanced vaccine-mediated antitumor
immunity in cancer patients (7). However, targeting the CD25
molecule may eliminate Tregs, leading to an increase in the
susceptibility to autoimmunity, and it can also deplete activated
CD25+ effector cells, which may be important for clearance of
cancer and infection (48). Therefore, studies should be tailored
toward developing selective depletion strategies directed against
Treg-related markers. Alternatively, triggering of TLR8 or OX40, and
potentially blocking adenosine, might improve the chances of
neutralizing Treg immunosuppression in cancer patients (49). In
conclusion, our findings should open opportunity for the clinical
manipulation of anti-WT1 Tregs for the treatment of leukemia
patients.
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Despite major advances in molecular bioloogy and targeted therapy of leukemia, curorent treatment strategies induce adverse side 
effects and fail to achieve and maintain remission in 
many patients. In acute myeloid leukemia (AML), the 
most deadly form of leukemia,1,2 the majority of adult 
patients younger than 60 years achieve a complete reo
mission following consolidation therapy. However, only 
approximately 30% to 40% maintain durable remission.3 
Furthermore, the complete remission rate and duration 
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BACKGROUND AND OBJECTIVES: There is an urgent need for the development of leukemia-targeted im-
munotherapeutic approaches using defined leukemia-associated antigens that are preferentially expressed by 
most leukemia subtypes and absent or minimally expressed in vital tissues. M-phase phosphoprotein 11 protein 
(MPP11) is extensively overexpressed in leukemic cells and therefore is considered an attractive target for leu-
kemia T cell therapy. We sought to identify potential CD8+ cytotoxic T lymphocytes that specifically recognised 
peptides derived from the MPP11 antigen. 
MATERIALS AND METHODS: A computer-based epitope prediction program SYFPEITHI, was used to predict 
peptides from the MPP11 protein that bind to the most common HLA- A*0201 molecule. Peptide binding ca-
pacity to the HLA-A*0201 molecule was measured using the T2 TAP-deficient, HLA-A*0201-positive cell line. 
Dendritic cells were pulsed with peptides and then used to generate CD8+ cytotoxic T lymphocytes (CTL). The 
CML leukemic cell line K562-A2.1 naturally expressing the MPP11 antigen and engineered to express the HLA-
A*0201 molecule was used as the target cell. 
RESULTS: We have identified a potential HLA-A*0201 binding epitope (STLCQVEPV) named MPP-4 derived 
from the MPP11 protein which was used to generate a CTL line. Interestingly, this CTL line specifically rec-
ognized peptide-loaded target cells in both ELISPOT and cytotoxic assays. Importantly, this CTL line exerted a 
cytotoxic effect towards the CML leukemic cell line K562-A2.1. 
CONCLUSION: This is the first study to describe a novel epitope derived from the MPP11 antigen that has been 
recognized by human CD8+ CTL. 
attained by older AML patients is less, with an overall 
survival rate of 20% to 40%.3 Therefore, there is an uro
gent need for the development of leukemiaotargeted imo
munotherapy designed to eliminate residual leukemic 
cells thus enhancing the graftoversusoleukemia (GVL) 
effect observed after allogeneic hematopoietic stem cell 
transplantation (HSCT) and/or prolonging a complete 
remission achieved by chemotherapy.4,5 
Leukemia cells express unique antigens or overexo
press normal cellular antigens.6,7 The overexpressed 
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normal antigens constitute attractive targets for the 
development of leukemia immunotherapy.6 Among 
this group of antigens are the Mophase phosphoproo
tein 11 (MPP11) proteins. MPP11 was discovered by 
MatsumotooTaniura et al8,9 using an MPM2 monoo
clonal antibody, which recognizes several important 
mitosis phosphoproteins found to be present during 
mitosis.8o10 Recently, it has been reported that MPP11 
functions as a ribosomeoassociated molecular chapero
one.11,12 MPP11 maps to the region of chromosome 
7q22o31.1, which is a critical common position in huo
man cancer.10,13 MPP11 has been detected by serologio
cal analysis of cDNA expression libraries (SEREX) 
in solid tumours and hematological malignancies 
including melanoma, breast, renal cell carcinoma, 
small cell lung cancer and leukemia.14,15 The humoral 
immune responses to MPP11 have been detected in 
patients with acute (AML) and chronic myeloid leuo
kemia (CML), but not in healthy donors or patients 
with autoimmune diseases.15 Moreover, this protein 
has been found to be expressed extensively in AML 
and CML patients as compared to normal controls.15o
18 Immunohistochemical staining of primary tumor 
sections and Western blot analysis of head and neck 
squamous cell cancer (HNSCC) cell lines revealed 
tumorospecific overexpression of MPP11 protein.13,15 
Additionally, fluorescence in situ hybridization analyo
sis carried out on HNSCC cell lines showed an ino
crease in the copy number of MPP11 along with chroo
mosome 7 suggesting an oncogenic role for MPP11.13 
The specific overexpression of MPP11 by tumor tiso
sues (with the exception of very low expression in teso
tis, kidney, and lung) makes it an attractive target for 
cancer immunotherapies.15,17 
We sought to identify potential CD8+ cytotoxic T 
lymphocyte (CTL) epitopes in the leukemiaoassocio
ated MPP11 antigen that bind to the most common 
HLAoA*0201 molecule and provoke specific CTL reo
sponses. Although various antigenic epitopes derived 
from leukemia antigens have been identified, progress 
in targeting specific immunotherapeutic approaches 
depends on the recognition of a wider range of leukeo
mia antigens. This would allow the use of these pepo
tides in leukemia immunotherapy by either expanding 
ex vivo tumororeactive specific CTLs for adoptive T 
cell therapy or actively inducing leukemia antigenospeo
cific Tocell immunity in vivo by vaccinating patients 
with wellodefined leukemiaoassociated antigens. 
MATERIALS AND METHODS 
Leukocyteorich buffy coats not older than eight hours 
were obtained from healthy volunteers from the blood 
bank. All samples were obtained with informed cono
sent at King Faisal Specialist Hospital and Research 
Centre (KFSHRC). Peripheral blood mononuclear 
cells (PBMCs) from healthy donors were isolated from 
heparinized blood by density gradient centrifugation 
over FicolloPaque PLUS (Amersham Biosciences) aco
cording to the manufacturers’ instructions. PBMCs 
were suspended in 90% Fetal Calf Serum (FCS) + 
10% dimethyl sulfoxide (DMSO), aliquoted and cryoo
preserved in liquid nitrogen until further processing. 
The HLA typing of these samples was carried out at 
the routine immunopathology laboratory. 
T lymphocyte epitope prediction and peptide synt
thesis 
The SYFPEITHI prediction algorithm is a datao
base comprising more than 4500 peptide sequences 
known to bind class I and class II MHC molecules. 
The scoring system of the SYFPEITHI program is 
based on the presence of certain amino acids in certain 
positions along the MHCobinding groove.19 Peptides 
qualified as positive if the score ranked ≥22. The 
amino acid sequences of MPP11 were entered into 
the specified program and candidate epitopes were seo
lected based on their predicted ability to bind to the 
HLAo A*0201 molecule. Four 9omer peptides derived 
from MPP11 were selected as potential epitopes for 
the generation of CTL responses. The four peptides 
were: MPPo1N=MMP11o421o429 (QLLIKAVNL), 
MPPo2=MP11o419o427 (DLQLLIKAV), MPPo
3=MPP11o313o321 (AIMLLLPSA), and MPPo
4=MPP11o437o445 (STLCQVEPV). In addition 
to the predicted peptides, we modified the sequence 
of the first predicted peptide derived from MPP11 by 
introducing a Y at its Noterminus (wild type MPPo
1N= QLLIKAVNL, analog MPPo1Y=MPP11o
1Y(YLLIKAVNL) according to our recent study.20 
This approach enhanced both the binding and the 
immunogenicity of the modified peptide. The amino 
acid sequences of the nonameric peptides with a puo
rity of ≥90% were synthesized and purified by Alta 
Bioscience, Birmingham, UK. 
T2 binding assay 
Peptide binding capacity to the HLAoA*0201 molo
ecule was measured using the TAPodeficient, HLAo
A*0201opositive cells as described previously.21 
Briefly, T2 cells were washed three times, suspended 
at 106 cells/mL and incubated for 18 hours at 37ºC 
in serumofree medium containing 30 µM of each pepo
tide and 1 mg/mL b2omicroglobulin (Sigma). Cells 
were then washed twice with cold FACS buffer (phoso
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phate buffered saline containing 2% FCS). Purified 
rabbit IgG (Sigma) was added to the cell suspension 
and incubated for 15 minutes on ice in order to block 
the FC receptors. FITCoconjugated mouse antio
HLAoA2 antibody was added to the cell suspension 
(1 µg/106 cells), with a control sample labelled with 
isotypeomatched monoclonal antibody and incubated 
for 30 min at 4ºC in the dark. The cells were washed 
twice with cold FACS buffer, and fixed with 300 µL 
of PBS/4% paraformaldehyde. The level of HLAo
A2 expression was analyzed using fluorescenceoactio
vated cell sorter (FACS) scan (Becton & Dickinson, 
Immunocytometry Systems, CA, USA). HLAoA2 
expression was quantified as fluorescence index (FI) 
according to the following formula: fluorescence index 
= (mean fluorescence intensity with peptideomean 
fluorescence intensity without peptide)/mean fluoreso
cence intensity without peptide. All T2 binding assays 
were carried out in duplicate. 
Cell lines 
The mutant TAPodeficient cell line T2 (ATCC numo
ber CRLo1992) and the HLAoclass I and II negative 
human CML cell line Ko562 (ATCC number CCLo
243) were purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA). Ko562 
cells transfected with the HLAoA*0201 gene22 were 
kindly provided by Dr. Wolfgang Herr (University 
of Mainz, Germany). The T2 and K562 cells were 
maintained in complete medium (CM) consisting of 
RPMI 1640 medium (Sigma, MO, USA) suppleo
mented with 10% FCS (Cambrex Bio Science, MD, 
USA), 2 mM Loglutamine, 100 IU/mL penicillin and 
100 mg/mL streptomycin (Sigma). K562/ A*0201 
were cultured in CM containing 0.5 mg/mL geneticin 
(G418, Sigma). Bolymphoblastoid cell lines (LCLs) 
were established from normal donors by transformao
tion of B cells using EpsteinoBarr virus (EBV) accordo
ing to a standard technique.23 Briefly, PBMCs (107 
cells) were incubated with the virus (EBV virus stock, 
B95.8) for an hour at 37ºC. The cells were cultured in 
CM containing 1µg/mL PHA (PHAoP, Sigma) and 
0.1 ug/mL cyclosporin A, and established LCLs lines 
were used after 3o4 weeks of culture. 
Generation of DC2d dendritic cells (FasttDC) 
Monocytes (CD14+ cells) were isolated from PBMCs 
of healthy HLAoA*0201 positive donors by plastic 
adherence. PBMCs were cultured at 5×106 cells/mL/
well of a 6owell plate (Sigma) in Xovivo 15 medium 
(DComedium), and allowed to adhere in a 5% CO2 
incubator at 37ºC for 90omin. Nonoadherent cells 
and media were removed and fresh DComedium was 
added to the cells. After a second incubation period, 
nonoadherent cells and media were removed and the 
adherent cells were washed carefully with preowarmed 
medium. The DC2d were generated according to preo
viously published protocols24,25 with minor modificao
tions. Briefly, DComedium supplemented with 100 
ng/mL rhGMoCSF and 50 ng/mL rhILo4 (R&D 
Systems) was added to monocytes cultured in 6owell 
plates. Maturation cytokines, 10 ng/mL rhTNFa, 10 
ng/mL rhILo1b, 10 ng/mL rhILo6 (R&D Systems) 
and 1 mM PGE2 (Sigma), were added to the cultures 
on the next day. Cultures were incubated for an addio
tional day before mature DC2d were harvested. 
Generation of antitpeptide specific CD8+ T lymphot
cytes 
CD8+ T lymphocytes were negatively separated from 
PBMCS obtained from healthy HLAoA*0201 posio
tive donors using MACS CD8+ T Cell Isolation Kit 
II (Miltenyi Biotec) according to the manufacturer’s 
protocols. Some of the CD8+ T lymphocytes lines 
were generated using a protocol adapted from previo
ous studies.21,26 Briefly, T2 cells were washed three 
times in serumofree medium and incubated with each 
peptide at concentrations of 50 µM/mL and 1 µg/mL 
b2omicroglobulin at 37 °C, 5% CO2 for 2 hours. The 
peptideopulsed T2 cells were then Xoirradiated (7500 
rads), washed and added to freshly purified CD8+ T 
lymphocytes (T lymphocytes:T2 ratio of 5:1). After 
7o10 days of stimulation, the second stimulation 
was performed and on the following day, 20 IU/mL 
of rhILo2 (R&D Systems) was added. The cultured 
T lymphocytes were maintained by reostimulations 
with peptideopulsed T2 cells. After the third in vio
tro stimulation, the generated T lymphocytes were 
tested for their specificity and cytotoxic activity using 
enzymeolinked immunospot assay (ELISPOT) and 
chromium release assays. DC2doloaded peptides were 
also used to in vitro prime some of the purified CD8+ 
T lymphocytes. Briefly, mature DC2d cells were haro
vested, washed in serumofree medium and incubated 
with the peptides at concentration of 50 µM/mL and 
5 µg/mL b2omicroglobulin for 2 hours at 37°C, 5% 
CO2. The peptide loaded DCs were then Xoirradiated 
(2500 rads), washed once and added to the CD8+ T 
lymphocytes at 20:1 to 5:1 T lymphocytes: DCs ratio. 
rhILo7 (20 ng/mL) and rhILo12 (100 pg/mL) (R&D 
Systems) were added to each culture. The cells were 
incubated in 2 mL T lymphocyte culture medium in 
24owell plates. After 7o10 days, T lymphocytes were 
harvested, washed and reostimulated with peptide 
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loaded DC2d as previously described and rhILo2 (20 
IU/mL) was added the following day. The cultured 
T lymphocytes were maintained by reostimulation 
with autologous peptideoloaded adherent monocytes 
and feeding with rhILo2 the next day. T lymphocytes 
lines against the different peptides were generated. 
Responder T lymphocytes were tested for their pepo
tide specificity and cytotoxic activity using enzymeo
linked immunospot assay (ELISPOT) and chromium 
release assay against different targets. 
Generation of T lymphocyte clones 
T lymphocytes lines were cloned by limiting dilution 
as described before25,27 with minor modifications. T 
lymphocytes were seeded at 1, 2 and 5 cells/well/200 µL 
T lymphocytes culture medium in 96owell Uobottomed 
plates. Allogeneic PBMCs were Xoirradiated (2500 
rads) and used as a feeder layer (25×103 cells/well). T2 
cells were incubated separately in XoVivo 15 medium 
(5×106 cells/mL) with 5 µg/mL b2omicroglobulin and 
50 µM/mL of MPP11 peptides for 2 hours at 37ºC. 
T2 cells were then irradiated (7500 rads), washed once 
and used for T lymphocytes stimulation (50×103 cells/
well) in the presence of 130 IU/mL of rhILo2.5ng/mL 
rhIL15 (R&D Systems), and 30ng/mL OKT3 (R&D 
Systems), were also added to the wells. The plates were 
incubated for 2o4 weeks. Cultures were reofed with 
fresh medium containing rhILo2 (130 IU/mL) every 
3o4 days. Wells with positive signs of growth were seo
lected for expansion. Growing clones were transferred 
to 96owell flatobottomed plates, and each clone was 
stimulated with Xoirradiated peptideopulsed T2 cells. 
The activation cycle was repeated after 7o10 days of culo
ture at T lymphocyte: T2 ratios of 20:1 to 5:1. Clones 
were screened for their lytic activity against T2opulsed 
with or without peptide using chromium release assay. 
Cytotoxicity assay (chromium release assay) 
Cytotoxicity assays were performed 5 days post in vio
tro stimulation. Target cells were removed from culture, 
washed in RPMI1640 serumofree medium, reosuso
pended in a minimal volume (± 50 µL) of RPMI1640 
and incubated with 51Cr (100 µCi) per target for 90 
min. Target cells labelled with peptide were concuro
rently incubated with the appropriate peptide at 50 
µM/mL. The cells were then washed and placed in 
96 Vobottomed wells at 103 cells/100 µL/well. The efo
fector T cells were washed, and added in triplicate at 
varying quantities to the target cells, to give varying efo
fector to target ratios (E:T ratios) in a final volume of 
200 µL/well. The plates were spun for 5 min (300 g) 
and incubated for 4 hours at 37ºC and 5% CO2 before 
100 µL supernatants were removed and transferred to 
1450 Microbeta Plus Wallac plates (Wallac, Turku, 
Finland). 150 µL scintillation fluids, Optiphase HiSafe 
2 (Wallac), were added to each well and the plates were 
heatosealed using a Microsealer system (Wallac). 
Chromium release was assessed by a liquid scintillao
tion counter (Wallac). Target cells were also incubated 
with 0.2% Tween 20 or medium alone to assess the 
maximum and minimum (spontaneous) release of the 
chromium respectively. Spontaneous release was never 
exceeded 20% of the maximum release. The percentage 
of specific lysis was calculated as: % specific lysis = (exo
perimental release–spontaneous release)/(maximal reo
lease–spontaneous release)×100. In some of the expero
iments 10 µg/mL antioclass I ABC blocking antibody 
(clone: W6/32, AbD Serotec) was added to target cells 
before T lymphocytes addition. 
Enzymetlinked immunospot assay (ELISPOT) 
ELISPOT assay was performed using IFNog, granzyme 
B, and perforin kits (Mabtech, Mariemont, OH) aco
cording to the manufacturer’s protocols. 5×103 to 5×104 
T lymphocytes/well and 2×104 to 105 cells/well of difo
ferent stimulators were seeded in Multiscreen 96owell 
plates (Millipore, MA) preocoated overnight (4ºC) with 
catchingoantibody. The plates were then blocked with T 
lymphocytes culture medium. After 40 hours incubation 
(37ºC, 5% CO2), cells were removed and after washing, 
biotinylated monoclonal antibodies specific for IFNo
g, granzyme B, or perforin were added and incubated 
for 3 hours at room temperature (RT). After washing, 
Streptavidinoalkaline phosphatase28 or Streptavidino
horseradish peroxidase (HRP) were added to each 
well and incubated at RT for 2 hours. After washing, 
the appropriate substrate (BCIP/NBT in case of ALP 
and AEC in case of HRP) was added to each well and 
incubated at RT until color developed according to the 
manufacturer’s instructions. Spots were counted uso
ing an automated ELISPOT reader (AID, Strasberg, 
Germany). Antigenospecific T lymphocytes frequencies 
were considered to be significantly higher if they were at 
least twoofold higher than in the control wells. 
RESULTS 
Selection of potential CTL epitopes derived from the 
MPP11 protein 
The amino acid sequences of MPP11 were entered into 
the computer program and potential candidate epitopes 
were selected, synthesized and tested for their capacity 
to bind to the HLAoA*0201 molecule and/or generate 
cytotoxic T lymphocytes responses. We selected four 
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native peptides derived from MPP11 protein using the 
Syfpeithi server available at www.syfpeithi.de. These 
peptides showed high theoretical binding affinity to the 
HLAoA*0201 molecule with binding scores ranging 
from 22 to 25. In addition to the predicted peptides, 
we have carried out tyrosine amino acid substitution in 
the P1 position of the first predicted epitope MPPo1Y 
(QLLIKAVNL). The binding score of the modified 
epitope, MPPo1Y (YLLIKAVNL), was enhanced from 
25 to 27 as assessed by the Syfpeithi program. The seo
quences of the peptides as well as their binding scores 
are presented in Table 1. 
We used the standard T2 binding assay to evaluate 
the ability of MPP11 candidate peptides to bind and 
stabilize the HLAoA*0201 molecule using the wello
characterized A2obinding peptides WT1o187 as a posio
tive control (WT1 derived peptide known to effectively 
bind to the HLAoA*0201 molecule.20,29 The human 
processingodefective T2 cell line express empty HLA 
class I molecules. The binding assay is based on the stao
bilization of HLA class I molecules on the cell surface 
by the addition of peptides exogenously. The T2 cells 
are incubated with peptides overnight and if the pepo
tide binds to the HLAoA*0201, the surface expression 
will be stabilized and there will be an upregulation of 
this molecule. Changes in its expression were assessed 
by staining HLAoA*0201 and quantifying the fluoreso
cence intensity by flow cytometry analysis. The peptides 
are assumed to bind if their fluorescence ratio is greater 
than 1. All T2 binding assays were done in duplicate. 
As shown in Figure 1, the MPPo3 and MPPo4 peptides 
(Fluorescence Index [FI] =1.1 and 2.5 respectively) 
stably bind to the HLA*Ao0201 molecule. The affinity 
of the MPPo4 peptide to the molecule was comparable 
with that observed for the positive control WT1o187 
epitope (FI=2.6). Because of their high binding affinio
ties, we selected MPPo3 and MPPo4 peptides for the 
generation of peptideospecific T lymphocytes lines. On 
the other hand, the peptides MPPo1N, MPP1oY, and 
MPPo2 were excluded from testing for immunogenicity 
since they did not show any binding or only very weak 
binding to the HLAoA*0201 molecule. 
Generation of MPP11tspecific T lymphocytes lines 
We tested the ability of the MPP11oderived peptides 
to induce specific cytotoxic T lymphocytes (CTLs). 
We used PBMCs obtained from four different HLAo
A*0201 positive healthy volunteers to generate CTLs 
specific to the selected peptides. The four donors were 
designated as BCo21, BCo32, BCo37 and BCo41. 
PBMCs from each donor were used as the source of 
the responder cells and antigen presenting cells. The 
responder cells were CD8+ T cells purified by MACS 
negative selection and stimulated in vitro with antigen 
presenting cells loaded with peptide for 7o10 days. 
Initially, we used T2 cells pulsed with peptides to prime 
and activate T lymphocytes raised against MPP11odeo
rived peptides. However, we did not observe any specific 
CD8+ T lymphocyte responses to any of the peptides 
tested including the WT1o126N positive control pepo
tide. Therefore, we used another protocol for the geno
eration of CD8+ T lymphocyte lines where peptideo
pulsed DC2d were used to prime the CD8+ T lymo
phocytes and peptideopulsed monocytes were used for 
subsequent T lymphocyte stimulations. To investigate 
whether the MPP11 synthetic peptides could stimulate 
peptideospecific CTLs, the generated T cell lines were 
tested against different HLAoA*0201+ targets in the 
presence or absence of autologous peptide using a chroo
Figure 1. The binding ability of Mpp11-derived peptides to the HlA-A*0201 molecule as 
measured by the T2 peptide-binding assay. The WT1-187n peptide served as a positive 
control. Mpp-3 and Mpp-4 peptides stably bind to the HlA-A*0201. The peptides 
Mpp-1n, Mpp-2 and the modified peptide Mpp-1y showed no binding to HlA-A*0201 
and thereby were not used to generate CTls. each value represents the average of 
duplicate assays and error bars indicate the Sd. 
Table  1. peptide Sequences derived from the Mpp11 protein and their binding 
prediction to the HlA- A*0201 molecule. 
    Given name Start position Sequence SYFPEITHI Score
   Mpp-1n 421 QlliKAvnl 25
   Mpp-1y y-422 ylliKAvnl 27
   Mpp-2 419 dlQlliKAv 24
   Mpp-3 13 AiMlllpSA 23
   Mpp-4 37 STlCQvepv 22
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mium release assay and an ELISPOT assay after 3 to 8 
rounds of stimulations. 
Cytotoxic T cell lines generated against MPPt4 
(STLCQVEPV) peptide produced specific IFNtg
After the third round of stimulation, the specificity of 
in vitro primed CTLs was first tested for specific IFNog 
release by stimulation with the corresponding peptides 
using an ELISPOT assay. The CTLs generated against 
the MPPo4 (STLCQVEPV) peptide produced specific 
IFNog  spots when stimulated with T2oloaded peptide 
whereas nonospecific production was seen in case of 
CTLs generated against the MPPo3 (AIMLLLPSA) 
peptide as shown in Figure 2A and B. 
Because CD8+ T lymphocytes are known to use 
cytotoxic factors such as granzyme B and/or perforin 
to induce killing of their target cells, so we tested the 
MPPo4o CTL for the release of granzyme B and/or 
perforin after 5 rounds of stimulation. MPPo4 pulsed 
T2 or autologous LCLs were used as stimulators. 
There was no specific production of granzyme B and/
or perforin to the peptide MPPo4 due to very high 
background responses seen when T lymphocytes were 
used alone in the assay (Figures 2c and 2d). 
T lymphocytes generated against the MPPt4 peptide 
specifically lyse MPPt4tpulsed target cells and leuket
mic cells 
The expanded MPP11 T lymphocyte lines genero
ated against the MPPo4 and MPPo3 peptides were 
tested for their specific cytotoxicity against T2 cells 
and autologous LCLs using a chromium release assay. 
Specific lysis of 17.8% against the T2 cells loaded with 
the MPPo4 peptide compared to 0% in the absence of 
peptide was recorded for TCL21 MPPo4 at effector 
to target ratio (E:T) of 50:1 (Figure 3A). In addition, 
35% specific lysis for the same T lymphocytes line 
was recorded against autologous LCL loaded with the 
MPPo4 peptide compared to 6% against autologous 
LCL in the absence of the peptide at E: T ratio of 50:1 
(Figure 3b). 
The cytotoxic activity of the MPPo4 T lymphoo
cytes line against the leukemic K562oA2.1 cell line 
was also measured (K562oA2.1 cells which naturally 
express the MPP11 antigen was transfected with the 
HLAoA*0201 molecule). Interestingly, the MPPo4 
CTLs exerted a lytic activity of 14% against this leuo
kemia cell line at an E:T ratio of 50:1, whereas only 
7% lysis towards the wild type Ko562 (lacking the 
Figure 2. Specificity of CTls generated against the Mpp-3 and Mpp-4 peptides using an eliSpOT assay. The CTl lines were 
established from bC-21, an HlA-A0201+ donor, following three to five rounds of in vitro T lymphocyte stimulations. Mpp-4-CTls 
releases specific iFn-g upon re-stimulation with T2 cells pulsed with Mpp-4 peptide (A). CTls generated against the Mpp-3 peptide 
did not release specific iFn-g (b). High and non-specific granzyme b (C) and perforin secretion by CTl-Mpp-4 (d). All assays were 
performed in triplicate and error bars indicate the Sd. 
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HLAoA2 expression) was recorded at the same E:T 
ratio (Figure 3c). Similar to the ELISPOT results, 
the T lymphocytes line generated against the MPPo
3 peptide did not show any specific cytotoxic activity 
(Figure 3d). 
DISCUSSION 
CD8+ CTLs recognize endogenously processed 
peptides3,30 consisting of 8o11 amino acids, most 
commonly 9 amino acids long, presented on the cell 
surface of target cells in the context of major MHC 
class I molecules. These cells are believed to play an 
important role in identifying and eliminating tumor 
cells.31 To date, several CD8+ CTL epitopes derived 
from leukemia antigens have been identified, and some 
of them have been investigated in clinical trials.32o34 
Importantly, the graftoversusoleukemia (GVL) effect 
often seen after allogeneic hematopoietic stem cell 
transplantation (AHSCT) has been found to be meo
diated mostly by donoroderived CD8+ T lymphocytes 
recognizing peptides derived from leukemia antigens 
and/or minor histocompatibilty antigens (mHAs) 
presented on recipient cells.35o37 Overexpressed antio
gens such as WT1, PRo3 and MUC1 represent poso
sible targets of specific GVL reactions.38o40 
Previous studies have reported the existence of a 
humoral response against the MPP11 protein as well 
as the overexpression of this protein in patients with 
myeloid leukemias.15o17 However, the identification of 
CD8+ CTL epitopes derived from this protein is a 
crucial contribution to the field of leukemia immunoo
therapy. In this study, we investigated potential CD8+ 
CTL epitopes derived from the MPP11 antigen uso
ing a reverse immunology approach.41 The reverse imo
munology approach permits the identification of class 
I as well as class II candidate epitopes derived from 
known tumor antigens on the basis of HLAobindo
ing motifs.42,43 Using this approach, numerous epito
opes were identified in leukemia21,29,44,45 as well as in 
solid tumours.46o51 We first examined the amino acid 
Figure 3. Cytotoxic activity of Mpp11 CTl lines generated from the bC-21 donor as tested using a standard chromium release assay. 
Mpp11-CTl lines were challenged with different HlA-A0201+ target cells at different e: T ratios. T2 and autologous lCls were pulsed 
with each peptide before challenge. Mpp-4 specific cytotoxic T cells specifically lysed peptide loaded T2 cells (A) and autologous lCl 
pulsed peptide (b). The same CTl lines lysed the leukemic cell line K-562-A2.1 and K-562 by TCl21 Mpp-4 (C). non-specific lysis of CTl 
line generated against Mpp-3 (d). 
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sequences derived from the MPP11 protein for the 
presence of peptides containing binding motifs for 
one of the most frequent A*0201 class I alleles,52 uso
ing a computerobased epitope prediction program. We 
identified four MPP11oderived peptides predicted to 
bind with high affinity to the HLAoA*0201 molecule. 
The peptides were named MPPo1N, MPPo2, MPPo3 
and MPPo4. Using the T2 binding assay, we tested the 
actual binding capacity of the selected peptides. The 
MPP11oderived peptides MPPo3 and MPPo4 recordo
ed binding scores lower than MPPo1N, and MPP2 
scores as determined by the SYFPEITHI software. 
However, in the actual T2 binding assay, MPPo3 and 
MPPo4 were found to have higher binding affinities 
compared to the two other peptides. This is probably 
due to a very poor dissolution of the MPPo1N and 
MPPo2 peptides since more hydrophobic amino acids 
are contained within their sequence. In addition to the 
four predicted peptides, we modified the amino acid 
sequence of the highest scoring peptide i.e., MPPo1N 
(QLLIKAVNL). We20 and others53,54 have shown that 
introducing a tyrosine amino acid residue at the first 
position (P1Y) of a peptide enhances epitope immuo
nogenicity. Therefore, a tyrosine amino acid residue was 
introduced in P1 of the MPPo1N peptide to boost its 
binding affinity and/or immunogenicity. The modificao
tion of MPPo1N peptide enhanced the binding affinity 
of the modified MPPo1Y peptide using the algorithm 
prediction but in the actual binding assay, the analogue 
peptide could not stabilize the HLAoA*0201 molecule 
which is again may be due to its poor dissolution. 
Consistent with other groups21,26,29 who have suco
ceeded in identifying CD8+ CTL epitopes using a 
simple method that employs T2 cells as antigenopreo
senting cells, we could not generate specific immune 
responses using this method to both MPP11oderived 
peptides as well as WT1o126N peptide which was ino
cluded as a positive control. Since MPP11 and WT1 
are self proteins, the majority of high avidity CD8+ 
T lymphocytes may have been deleted during thymic 
maturation.55 Thus it is more difficult to generate CTL 
responses from the remaining low avidityonaïve precuro
sors because their activation requires more stringent coo
stimulatory requirements.56,57 Therefore, we used DCs 
as antigenopresenting cells for the generation of antio
MPP11 CTL responses. DCs are known as the profeso
sional antigen presenting cells because of their unique 
ability to stimulate naïve T lymphocyte responses. The 
conventional protocol for generating monocyteoderived 
DCs included 7o9 days of culture, however, Dauer et 
al,24 described a rapid protocol for the generation of 
mature DCs from monocytes within only two days of 
in vitro culture. Such cells, termed fast DC or DC2d, 
were found to be capable of inducing tumorospecific 
CD8+ CTL responses as effectively as DCs genero
ated according to the conventional 7oday protocol.25,58 
Moreover, CTL lines primed with the DC2d cells exo
panded more effectively and showed greater lytic activo
ity than lines stimulated with the DC7d cells.25,58 Using 
the DC2d protocol, we were able to detect antigenospeo
cific responses by the CTLo21 line generated against the 
MPPo4 peptide. MPPo4oCTLs selectively recognized 
peptideoloaded T2 cells and specifically responded to 
the targets by releasing IFNog in an ELISPOT assay. 
Importantly, these T lymphocytes specifically killed 
T2 cells and autologous LCLs when loaded with the 
MPPo4 peptide. Moreover, they were capable of reco
ognizing the leukemia cell line K562oA2.1 expressing 
the MPP11 protein. Even though T2 cells were not efo
ficient at priming and generating specificoCD8+ CTL 
immunity, these cells were very useful as targets when 
conducting functional assays such as cytotoxicity and 
ELISPOT assays. 
We have attempted to generate MPPo4ospecific 
CTLs from four healthy HLAoA*0201 positive indio
viduals; however, specific responses could only be obo
served in one CTL line established from one donor 
(BCo21). The failure to obtain specific CTL responses 
to tumor antigens in all donors tested was observed 
in a previous study was thought to be due to the low 
frequency of peptideospecific CD8+ T lymphocyte 
precursors in healthy individuals.59 We aimed to clone 
the MPPo4 CTL line before testing its capability of 
recognizing fresh A*0201opositive leukemic cells that 
overexpress the MPP11 protein. Unfortunately, regardo
less of our attempts to generate MPPo4ospecific clones, 
we could not generate any specific clones. Standard 
techniques for cloning T cells employ stimulation with 
antigen loadedoAPCs in the presence of ILo2 and alloo
geneic feeder cells in limiting dilution cultures followed 
by repeated reostimulations to maintain growth and 
specificity. In the first attempt, the MPPo4 CTL line 
was cloned by stimulation with peptide pulsedoT2 cells 
in the presence of allogeneic feeder cells in the preso
ence of ILo2, ILo15 and OKT3. ILo2 is the cytokine 
frequently used to promote the survival and expansion 
of cultured T cells.60 ILo2 and ILo15 share the bochain 
and the common gochain receptor (ILo2/ILo15 Rbgc), 
but each cytokine has its unique αochain receptor.61,62 
ILo15 was initially identified by its capability to proo
mote the development of NK cells and the survival of 
CD8+ memory T lymphocytes in vivo.63o65 However, it 
has been reported that antitumoroCTLs expanded and 
survived for relatively long time periods in vitro in the 
original research report nOvel pepTide reCOgnized by Cd8+ CTl
Hematol Oncol Stem Cell Ther 3(1)     First Quarter 2010 hemoncstem.edmgr.com32
presence of ILo15 whereas CTLs maintained in ILo2 
died at earlier stages.66 Furthermore, ILo15omaintained 
CTLs retained their effector function as CTLs and did 
not switch into memory cells.66 For TCR triggering, we 
used OKT3 as reported previously.25 Because all of the 
generated clones were not specific, we conducted anotho
er attempt to clone the line but without the addition of 
either ILo15 or OKT3 antibody. The generated T lymo
phocytes clones were very few and died at early stage 
perhaps as a result of an old T lymphocyte culture. 
In summary, our data suggests that CD8+ CTL reaco
tive to the MPPo4 peptide could be generated from the 
T lymphocytes repertoire of HLAoA*0201+ healthy 
individuals. More importantly, these CTLs were able to 
specifically lyse the K562oA2.1 leukemic cells naturally 
expressing the MPP11 antigen. 
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